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Abstract 
 
Toll-like Receptors (TLR)s are an essential class of Pattern Recognition Receptors 
(PRR)s used by the innate immune system to recognise conserved microbial motifs 
which are characteristic of invading pathogens.  Activation of TLRs initiates 
signalling cascades resulting in the activation of transcription factors such as NF-κB 
and members of the interferon regulatory factor (IRF) family which regulate gene 
expression and mediate an immune response to the pathogen.  Dysregulation of TLR-
signalling can result in inflammatory and autoimmune diseases and for this reason 
they are subject to tight regulation.  This study demonstrates Cactin to be a novel 
negative regulator of TLR-signalling pathways.  Overexpression of Cactin inhibits 
activation of NF-κB whilst suppressed expression of Cactin leads to stronger and more 
prolonged activation of NF-κB in response to LPS.  The expression of Cactin is 
regulated by NF-κB, thus representing a novel negative feedback mechanism for 
suppression of the inflammatory response.  Cactin protein is stabilised due to 
phosphorylation in cells treated with the pro-inflammatory cytokine IL-1β.  Similarly, 
the stabilisation of Cactin was observed in response to the TLR ligands LPS and 
Poly(I:C).  Cactin also negatively regulates the activation of IRF3 and IRF7 and 
suppression of endogenous Cactin augments Poly(I:C)-mediated IFNβ induction.  
Cactin localises to the nucleus by virtue of two nuclear localisation sequences (NLS)s 
and its nuclear expression is essential for manifesting its inhibitory effects.  Within the 
nucleus Cactin inhibits the DNA-binding activity of the NF-κB subunit p65.  
Suppression of endogenous Cactin leads to increased binding of IRF3 to the IFNβ 
promoter, though Cactin had no effect on IRF3 phosphorylation or translocation.  This 
indicates that Cactin also targets IRF3 at the level of DNA binding.  Furthermore, 
Cactin negatively regulates IRF7-mediated IFNα induction and affects the protein 
stability of IRF7.  Notably, these inhibitory effects are transcription factor specific as 
Cactin positively regulates the activation of AP-1 subunit c-Jun, demonstrating that 
Cactin can differentially regulate transcription factor activation.  A number of Cactin-
interacting proteins were also identified in this study. Interestingly Cactin interacts 
with a nuclear member of the IκB family, IκBL.  Cactin and IκBL show very similar 
nuclear expression patterns and exhibit similar negative regulatory effects on NF-κB, 
IRF3 and IRF7.  However, these two proteins function independently to inhibit the 
vii 
activation of these transcription factors. In summary this study highlights Cactin as a 
novel regulator of TLR signalling pathways by regulating the ability of specific 
transcription factors to bind to their cognate DNA sequences and induce transcription.   
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Chapter 1 
 
 
 
General Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1  The Mammalian Immune System 
 
The mammalian immune system is divided into two arms of defence against 
invading pathogens.  The adaptive immune system is the late phase of response while 
the innate immune system represents the first line of defence against infectious agents.  
The adaptive immune system, or acquired immune system, is associated with 
immunological memory and pathogen specific responses. It is mediated by 
lymphocytes, T cells and B cells, which recognise a vast selection of pathogens via 
cell surface receptors.  Each lymphocyte has a unique antigen receptor generated by 
somatic gene rearrangement which occurs during lymphocyte development.  The 
result of this gene rearrangement is a huge repertoire of antigen specific receptors 
which can recognise virtually any pathogen (Janeway et al., 2005).  Lymphocytes 
circulate through the lymphatic system as small inactive cells which have no effector 
function.  Recognition of their specific antigen promotes lymphocyte proliferation and 
differentiation to effector cells which mount an immune response to the invading 
pathogen.  However, antigen recognition alone is not sufficient for lymphocyte 
activation.  Co-stimulatory molecules, provided by antigen presenting cells (APC)s of 
the innate immune system, must also be present to stimulate lymphocyte 
differentiation (Medzhitov and Janeway, 1997).  In fact the presentation of antigens to 
lymphocytes in the absence of co-stimulatory molecules causes their inactivation.  
Cells of the innate immune system also release cytokines which regulate the effector 
responses employed by the adaptive immune system (Janeway et al., 2005). 
Following activation, B cells differentiate into plasma cells which secrete 
antibodies that recognize and bind extracellular pathogens.  Antibodies utilise three 
effector mechanisms for effective removal of invading pathogens.  They bind to 
pathogens preventing them from entering cells, a process known as neutralization.  
Opsonization is the coating of pathogens with antibody to promote phagocytosis by 
innate immune cells.  Antibodies can also activate the complement system which is a 
component of the innate immune system.  It is a series of plasma proteins that 
assemble on the surface of pathogens and create pores which can destroy bacteria 
directly.  More often, however, coating of pathogens with complement promotes their 
removal by phagocytosis.  T cells are responsible for cell-mediated immune response 
to intracellular pathogens.  Cytotoxic T cells destroy virus infected cells which present 
viral derived peptides to T cells in cell surface major histocompatibility (MHC) 
1 
complex class I molecules.  Helper T cells guide other cells of the immune system.  
TH1 cells recognise intracellular vesicle derived peptides displayed in MHC class II 
molecules on the cell surface of macrophages and subsequently promotes fusion of 
pathogen containing vesicles with lysosomes containing bactericidal agents.  TH2 cells 
also recognise vesicle derived peptides presented in MHC class II molecules and 
promote B cell activation (Janeway et al., 2005).  Adaptive immunity occurs in the 
late phase of infection, typically 4 days or more after infection.  This is due to the 
need for specific T and B cells to undergo clonal expansion and differentiation into 
effector cells.  Conversely the innate immune response is rapidly induced and prevents 
the spread of infection during this time.    
The innate immune system is the first line of defence against invading 
pathogens.  In fact, many infections are cleared efficiently by cells of the innate 
immune system without requiring the induction of an adaptive immune response.  
Furthermore, the innate immune system is essential for the initiation and direction of 
adaptive immunity (Medzhitov and Janeway, 1997).  Mechanisms of innate immunity 
include the epithelial surfaces of the body which act as an effective physical barrier 
against most microorganisms. Pathogens which pass these barriers are immediately 
faced with tissue macrophages which engulf the invading pathogen by phagocytosis.  
Furthermore, recognition of invading pathogens by macrophages leads to the initiation 
of an inflammatory response. The release of pro-inflammatory cytokines increases the 
permeability of blood vessels while chemokines attract immune cells to the site of 
infection.   Neutrophils are the first cells recruited which help to phagocytose and 
remove the invading pathogen.  These are followed by monocytes, the precursor of 
macrophages, which differentiate into additional macrophages at the site of infection.  
These phagocytes also produce toxic agents such as nitric oxide (NO) and 
antimicrobial peptides such as defensins and cationic proteins.  Other cells recruited to 
the site of infection include granulocytes, such as mast cells, which release granules 
containing the small inflammatory molecule histamine and the cytokine TNF-α, and 
innate natural killer (NK) cells which kill virus infected cells.  In addition to 
leukocytes, plasma proteins also accumulate at the site of infection including 
components of the complement system which assemble on the surface of pathogens 
and promote their removal by phagocytosis.  The inflammatory response also 
promotes clotting of the blood in microvessels in the site of infection, serving to 
prevent the spread of infection.  Recognition of invading pathogens also leads to the 
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expression of costimulatory molecules, CD80 and CD86, on the cell surface of 
macrophages and dendritic cells (DC)s.  DCs travel to nearby lymph nodes and 
present pathogen-derived peptides to lymphocytes in MHC class II molecules, along 
with co-stimulatory molecules, to activate an adaptive immune response to the 
invading pathogen (Iwasaki and Medzhitov, 2004). 
   
1.2 Pathogen Recognition Receptors (PRRs) 
 
The innate immune system lacks the antigen specificity of adaptive immunity.  
It does, however, have the ability to discriminate between self and non-self via the use 
of a number of germline encoded receptors called pattern recognition receptors 
(PRR)s.  These receptors recognise repeating patterns of molecular structure found on 
invading pathogens, which are not present in host cells (Janeway, 1989).  For 
example, the DNA of bacteria contains unmethylated repeats of the dinucleotide CpG 
which can be detected by the innate immune system.  These patterns are collectively 
known as pathogen associated molecular patterns (PAMPs).  PAMPs are conserved 
structures shared by large groups of pathogens (Medzhitov and Janeway, 1997).  
Lipopolysaccharide (LPS), for example, is found in the cell walls of all gram negative 
bacteria.  Double stranded (ds)RNA which is used by almost all viruses at some stage 
of their life cycle is also detected by PRRs.  PAMPs are also essential for microbial 
viability, making them perfect targets for the non-specific immune system.  Bacteria, 
viruses, fungi and protazoa all contain PAMPs and can activate an innate immune 
response.  Some PRRs recognise PAMPs directly while others recognise products 
generated by PAMP recognition.  There are three types of PRRs, secreted proteins, 
transmembrane receptors and intracellular receptors (Medzhitov and Janeway, 1997).    
  
 1.2.1 Secreted PRRs 
 
Secreted PRRs, including collectins, ficolins and pentraxins, bind to microbes 
and activate the complement system.  For example, Mannose-binding lectin (MBL) is 
a member of the collectin family which recognises a particular orientation of sugar 
residues on the surface of many microorganisms and initiates the complement cascade 
(Janeway et al., 2005). 
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Table 1.1 PAMP detection by TLRs 
 
 
 
Species PAMPs TLRs
Bacteria, mycobacteria LPS TLR4
Lipoproteins TLR2/1, TLR2/6
Lipoarabinomannan TLR2/1, TLR2/6
PGN TLR2/1, TLR2/6
LTA TLR2/1, TLR2/6
Flagellin TLR5
CpG DNA TLR9
RNA TLR7
Viruses DNA TLR9
RNA TLR3, TLR7, TLR8
Envelope protein TLR4
Structural protein TLR2, TLR4
Fungus zymosan, β-glucan TLR2, TLR6
Mannan TLR2, TLR4
DNA TLR9
RNA TLR7
Parasites tGPI-mutin (Trypanosoma ) TLR2
glycoinositolphospholipids (Trypanosoma ) TLR4
DNA TLR9
hemozoin (Plasmodium ) TLR9
profilin-like molecule (Toxoplasma gondii ) TLR11
Host HSP 60, 70 TLR4
Fibrinogen TLR4  
 
 
 
 
 
 
 
 
 
 
 1.2.2 Transmembrane PRRs   
 
Transmembrane PRRs include the C-type lectins, such as Dectin-1 which 
recognises β-glucans in fungal cell walls, and macrophage mannose receptor (MMR) 
(Janeway and Medzhitov, 2002).  PAMP recognition by these receptors triggers 
cellular processes such as phagocytosis and production of reactive oxygen species 
(ROS).  Another class of transmembrane PRRs which have been extensively studied 
are toll-like receptors (TLRs) and they recognise a wide range of PAMPS (Table 1.1).   
The expression of TLRs is cell-type specific (Iwasaki and Medzhitov, 2010).  They 
are primarily expressed on innate immune cells such as macrophages, DCs, 
neutrophils and NK cells, but can be expressed on lymphocytes and also on some non-
immune cells such as epithelial cells (Iwaski and Medzhitov, 2004).  Cell surface 
TLRs recognise PAMPs on the surface of pathogens.  TLR4 recognises LPS on the 
surface of gram-negative bacteria (Chow et al., 1999), TLR5 recognises bacterial 
flagellin (Hayashi et al., 2001) and TLR2 forms heterodimers with TLR1 or TLR6 to 
recognise a diverse range of bacterial lipopeptides (Farhat et al., 2008).  Other TLRs 
are located on the membranes of intracellular endosomes and detect microbial nucleic 
acids.  TLR3 recognises viral dsRNA (Alexopoulou et al., 2001), TLR7 recognises 
viral ssRNA (Diebold et al., 2004) and TLR9 can detect bacterial DNA by the 
presence of CpG repeats (Bauer et al., 2001).  TLRs also recognise PAMPs derived 
from fungi and parasitic-protazoa (Kumar et al., 2009).  PAMP recognition by TLRs 
initiates a signalling cascade which results in the activation of transcription factors, 
such as nuclear factor (NF)-κB and members of the interferon regulatory factor (IRF) 
family of transcription factors (Iwaski and Medzhitov, 2004).  These transcription 
factors up-regulate the expression of genes encoding pro-inflammatory cytokines, 
such as interleukin (IL)-1β and IL-6, pro-inflammatory chemokines, such as IL-8 (also 
known as CXCL8), antiviral interferons (IFN)s  and the co-stimulatory molecules 
CD80 and CD86 (Medzhitov et al., 1997). 
  
 1.2.3  Cytoplasmic PRRs 
 
Cytoplasmic PRRs include retinoic acid-inducible gene I (RIG-I)-like 
receptors (RLR)s, such as RIG-I and melanoma differentiation factor 5 (MDA5).  
RLRs are expressed in most cell types and detect the presence of viral RNA through 
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their helicase domains. Activation of RLRs by viral RNA leads to the recruitment of 
mitochondrial antiviral signalling protein (MAVS) also called IFNβ promoter 
stimulator (IPS)-1 which leads to downstream activation of the transcription factors 
NF-κB and IRF3 (Iwasaki and Medzhitov, 2010).  Another family of cytoplasmic 
PRRs are NOD-like receptors (NLR)s which can detect stress signals and microbial 
products.  They have C-terminal leucine rich repeats (LRR)s responsible for PAMP 
recognition, a central nucleotide –binding oligomerization domain (NOD) for self 
oligomerization and an N-terminal effector domain.  Some NLRs, such as NOD1, 
activate NF-κB.  Other NLRs, such as NALP1 and NALP3, form protein complexes 
with apoptosis-associated speck-like protein containing a CARD (ASC) and Caspase-
1, known as inflammasomes.  The inflammasome mediates the cleavage of pro-IL-1β 
and pro-IL-18 by caspase-1 to active IL-1β and IL-18 (Creagh and O’Neill, 2006).   
TLR signalling leads to the production of pro-IL-1β while NLRs are required for the 
cleavage of pro-IL-1β to its active form. Given that IL-1β is a key mediator of 
inflammation, it is clear that co-operation of these two PRRs is necessary for effective 
activation of the inflammatory response. 
 
1.3 Toll-like Receptors (TLR)s 
 
To date, 10 functional TLRs have been identified in humans while 12 have 
been identified in mice (Kawai and Akira, 2011).  TLRs are type 1 transmembrane 
receptors with N-terminal extracellular LRRs, which are responsible for PAMP 
recognition, and a C-terminal intracellular signalling domain.  The intracellular 
domain of TLRs is similar to that of the IL-1 Receptor (IL-1R) family and is 
consequently termed the Toll/IL-1R (TIR) domain.  In fact, members of the IL-1R 
family use many of the same signalling intermediates as TLRs (Martin and Wesche, 
2002).  Unlike TLRs, however, IL-1R family members have extracellular 
Immunoglobulin (Ig)-like domains which mediate ligand recognition.  Following 
PAMP recognition, TLRs form homo- or heterodimers which allows for the 
recruitment of various TIR domain containing adaptor proteins to the receptor.  This 
initiates a signalling cascade which results in the downstream activation of 
transcription factors which regulate gene expression.  NF-κB and AP-1 regulate the 
expression of pro-inflammatory cytokines and chemokines while IRF3 and IRF7 
regulate the expression of Type I IFNs.  Myeloid differentiation factor 88 (MyD88) is 
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the universal adaptor protein recruited by all TLRs, with the exception of TLR3, and 
also by members of the IL-1R family (Medzithov et al., 1998).  Recruitment of 
MyD88 by all receptors results in downstream activation of NF-κB and AP-1. In 
plasmacytoid DCs (pDCs) the recruitment of MyD88 by endosomal TLR7 and TLR9 
can also lead to the activation of IRF7 (Kawai et al., 2004, Honda et al., 2004).  TLR3 
and TLR4 both recruit TIR domain –containing adaptor-inducing IFN-β (TRIF) 
leading to subsequent activation of IRFs and NF-κB (Jiang et al., 2004).  TLR2 and 
TLR4 require an additional adaptor protein, MyD88 adaptor like (Mal) which acts as a 
bridge between MyD88 and the receptor (Yamamoto et al., 2002).  Similarly, TLR4 
utilises TRIF-related adaptor molecule (TRAM) as a bridging adaptor for TRIF 
(Oshiumi et al., 2003).  
   
1.3.1 TLR4   
 
TLR4 was the first mammalian TLR discovered (Medzhitov et al., 1997).  It 
detects LPS which is one of the best studied immunostimulatory components of 
bacteria. TLR4 is expressed on the cell surface of innate immune cells such as 
monocytes/macrophages, myeloid (m)DCs and mast cells. TLR4 is also expressed on 
the surface of B lymphocytes (Gerondakis et al., 2007).   Furthermore, TLR4 can be 
expressed by non-immune cells.  For example, TLR4 can be found in the Golgi 
apparatus of intestinal epithelial cells where it recognises internalised LPS (Hornef et 
al., 2003). 
LPS is an essential structural component of the cell walls of gram negative 
bacteria.  LPS is sometimes called endotoxin and consists of a core oligosaccharide, 
an O side chain and a highly conserved Lipid A part which serves as the PAMP that 
activates TLR4. Cellular recognition of LPS, however, requires several different 
molecules including LPS-binding protein (LBP), cluster of differentiation (CD)14, 
myeloid differentiation protein (MD)-2 and TLR4.  LBP is an acute-phase protein 
which is present in the bloodstream and binds LPS (Wright et al., 1989).  LBP then 
transfers LPS to cell surface receptor CD14 (Wright et al., 1990).  CD14 is a 55 kDa 
glycoprotein with multiple LRRs (Setoguchi et al., 1989).  It lacks a characteristic 
transmembrane region but instead is anchored in the cell membrane by a 
phosphatidylinositol linkage (Haziot et al., 1988).  CD14 is expressed primarily on 
myeloid cells including macrophages, DCs and neutrophils.  The CD14/LPS complex 
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then interacts with TLR4/MD-2 complexes.  MD-2 is a small soluble protein that 
binds non-covalently to TLR4 and is essential for TLR4 recognition of LPS (Shimazu 
et al., 1999).  The interaction of the CD14/LPS complex with TLR4/MD-2 complexes 
causes receptor oligomerization and initiates downstream signalling (Alexander and 
Rietschel, 2001).  
TLR4 is unique among TLRs in that it activates two distinct signalling 
pathways.  The TIR domain-containing adaptor proteins recruited to the receptor 
dictates the signalling pathway which ensues.  TLR4 is also unique as it utilises all 
four TIR domain-containing adaptor proteins.  Two distinct signalling pathways are 
activated by TLR4 and classified as the MyD88-dependent and MyD88-independent 
signalling pathways.  It was originally thought that these signalling pathways were 
initiated simultaneously following ligand recognition.  However it now appears that 
these pathways are initiated sequentially (Kagan et al., 2008).  Recognition of LPS by 
TLR4 initiates MyD88-dependent signalling and activation of NF-κB and AP-1.  
MyD88 is recruited to the receptor at the plasma membrane with the help of bridging 
adaptor Mal (Yamamoto et al., 2002).  The LPS-TLR4 complex is then internalised 
into early endosomal structures in a process dependent on clatherin and the GTPase 
dynamin (Husebye et al., 2006).  Once the LPS-TLR4 complex is endocytosed, 
MyD88-dependent signalling is abolished.  TRIF can now be recruited to the receptor 
with the help of bridging adaptor TRAM (Oshiumi et al., 2003).  Recruitment of TRIF 
leads to downstream activation of members of the IRF family of transcription factors 
and the induction of Type I IFNs.  Interestingly, all pathways leading to the induction 
of Type I IFNs are initiated intracellularly.  It was thought that TLR4 was an 
exception to this rule.  It appears, however, that TLR4 signalling through TRIF is 
dependent on endocytosis of the receptor (Kagan et al., 2008).  It is possible that the 
localization of TRAF3, a key signalling intermediate in activation of Type I IFNs, 
dictates that these signalling pathways must be initiated from intracellular locations.  
Therefore, internalisation of TLR4 brings it into close proximity to TRAF3.  Once 
TRIF is recruited to the receptor it can interact with TRAF3 leading to downstream 
activation of IRFs and the induction of Type I IFNs (Kagan et al., 2008).  The LPS-
TLR4 complex is then trafficked to late endosomes or lysosomes for degradation and 
loading of associated antigens into MHC Class II molecules for presentation to helper 
T cells (Husebye et al., 2006).   
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 In addition to LPS, TLR4 has also been implicated in the recognition of a 
diverse range of other PAMPs.  TLR4 and CD14 recognise fusion (F)-protein of 
respiratory syncytial virus (RSV) (Kurt-Jones et al., 2000).  Furthermore, TLR4 
recognises the envelope protein from mouse mammary tumor virus (MMTV) (Rassa 
et al., 2002).  TLR4 has also been implicated in the recognition of fungal pathogens.  
TLR4 recognises some strains of Candida Albicans (Netea et al., 2010) and pertussis 
toxin isolated from Bordetella pertusis (Kerfoot et al., 2004).  Candida Albicans and 
Saccharomyces Cerevisiae derived mannan has also been shown to induce TNF-α 
through activation of TLR4 (Tada et al., 2002).  In addition, TLR4 can also initiate an 
immune response to endogenous molecules.  Heat-shock protein (HSP)60 serves as a 
danger signal for the innate immune system and activates TLR4 (Ohashi et al., 2000).  
Hyaluronic acid is one of the major components of the extracellular matrix and 
undergoes rapid degradation at sites of inflammation.  Fragments of hyaluronic acid 
have been shown to activate TLR4 on DCs (Termeer et al., 2002).  Similarly, anti-
microbial β-defensin 2 released during inflammation activates TLR4 on DCs (Biragyn 
et al., 2002).  Activation of TLR4 induces the expression of co-stimulatory molecules 
and maturation of DCs into mature APCs which activate cells of the adaptive immune 
system. 
 
1.3.2 TLR3 
 
 TLR3 is expressed on the endosomes of immune cells such as macrophages, 
NK cells and mDCs and recognises viral nucleic acids (Kumar et al., 2009).  TLR3 is 
not, however, expressed by pDCs which are specialized at producing high levels of 
Type I IFNs in response to viral infection via signalling by TLR7 and TLR9.  This 
differential expression on DCs suggests a role for TLR3 in the activation of adaptive 
immunity by stimulating the maturation of mDCs into APCs, rather than primary 
production of IFNs.  TLR3 is also expressed by non-immune cells including 
fibroblasts (Matsumoto et al., 2003), intestinal epithelial cells (Cario and Podolsky, 
2000) and airway epithelial cells (Sha et al., 2004).  In fibroblasts and epithelial cells 
TLR3 can be found on the cell surface as well as intracellularly (Matsumoto et al., 
2003).  While cell surface TLR3 may have a role in ligand recognition, in all cases 
TLR3 signalling is initiated from intracellular endosomes (Matsumoto and Seya, 
2008).  Notably, in human embryonic kidney (HEK) 293 cells engineered to express 
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TLR3, the receptor was found to localise to intracellular vesicles where signalling was 
initiated (Funami et al., 2004).  TLR3 is expressed by neurons and induces 
inflammatory and antiviral responses in the brain (Lafon et al., 2006).  The expression 
of TLR3 is up-regulated by viral infection due to the presence of an IFN-response 
element (ISRE) in the TLR3 promoter region (Tanabe et al., 2003). 
 TLR3 recognises viral dsRNA which is the genetic information of some 
viruses (Alexopoulou et al., 2001).  dsRNA is also produced by most other viruses at 
some point in their replication process.  TLR3 also recognises the stable synthetic 
dsRNA polyriboinosinic : polyribocytidylic acid (Poly(I:C)) which is frequently used 
to mimic viral infection in cells.  Furthermore, endogenous RNA released from 
necrotic cells can also serve as a ligand for TLR3 activation (Kariko et al., 2004).  
TLR3 has been implicated in the response to West Nile Virus (WNV).  However, 
some reports suggested TLR3 response to WNV infection facilitates disruption of the 
blood-brain barrier and lethal encephalitis and so contributes to disease pathogenesis 
rather than protection (Wang et al., 2004).  Conversely, other reports suggest a 
protective role of TLR3 in WNV infection as TLR3 signalling reduced the spread of 
viral infection the brain and CNS (Daffis et al., 2008).  TLR3 has also been implicated 
in anti-viral responses to RSV (Rudd et al., 2006), influenza A virus (IAV) (Goffic et 
al., 2006), phlebovirus (Gowen et al., 2006) and murine cytomegarovirus (MCMV) 
(Tabeta et al., 2004).  TLR3 is unique among TLRs as it does not recruit the TIR-
domain containing adaptor MyD88 for signal transduction.  Instead TLR3 signals 
through TRIF leading to downstream activation of IRFs, NF-κB and AP-1 and the 
induction of Type I IFNs, pro-inflammatory cytokines and co-stimulatory molecules.   
 
 
1.4 TLR signalling pathways and activation of transcription factors 
 
MyD88 is the universal adaptor recruited by all TLRs, with the exception of 
TLR3, and for this reason the signalling cascades activated by TLRs are often 
classified as MyD88-dependent and MyD88-independent pathways (Figure 1.1).  The 
MyD88-dependent pathway is also utilised by the widely expressed IL-1R. 
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Figure 1.1 TLR3- and TLR4-mediated signalling pathways 
Upon activation TLR4 recruits MyD88 to the receptor with the help of bridging 
adaptor Mal.  This leads to the recruitment and activation of IRAKs which in turn 
activates TRAF6.  TRAF6 ubiquitinates and activates TAK1 which in turn activates 
the  IKK complex.  The active IKK complex phosphorylates the IκB proteins marking 
them as targets for proteosomal degradation.  The NF-κB dimer then translocates to 
the nucleus and binds to the promoter regions of its target genes.  TAK1 also activates 
MAPKs leading to activation of AP-1 which co-operates with NF-κB to regulate the 
expression of pro-inflammatory cytokines.  Endocytosed TLR4 then recruits TRIF 
with the help of bridging adaptor TRAM.  TLR3 also signals through TRIF.  TRIF 
associates with TRAF3 which recruits the TBK1/IKKi kinase complex leading to 
phosphorylation of IRF3 and IRF7 promoting their dimerisation and translocation to 
the nucleus where they regulate the expression of Type 1 IFNs.  TRIF also signals 
through RIP1 or TRAF6 to activate TAK1 leading to downstream activation of NF-κB 
and AP-1.  
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1.4.1 The MyD88-dependent pathway 
 
Upon binding of the appropriate ligand, TLRs dimerise.  This causes a 
conformational change that creates a platform for the recruitment of TIR-domaining 
adaptor proteins to the receptor.  MyD88 is recruited to the receptor with or without 
the aid of the bridging adaptor Mal.  In addition to its TIR domain, MyD88 has an N-
terminal death domain (DD).  Upon recruitment, MyD88 associates with members of 
the IL-1R associated kinase (IRAK) family of protein kinases, through homotypic 
association of their DDs (Wesche et al., 1997).  IRAK4 is thought to be recruited 
upstream of other IRAKs (Lye et al., 2004).  IRAK4 phosphorylates critical residues 
in the N-terminal of IRAK1 causing its activation (Li et al. 2002).  IRAK1 is then 
hyperphosphorylated by itself and other kinases triggering its dissociation from 
MyD88.  IRAK2 also becomes phosphorylated and dissociates from the complex.  
Once dissociated, IRAK1 and IRAK2 interact with the downstream adaptor, tumour 
necrosis factor (TNF)-receptor associated-factor 6 (TRAF6) (Flannery and Bowie, 
2010).  TRAF6 is a RING domain containing E3 ubiquitin ligase which, along with 
E2 ubiquitin conjugating enzyme (Ubc)13 and ubiquitin-conjugating enzyme E2 
variant 1 isoform A (Uev1A), catalyses the formation of polyubiquitin chains through 
lysine (K)63 of ubiquitin (Deng et al., 2000).  Unlike K48-linked ubiquitination, this 
modification is not associated with proteosomal degradation.  Instead, K63-linked 
polyubiquitination has been associated with various processes such as DNA repair, 
vesical trafficking and protein kinase activation (Sun and Cheng, 2004).  IRAK2 plays 
a central role in the activation of TRAF6 (Keating et al., 2007).  Interaction of IRAK2 
and TRAF6 triggers the polyubiquitination of TRAF6, a process involving 
autoubiquitination by TRAF6 (Keating et al., 2007).   
Activated TRAF6 then associates with transforming growth factor-β (TGF-β) 
activating kinase (TAK1) and its regulators, the TAK1 binding proteins, TAB1 and 
TAB2.  TAK1 is an ubiquitin-dependant kinase, which is activated by K63 
ubiquitination using the E3 ligase activity of TRAF6 (Wang et al., 2001).  The 
inhibitory (I)-κB Kinase (IKK) complex is made up of two protein kinases, IKKα and 
IKKβ, and a scaffolding protein IKKγ which is essential for regulation and activation 
of the complex (Rothwarf et al., 1998).  Ubiquitinated TAK1 phosphorylates IKKβ 
and activates the IKK complex (Shim et al., 2005). In the unstimulated cell NF-κB is 
found in association with IκB proteins.  The activated IKK complex phosphorylates 
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these IκB proteins marking them as targets for K48-linked ubiquitination and 
subsequent degradation in the 26S proteosome (Hayden and Gosh, 2004).  NF-κB is 
then free to bind to κB sites in the promoter regions of its target genes, including 
genes encoding pro-inflammatory cytokines and chemokines.   
Mitogen activating protein kinases (MAPK)s are a group of intracellular signal 
transducing enzymes (Barr and Bogoyevitch, 2001).  They are serine/threonine 
kinases that are activated sequentially in response to a stimulus, such as stress or 
microbial infection.  The MAPK is phosphorylated and activated by a MAPK kinase 
(MAPKK or MAP2K) which is phosphorylated and activated by a MAPKK kinase 
((MAPKKK or MAP3K).  TAK1 is a MAP3K which can phosphorylate and activate 
MKK3 and MKK6 (Moriguchi et al., 1996).  These MAP2Ks in turn phosphorylate 
and activate MAPKs JNK and p38.  MAPK activation leads to subsequent activation 
of the transcription factor activator protein (AP)1.  AP1 co-operates with NF-κB to 
regulate gene expression.   
 
1.4.2 The MyD88-independent pathway 
 
NF-κB and AP-1 can also be activated by a MyD88-independent pathway, 
involving the TIR domain containing adaptor protein TRIF. TRAM acts as a bridging 
adaptor for TLR4 and TRIF (Oshiumi et al., 2003), while TRIF interacts directly with 
TLR3.  Following recruitment TRIF interacts with receptor interacting protein 1 
(RIP1) (Meylan et al., 2004).  RIP1 interacts with the C-terminal domain of TRIF via 
a RIP homotypic interaction motif.  Furthermore, the N-terminal region of TRIF 
contains three characteristic TRAF6 binding motifs and TRAF6 has been implicated 
in TRIF-mediated NF-κB activation in some cell types (Gauzzi et al., 2010).  
Activation of RIP1 or TRAF6 leads to downstream activation of TAK1.  As in 
MyD88-dependent signalling TAK1 then activates the IKK complex and MAPKs.  
The activated IKK complex phosphorylates IκB proteins marking them as targets for 
ubiquitination and proteosomal degradation which releases NF-κB.  MAPK activation 
leads to subsequent activation of the transcription factor AP-1.  NF-κB and AP-1 
regulate the expression of genes encoding proinflammatory cytokines and 
chemokines. 
MyD88-independent signalling also leads to the activation of members of the 
IRF family of transcription factors, IRF3 and IRF7.  TRIF is first recruited to the 
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receptor which leads to the recruitment of TRAF3 (Matsumoto and Seya, 2008).  This 
leads to subsequent recruitment and activation of tank binding kinase 1 (TBK1) and 
inducible IKK (IKKi).  NF-κB-activating kinase (NAK)-associated protein 1 (NAP1) 
also plays a role in the recruitment of these kinases (Sasai et al., 2005).  TBK1 and 
IKKi phosphorylate key serine/threonine residues in the C-terminal region of IRF3 
and IRF7 (Sharma et al., 2003).  Phosphorylation of IRFs promotes their dimerisation 
and nuclear translocation and allows for interaction with the transcriptional co-
activators cAMP responsive element binding protein (CBP)/p300 (Gauzzi et al., 
2010).  CBP/p300 acetylates IRF3 homodimers, which causes a conformational 
change that unmasks its DNA binding domain (Lin et al., 1999).  IRF3 and IRF7 bind 
to the promoter regions and upregulate the expression of genes encoding Type I IFNs.   
 
 1.4.3 NF-κB 
 
NF-κB is a key regulator of inflammation and cell survival.  It was discovered 
in 1986 and has been extensively studied since this time (Sen and Baltimore, 1986).  
There are five mammalian NF-κB/Rel proteins to date, p65 (RelA), NF-κB1 (p50 and 
precursor p105), NF-κB2 (p52 and precursor p100), c-Rel and RelB (Albert and 
Baldwin, 1996), each containing a conserved 300 amino acid N-terminal domain.  
This domain is termed the rel homology (RH) domain and is responsible for nuclear 
translocation, DNA-binding and dimerisation of Rel/NF-κB family members (Ghosh 
et. al, 1998).  RelB, c-Rel and p65 also possess a C-terminal transactivation domain.  
Rel subunits form homo- or heterodimers and the various dimeric combinations 
formed target slightly different DNA sequences allowing for distinct transcriptional 
activity of different NF-κB dimers (Kunsch et al., 1992).  The predominant form of 
NF-κB is a p65-p50 heterodimer.  Due to the lack of a C-terminal transactivation 
domain p50 and p52 homodimeric complexes cannot activate transcription but instead 
act as transcriptional repressors (Hayden and Ghosh, 2004).  NF-κB regulates the 
expression of a range of proteins including proinflammatory cytokines, such as IL-1β, 
IL-8, IL-6 and TNFα, adhesion molecules, such as intracellular adhesion molecule 
(ICAM)-1 and vascular cellular adhesion molecule (VCAM)-1, and inducible 
enzymes such as inducible nitric oxide synthase (iNOS) which mediate the innate 
immune response to the invading pathogen (Pahl, 1999).  Furthermore, NF-κB 
regulates genes encoding co-stimulatory molecules, MHC and cytokines required for 
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activation and regulation of the adaptive immune system (Moynagh, 2005).  NF-κB 
can also promote cell survival by inducing the expression of anti-apoptotic proteins 
(Li and Verma, 2002).   
In the unstimulated cell, NF-κB is mainly cytoplasmic and is found in 
association with members of the IκB family.  IκB proteins bind to the NF-κB dimer 
through multiple ankyrin repeats and inhibit their DNA-binding activity (Whiteside 
and Israel, 1997).   Cytoplasmic IκB proteins, IκBα, IκBβ and IκBε, were originally 
thought to sequester NF-κB in the cytoplasm by masking its nuclear localisation 
sequences (NLS)s.  IκBα, however, only blocks one NLS of the NF-κB dimer and the 
complexes maintain the ability to translocate to the nucleus (Malek et al., 2001).  IκBα 
encodes an N-terminal nuclear export signal (NES) which is responsible for shuttling 
the IκBα-NF-κB complexes out of the nucleus (Huang et al., 2000).  Similarly, IκBε-
NF-κB complexes have been reported to shuttle between the nucleus and the 
cytoplasm (Lee and Hanink, 2002).  IκBβ, in contrast, masks both NLSs of the NF-κB 
dimer and thus sequesters the transcription factor in the cytoplasm (Malek et al., 
2001).  The N-terminal region of IκB proteins is phosphorylated on key serine 
residues by the IKK complex (Yamamoto and Gaynor, 2004).   Phosphorylated IκBs 
are targets for the ubiquitin ligase machinery of the cell and are polyubiquitinated and 
subsequently degraded by the 26S proteosome.  The p65-p50 hererodimer is primarily 
bound by IκBα which is rapidly degraded in response to NF-κB activating stimuli.  
Active NF-κB promotes the expression of IκBα which is an important negative 
feedback regulatory mechanism which ensures termination of the NF-κB response 
(Klement et al., 1996).  IκBβ and IκBε are also degraded and resynthesized in 
response to NF-κB signalling but with delayed kinetics when compared with IκBα 
(Hoffmann et al., 2002, Kearns et al., 2006). 
The NF-κB precursor proteins p100 and p105 have C-terminal ankyrin repeats 
in addition to their RH domains and serve as IκB proteins.  p100 and p105 are 
processed, resulting in the removal of their C-terminal ankyrin repeats.  p105 is 
constitutively processed to p50 resulting the presence of both p50- and p105-
containing dimers, while p100 processing to p52 is stimulus dependent (Oeckinghaus 
and Ghosh, 2009).  p100 preferentially binds RelB and following stimulus dependent 
ubiquitination and processing to p52, the RelB-p52 complex induces genes essential 
for B-cell development and lymphoid organogensis (Moynagh, 2005).  A number of 
ankyrin repeat containing proteins found in the nucleus and termed nuclear IκBs 
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regulate NF-κB transactivation.  However, the nuclear IκBs characterised to date, 
including Bcl-3, IκBζ and IκBNS, interact with NF-κB dimers and have been shown 
to both positively and negatively regulate the expression of NF-κB inducible genes 
(Yamamoto and Takeda, 2008).   
 
1.4.4 The Interferon Regulatory Factors (IRFs) 
 
The IRF family consist of nine members (IRF1-9) which all possess an N-
terminal DNA binding domain (DBD) and a C-terminal IRF association domain 
(IAD) (Savitsky et al., 2010).  They regulate the expression of Type I IFNs which are 
a family of cytokines involved in antiviral defence, immune activation and cell growth 
and regulation (Goodbourn et al., 2000).  Type I IFNs prevent viral replication and 
limit the spread of infection.  Secreted IFNs bind to common cell surface interferon 
receptors (IFNAR)s on surrounding infected and uninfected cells.  This causes the 
activation of endoribonucleases that degrade viral RNA.  Furthermore, PKR kinase is 
activated which phosphorylates the eukaryotic protein synthesis initiation factor eIF-2, 
preventing the translation of viral RNA.  Type 1 IFN production also promotes the 
activation of cytotoxic T cells, by increasing the cell surface expression of MHC class 
I molecules on surrounding infected cells, and innate NK cells which kill virus 
infected cells (Janeway et al., 2005).   
Type I IFNs are encoded by one IFNβ gene and several IFNα genes.  Of the 
nine family members, IRF3 and IRF7 are the most important in terms of regulation of 
Type I IFNs in response to viral infection (Taniguchi et al., 2001).  IRF3 and IRF7 are 
activated by TLR-signalling pathways and also by the cytoplasmic viral sensing 
RLRs, RIG-I and MDA5 (Kawai et al., 2005).  When activated they bind to IFN-
stimulatory response elements (ISRE) found in the promoters of Type I IFNs and 
other genes involved in immunity and oncogenesis (Honda and Taniguchi, 2006).  
IRF3 is expressed at high constitutive levels in most cells and is responsible for the 
initial induction of IFNβ in response to infection (Taniguchi et al., 2001).  TBK1- or 
IKKi-mediated phosphorylation of IRF3 promotes its dimerisation and nuclear 
translocation (Sharma et al., 2003).  IRF3 then co-operates in a multiprotein 
transcription enhancer called the enhanceosome to activate the transcription of IFNβ 
(Panne, 2008).  The enhanceosome requires the transcription factors IRF3 or IRF7, 
NF-κB and ATF-2/c-Jun which bind to positive regulatory domains (PRD)s in the 
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IFNβ promoter.  Furthermore, architectural protein HGM1 is required for the 
recruitment of histone acetyl transferases CBP/p300 to acetylate lysine residues of 
histone, leading to subsequent chromatin remodelling which is essential for efficient 
transcription of IFNβ (Noppert et al., 2007).   
IFNβ is produced and binds to the cell surface IFN receptor termed IFNAR.  
Stimulation of the IFNAR results in the activation of Jak/STAT pathway (Stark et al., 
1998).  The IFNAR is made up of two major subunits, IFNAR1 and IFNAR2 
(Mogensen et al., 1999).  In the unstimulated cell IFNAR is found in association with 
the Janus tyrosine kinase Tyk2 (Colamonici et al., 1994), while the IFNAR2 is 
associated with Jak1 and signal transducer and activator of transcription (STAT)2 (Li 
et al., 1997).  Upon IFNβ binding, IFNAR1 and IFNAR2 interact facilitating 
transphosphorylation and activation of Tyk2 and Jak1 (Novick et al., 1994).  
Activated Tyk1 then phosphorylates IFNAR1 creating a new binding site for STAT2 
(Yan et al., 1996).  STAT2 is phosphorylated and subsequently recruits STAT1 which 
in turn is phosphorylated (Shaui et al., 1993).  The activated STAT1/STAT2 
heterodimer translocates to the nucleus where it interacts with IRF9 to form the 
transcription factor complex IFN-stimulated gene factor 3 (ISGF3) (Tanaguchi et al., 
2001).  IRF7, which is expressed at low levels in most cells is strongly induced by 
ISGF3 (Genin et al., 2003).  IRF7 is also phosphorylated in its C-terminal region, in a 
manner similar to IRF3, which promotes its dimersation and translocation to the 
nucleus.  IRF7 is responsible for IFNα and IFNβ production in the late phase of the 
IFN response.  The positive feedback mechanism described above ensures the 
efficient induction of IFNs in response to viral infection.  However IRF7 and IRF3 are 
subject to ubiquitin-dependent proteosomal degradation (Yu and Hayward, 2010) 
which ensures that the production of Type I IFNs only occurs for a short time, while 
the viral infection persists.   
 
1.4.5 Activating Protein (AP)-1 
 
AP-1 is a dimeric transcription factor composed of subunits from Fos, Jun, 
activating transcription factor (ATF) and the Maf subfamilies and it binds to TPA-
response or cAMP-response elements in its target genes (Shaulian and Karin, 2002).  
AP-1 regulates a wide range of cellular processes including cell proliferation, cell 
survival and differentiation.  TLR-signalling leads to the activation of MAPKs c-Jun 
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N-terminal kinase (JNK), p38 and extracellular signal regulated kinase (ERK) which 
phosphorylate and activate the subunits of the AP-1 transcription factor.  Among the 
AP-1 subunits c-Jun, which is phosphorylated and activated by JNK, is considered the 
most important in terms of regulation of pro-inflammatory cytokines (Kawai and 
Akira, 2006).  In response to some stimuli phosphorylated JNKs can also translocate 
to the nucleus where they phosphorylate c-Jun thereby increasing its transcriptional 
activity (Robinson et al., 2001).  The various dimeric combinations of different AP-1 
subunits govern the genes they regulate (Johnson and Lapadat, 2002).  Furthermore 
the activation of differential subunits can be stimulus dependent.  For example CpG 
stimulation of TLR9 induces JNK and p38 activation leading to subsequent 
phosphorylation of c-Jun and ATF2 and the upregulation of TNF-α and IL-12 (Hacker 
et al., 1998) whereas Pam3Cys stimulation of TLR2 enhances c-Fos activation and the 
increased expression of IL-10 (Dillon et al., 2004). 
 
1.5 Negative Regulators of TLR-signalling 
 
TLRs are essential for the detection of invading pathogens and the activation 
of innate and adaptive immune responses.  However dysregulation of these pathways 
can be detrimental to the host and TLRs have been implicated in a wide range of 
autoimmune and inflammatory diseases.  Most significantly, an uncontrolled 
inflammatory response to LPS during bacterial infection can lead to systemic 
inflammation and septic shock resulting in multiple organ failure and death.  TLR4 is 
central to the progression of sepsis and TLR4-deficient mice are hyporesponsive to 
LPS and are thus protected from septic shock (Hoshino et al., 1999).  Furthermore, 
MyD88-deficiency and IRAK4-deficiency also confer some resistance to sepsis in 
response to LPS (Weighardt et al., 2002, Suzuki et al., 2002).  LPS antagonists, such 
as synthetic E5564, prevent the activation of TLR4 by LPS and thus represent possible 
novel treatments for septic shock (Mullarkey et al., 2003).   
TLRs have also been implicated in other diseases.  MyD88-deficient mice are 
less prone to the development of atherosclerosis (Michelsen et al., 2004).   
Furthermore, TLR4 is highly expressed in endothelial cells of human atherosclerotic 
lesions but poorly expressed in normal human arteries (Edfelt et al., 2002).  TLR3 has 
also been implicated in the pathogenesis of some diseases.  TLR3-deficient mice are 
more resistant to severe encephalitis caused by lethal West Nile virus (WNV) (Wang 
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et al., 2004).  In this case the activation of TLR3 leads to the production of pro-
inflammatory cytokines and disruption of the blood-brain barrier.  TLRs also play a 
central role in the development of chronic inflammatory disorders such as asthma 
(Eisenbarth et al., 2002) and rheumatoid arthritis (RA) (Pierer et al., 2004).  The 
recognition of self nucleic acids by TLR7 and TLR9 has also been implicated in the 
development of experimental lupus (Pawar et al., 2007).  In fact most autoimmune and 
inflammatory diseases are likely to involve TLRs at some stage of disease 
progression, either by the initiation of inflammation or via the activation of an 
adaptive immune response.  
As prolonged activation of TLR responses is detrimental to the host TLR 
signalling is tightly regulated at various stages (Figure 1.2).  Some regulators of TLRs 
are induced by TLR ligands or cytokines as a regulatory mechanism to ensure that the 
response to the invading pathogen is transient.  Meanwhile, other inhibitors are 
constitutively expressed and ensure that an immune response is not activated in the 
absence of a stimulus.   
 
1.5.1 Soluble decoy TLRs 
 
One regulatory mechanism employed by TLRs is the release of soluble or 
decoy TLRs which prevent PAMP recognition and thus attenuate the TLR response to 
microbial ligands.  There is a single copy of the TLR4 gene in mammals but several 
mRNA products have been detected (Qureshi et al., 1999).  One of these isoforms in 
mice encodes a soluble form of TLR4 (Iwami et al., 2000).  This soluble TLR4 was 
found to attenuate LPS mediated NF-κB activation and TNF-α production in a mouse 
macrophage cell line.  Furthermore, it was found to be upregulated following LPS 
stimulation suggesting that it acts as a regulatory feedback mechanism to inhibit an 
excessive response to LPS (Iwami et al., 2000).   
A similar mechanism might also exist in humans.  A recombinant sTLR4 was 
found to inhibit LPS mediated NF-κB activation and IL-8 production in human 
embryonic kidney (HEK) 293 cells (Hyakushima et al., 2004).  Furthermore, sTLR4 
was found to interact with MD-2, which is essential for TLR4 recognition of LPS.  
These soluble TLR4s represent a potential therapy for suppressing the immune 
response to LPS and the prevention of septic shock (Hyakishima et al., 2004). 
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Figure 1.2 Negative regulators of TLR signalling 
Soluble TLRs prevent ligand binding and activation of TLR signalling pathways.  TIR 
domain containing transmembrane receptors, SIGIRR, ST2 and RP105, block 
MyD88-dependent signalling to NF-κB.  A range of intracellular regulators target 
multiple levels of the signalling cascade.  Finally, transcription factor transactivation 
is regulated by nuclear regulators of TLR signalling. 
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Six soluble isoforms of TLR2 are produced due to post-translational 
modification in an intracellular compartment, creating an intracellular pool of sTLR2 
(LeBourder et al., 2003).  This suggests that sTLR2 might serve as an important first-
line regulatory mechanism preventing an uncontrolled response to bacterial infection.   
These soluble TLR2s are naturally present in blood and breast milk and are released 
by monocytes in response to bacterial infection.  sTLR2 attenuated TNF-α and IL-8 
production in response to a synthetic triacylated bacterial lipopeptide, Pam3Cys, in a 
human monocytic cell line.  This inhibition is likely due to its association with the co-
receptor CD14 (LeBouder et al., 2003).   
 
1.5.2 Transmembrane negative regulators 
 
 Some negative regulators are membrane bound and prevent downstream 
signalling from TLRs.  ST2 is present in two forms, ST2L and sST2, due to mRNA 
splicing (Bergers at al., 1994).  ST2L is a type 1 transmembrane receptor with 
extracellular Ig-like domains and an intracellular TIR domain.  ST2L is preferentially 
expressed on TH2 cells and has been implicated in TH2 cell effector functions 
(Lohning et al., 1998).  IL-33 is a member of the IL-1 family which favors TH2 
responses and is recognised by a receptor complex involving ST2L and IL-1R 
accessory protein (IL-1RAcP) (Schmitz et al., 2005).  ST2L can drive IL-33 mediated 
NF-κB and MAPK activation in TH2 cells in vitro (Schmitz et al., 2005).  However, 
ST2L has also been implicated as a negative regulator of NF-κB activation.  
Overexpression of ST2L failed to activate NF-κB in murine thymoma EL4 cells (Brint 
et al., 2002).  Furthermore, ST2L can interact with MyD88 and Mal preventing their 
interaction with downstream regulators of the signalling pathway (Brint et al., 2004).  
Thus, ST2L acts as a negative regulator of MyD88-dependent but not MyD88 
independent pathways and ST2L-deficient mice show enhanced production of pro-
inflammatory cytokines in response to IL-1 and LPS but not the TLR3 ligand 
Poly(I:C) (Brint et al., 2004).  However, ST2L-deficient mice were no more 
susceptible to septic shock than wild-type mice.  This is because ST2L is not 
constitutively expressed on the cell surface.  The expression of ST2L was detected on 
the cell surface of macrophages following 4 h stimulation with LPS (Brint et al., 
2004).  So this appears to be an autoregulatory mechanism to prevent the prolonged 
activation of NF-κB in response to microbial infection.   
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The soluble form of ST2, sST2, is also a negative regulator of inflammation 
which is upregulated by proinflammatory cytokines and LPS (Kumar et al., 1997, 
Saccani et al., 1998).  sST2 competes with ST2L for IL-33 binding and negatively 
regulates cytokine production by TH2 cells (Hayakawa et al., 2007).  sST2 is present 
in normal human serum but its levels are elevated in autoimmune diseases such as 
SLE (Kuroiwa et al., 2001) and asthma (Oshikawa et al., 2001).  sST2 binds to its 
receptor on bone marrow derived macrophages (BMDMs).  This receptor is 
upregulated by LPS stimulation.  Administration of sST2 in vivo attenuated LPS-
mediated IL-6, IL-12 and TNF-α production and reduced the toxic effects of LPS 
(Sweet et al., 2001).  Furthermore, sST2 downregulated the mRNA expression of 
TLR4 and TLR1 in LPS stimulated macrophages (Sweet et al., 2001).   
Single-immunoglobulin interleukin-1 receptor –related (SIGIRR) is another 
TIR domain containing receptor which negatively regulates TLR signalling.  SIGIRR 
is an orphan receptor with a single extracellular Ig-like domain and an intracellular 
TIR domain (Thomassen et al., 1999).  The extracellular domain of SIGIRR interferes 
with the interaction of the IL-1R with IL-1RAcP and inhibits downstream signalling 
to NF-κB (Qin et al., 2005).  Furthermore the TIR domain of SIGIRR interacts with 
MyD88, IRAK1 and TRAF6 (Qin et al., 2005) thus preventing their recruitment by 
TLRs and the IL-1R.  By this mechanism SIGIRR inhibits MyD88-dependent NF-κB 
activation. Primary kidney cells from SIGIRR-deficient mice showed enhanced NF-
κB activation in response to IL-1 and LPS but not TNFα (Wald et al., 2003).  This is 
not unexpected as the TNF receptor TNFR does not utilise MyD88.  SIGIRR is highly 
expressed in the gut (Liew et al., 2005).  This suggests that it may have a role in the 
suppression of intestinal inflammation in response to commensal bacteria.  The 
expression of SIGIRR is down-regulated following LPS stimulation (Polentarutti et 
al., 2003) to allow for an immune response to invading pathogen.   
TNF-related apoptosis–inducing ligand receptor (TRAILR) is a member of the 
TNF superfamily and is the receptor for TRAIL, another cell surface transmembrane 
protein.   TRAIL-R induces apoptosis in transformed cancer cells but not non-
transformed cells (Wu et al., 1999).  TRAILR also has a role in the regulation of TLR-
signalling.  Cells from TRAILR-deficient mice showed enhanced cytokine production 
in response to stimulation by TLR2, TLR3 and TLR4 ligands but not the TLR9 ligand 
CpG DNA (Diehl et al., 2004).  TRAILR has no effect on early TLR signalling events 
and, although its mechanism of action is unknown, it appears to affect the stabilisation 
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of IκBα leading to decreased nuclear translocation of NF-κB at later time points 
(Diehl et al., 2004). 
Finally RP105 is a TLR4 homologue which has a similar extracellular and 
transmembrane domain but lacks an intracellular signalling domain.  It has a similar 
expression pattern to TLR4 and its cell surface expression is dependent on the co-
expression of MD-2 homologue MD-1 (Divanovic et al., 2005). RP105 knockout mice 
show enhanced production of pro-inflammatory cytokines in response to LPS.  RP105 
interacts directly with the TLR4-MD2 receptor complex and inhibits the complex 
binding to LPS (Divanovic et al., 2005). 
 
1.5.3 Intracellular negative regulators 
 
Intracellular regulators of TLR-signalling target various stages in the 
signalling pathway to inhibit the activation of transcription factors in response to TLR 
ligands.  One such regulator is a splice variant of MyD88, termed MyD88s.  This 
protein, like full length MyD88, has a C-terminal TIR domain and an N-terminal DD 
but lacks the small intermediate domain (ID) (Janssens et al., 2002).  MyD88s is 
preferentially expressed in the spleen and is up-regulated in monocytes in response to 
LPS stimulation (Janssens at al., 2002).  MyD88s recruits IRAK1 but not IRAK4 to 
IL-1R/TLRs (Burns et al., 2003).  This prevents IRAK4-mediated IRAK1 
phosphorylation and prevents downstream signalling events from IRAK1.  MyD88s 
negatively regulates IL-1- and LPS- but not TNF-mediated NF-κB activation (Janssen 
et al., 2002).  Interestingly, however, the overexpression of MyD88s activates AP-1 
(Janssens et al., 2003).  This suggests that these signalling pathways may diverge at 
the level of MyD88 and suggests the importance of mRNA splicing in the regulation 
of TLR responses.  A chemically modified antisense oligonucleotide (ASO) has been 
shown to decrease MyD88 expression and increase MyD88s expression thus 
attenuating MyD88-dependent signalling to NF-κB (Vickers et al., 2006).  This might 
prove an interesting potential therapy for inflammatory diseases. 
Sterile α- and armadillo –motif containing protein (SARM) is a TIR domain 
containing adaptor protein.  SARM has a C-terminal TIR domain and two α-motif 
(SAM) domains and heat-armadillo motifs in its N-terminal region (O’Neill et al., 
2003).  SARM interacts with TRIF and inhibits TRIF-mediated NF-κB, IRF3 and 
IRF7 activation (Carty et al., 2006).  Both the TIR domains and SAM domains are 
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required for this inhibitory effect.  The protein expression of SARM is enhanced 
following LPS stimulation (Carty et al., 2006).  In addition, SARM negatively 
regulates both TRIF- and MyD88-dependent AP-1 activation (Peng et al., 2010).  
Interestingly, however, SARM-deficiency in mice had no effect on the cytokine 
production of macrophages treated with TLR ligands (Kim et al., 2007).  Murine 
SARM was found to be highly expressed in the brain where it co-localised with JNK3 
and it appears to have role in the stress response in neurons (Kim et al., 2007).  It is 
possible, however, that SARM has differential functions in mice and humans. 
The TIR domain containing adaptor protein MyD88 is required for signalling 
from all TLRs with the exception of TLR3.  Interestingly, however, MyD88 can 
negatively regulate TLR3 mediated IFNβ induction (Siednienko et al., 2011).  MyD88 
inhibits IKKi- but not TBK1-mediated IRF3 activation and inhibits subsequent IFNβ 
induction (Siednienko et al., 2011).  Similarly, an inhibitory role for TIR domain 
containing adaptor Mal in TLR3 signalling has also been proposed (Kenny et al., 
2009).  Mal can interact directly with IRF7, but not IRF3, and inhibit IFNβ induction 
by preventing IRF7 from binding to a positive regulatory domain in the IFNβ 
promoter (Siednienko et al., 2010). 
IRAK-M is a member of the IRAK family, but unlike other family members it 
is a negative regulator of TLR-signalling.  IRAK-M was originally thought to be 
expressed preferentially by cells of monocytic lineage but IRAK-M expression has 
also been detected in other cells such as epithelial cells (Harada et al., 2006).  IRAK-
M prevents the dissociation of IRAK from MyD88 and the downstream formation of 
IRAK-TRAF6 complexes (Kobayashi et al., 2002).  IRAK-M-deficient mice show 
enhanced cytokine production and inflammatory response to bacterial infection 
compared with wild type mice (Kobayashi et al., 2002).  LPS induces the expression 
of IRAK-M and LPS-tolerance was reduced in IRAK-M-deficient mice (Kobayashi et 
al., 2002).  IRAK-M appears to have an important regulatory role in sepsis and 
increased IRAK-M expression has been observed in monocytes isolated from patients 
with sepsis (Escoll et al., 2003).  Though the mechanism of action is unknown IRAK-
M appears to regulate chromatin remodelling which downregulates the expression of 
pro-inflammatory mediators during sepsis (Lyn-kew et al., 2010). 
Splice variants of IRAK2 and IRAK1 can also act as negative regulators of 
TLR signalling.  Overexpression of IRAK2a and IRAK2d, which both lack DDs, 
inhibits LPS-mediated NF-κB activation (Hardy et al., 2004).  Furthermore, a splice 
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variant of IRAK1, IRAK1c, negatively regulates NF-κB activation in response to LPS 
and CpG (Rao et al., 2005).  IRAK1c lacks kinase activity and is not phosphorylated 
by IRAK4 but still interacts with IRAK2, MyD88 and TRAF6 and prevents 
downstream signalling to NF-κB.  IRAK1c is highly expressed in the brain, while 
IRAK1 is not, suggesting that IRAK1c may be crucial for maintaining a non-
inflammatory state in the brain (Su et al., 2007). 
Toll interacting protein (Tollip) was first identified in a yeast 2 hybrid screen 
using the cytoplasmic tail of IL-1AcP as bait and was found to inhibit IL-1β-mediated 
NF-κB and JNK activation (Burns et al., 2000).  Tollip also associates with TLR2 and 
TLR4 and its overexpression inhibits MyD88-dependent signalling to NF-κB (Zhang 
and Ghosh, 2002).  When IRAK1 is recruited to the receptor complex it is in 
association with Tollip.  Hyperphosphorylation of IRAK1 following its recruitment 
leads to its dissociation from Tollip and interaction with downstream signalling 
protein TRAF6 (Takeda and Akira, 2004).  IRAK1 also phosphorylates Tollip which 
may facilitate its dissociation from IRAK1 (Zhang and Ghosh, 2002).  IRAK1 and 
Tollip are both targets for the ubiquitin ligase machinery of the cell and following 
ubiquitination they are subsequently degraded in the proteosome and their dissociation 
may facilitate this process (Zhang and Ghosh, 2002). The N-terminal of Tollip has a 
C2 domain which mediates its interaction with products of phosphotidylinositol-3 
kinase (PI3K), phosphotidylinositol-3-phosphate and phosphotidylinositol-3,4,5-
phosphate, and this interaction appears to be important for its negative regulatory role 
in TLR-signalling (Li et al., 2004).  Tollip is also required for efficient degradation of 
IL-1R by trafficking it to late endosomes (Brissoni et al., 2006).  Interestingly, 
however, Tollip-deficient mice showed no enhancement of IL-1β- or LPS-mediated 
NF-κB or MAPK activation (Didierlaurant et al., 2006).  Furthermore, the production 
of cytokines IL-6 and TNFα by these mice was reduced compared to wildtype mice 
following stimulation with IL-1β and low doses of LPS (Didierlaurant et al., 2006). So 
it appears the situation is more complex than originally thought and Tollip may 
regulate the extent of cytokine production following TLR and IL-1R activation. 
 The suppression of cytokine signalling (SOCS) family consists of eight family 
members which all possess  a central Src homology 2 (SH2) domain which binds to 
phosphotyrosine motifs, a variable N-terminal domain and a conserved C-terminal 
domain known as the SOCS box (Piessevaux et al., 2008).  The SOCS box mediates 
the formation of complexes that function as E3 ubiquitin ligases, through association 
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with other proteins such as Elongin C and Cullin-2 (Piessevaux et al., 2008).  SOCS1 
and SOCS3 possess an additional kinase inhibitory region (KIR) in their N-terminus 
(Dalpke et al., 2008).  SOCS proteins are induced by cytokines and inhibit Jak/STAT 
signalling pathways that are employed by cytokine receptors.  SOCS are also induced 
by TLR4 and TLR9 ligands LPS and CpG DNA (Dalpke et al., 2008).  SOCS1 
interacts with phosphorylated Mal, leading to its ubiquitination and subsequent 
degradation and inhibition of TLR2 and TLR4 signalling to NF-κB (Mansell et al., 
2006).  SOCS1 has also been implicated in the ubiquitination and proteosomal 
degredation of p65-containing NF-κB dimers (Ryo et al., 2003).  Furthermore, 
overexpression of SOCS1 inhibits the phosphorylation of STAT1 which is involved in 
Type-1 IFN signalling (Baetz et al., 2004).  SOCS1, therefore, indirectly down-
regulates TLR-mediated IFNα/β production.   
The zinc finger protein A20 was identified as the product of a gene that is 
rapidly induced following TNF-α stimulation (Opipari et al., 1990).  The gene coding 
for A20 was found to be up-regulated by NF-κB (Krikos et al., 1992).  A20-deficient 
mice show increased production of inflammatory cytokines in response to TNFα and 
LPS (Boone et al., 2004).  A20 also appears to confer some resistance to septic shock 
(Boone et al., 2004).  Furthermore, A20 is phosphorylated and activated by the IKK 
complex subunit IKKβ indicating a negative feedback loop to terminate NF-κB 
signalling (Hutti et al., 2007).  The N-terminal region of A20 contains a de-
ubiquitinating domain while the C-terminus acts as an ubiquitin ligase (Wertz et al., 
2004).  A20 cleaves K63 linked polyubiquitin chains from TRAF6 thus inhibiting the 
downstream activation of TAK1 and subsequent NF-κB activation (Boone et al., 
2004).  Similarly, A20 cleaves K63 linked ubiquitin chains from RIP1. A20 then 
catalyses K48-linked polyubiquitination which leads to subsequent proteosomal 
degradation of RIP1 (Wertz et al., 2004).  Furthermore A20 interacts with TBK1 and 
IKK-i and inhibits phosphorylation and activation of IRF3 (Saitoh et al., 2005).   
These negative regulators, along with others, regulate the signalling pathways 
leading to transcription factor translocation to the nucleus.  However, these 
transcription factors can also be regulated at a nuclear level. 
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1.5.4 Nuclear regulators of TLR-signalling 
 
The transcriptional activity of NF-κB is regulated by transcriptional co-
activators and transcriptional co-repressors.  The transcriptional activators include 
p300/CBP, p106 proteins (steroid receptor-co-activator- (SRC)-1-3) and p300/CBP-
associated factor (p/CAF).  These co-activators are also important for the 
transactivation of nuclear receptors.  p300/CBP and p106 proteins both have intrinsic 
histone acetylase (HAT) activity which is necessary for histone acetylation-dependent 
chromatin remodelling to allow for gene transcription (Rosenfeld and Glass, 2001).  
p106 proteins, however, display less HAT activity in the absence of p300/CBP.  The 
NF-κB subunit p65 is phosphorylated by Protein Kinase A (PKA) which facilitates its 
interaction with p300/CBP (Zhong et al., 1998).  Furthermore, p65 is acetylated by 
p300/CBP and p/CAF which is essential for full transcriptional activity of NF-κB and 
also decreases the binding ability of IκBα (Chen and Greene, 2002). NF-κB co-
repressors include Histone Deacetylase (HDAC)-1, HDAC2 and HDAC-3.  The 
HDACs de-acetylate p65 which represses its DNA binding activity and increases its 
affinity for  IκBα. (Ashburner et al., 2001, Chen et al., 2001).  HDACs also de-
acetylate histone proteins and return them to their previous basal state which represses 
gene transcription (Barns et al., 2005).  
NF-κB repressor factor (NRF) is a nuclear protein which binds to negative 
regulatory elements (NRE)s  in the IFNβ-promoter and mediates constitutive silencing 
of IFNβ (Nourbakhsh and Hauser, 1999).  The activation of the IFNβ transcription 
enhanceosome overcomes this repression, although NRF remains bound to DNA 
(Nourbakshs et al., 2000).  NRF interacts directly with NF-κB and is therefore known 
as an active gene repressor.  The promoter region for iNOS also has a NRE and NRF 
inhibits both basal and cytokine induced iNOS gene expression (Feng et al., 2002).  
Similarly, the promoter region for IL-8 encodes a NRE.  Suppression of endogenous 
NRF leads to spontaneous transcription of IL-8 in the absence of a stimulus 
(Nourbakshs et al., 2001).  Conversely, mutation of the NRE prevents IL-1β-mediated 
IL-8 expression (Nourbakshs et al., 2001).  This suggests a dual role for NRF where   
it inhibits basal IL-8 production but co-operates in IL-8 transcription following 
treatment with a pro-inflammatory stimulus.  Furthermore, disruption of the NF-
κB/NRF interaction, with a synthetic peptide that targets the Rel binding central 
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domain of NRF, decreased the expression of IL-8 in response to bacterial infection 
(Bartels et al., 2007).    
 A range of other proteins also regulate transcription factors in the nucleus.  
Glycogen synthase kinase (GSK)3-β affects the DNA-binding activity of p65 and is 
required for efficient expression of some NF-κB regulated genes (Steinbrecher et al., 
2005).  Prior to gene transcription the pre-initiation complex (PIC) assembles on the 
promoter region with RNA Polymerase II, which is subsequently phosphorylated.  
The glucocorticoid receptor (GR) inhibits NF-κB regulated gene transcription by 
interfering with the phosphorylation of RNA Pol II (Nissen and Yamamoto, 2000). 
PRDI-BF1 is a viral inducible protein that binds to PRD1 of the IFNβ -promoter and 
represses IFNβ expression (Keller and Maniatis, 1991).  PRD1-BF1 recruits histone 
H3 methyltransferase G9a to the promoter which mediates chromatin remodelling and 
gene silencing (Gyory et al., 2004).  Furthermore, nuclear IκB proteins regulate the 
transactivation of NF-κB  (Yamamoto and Takeda, 2008). 
 
1.6 Drosophila Toll  
 
The Toll transmembrane receptor was first identified in Drosophila Melanogaster as a 
protein essential for dorso-ventral patterning in embryo development (Hashimoto et 
al., 1988).  It was subsequently shown to play a critical role in the immune response to 
Aspergillus fumigatus in Drosophila (Lemaitre et al., 1996).  This led to the discovery 
of the human Toll receptor, now known as TLR4 (Medzhitov et al., 1997).  There are 
three NF-κB/Rel proteins in Drosophila, dorsal, dorsal-related immunity factor (DIF) 
and Relish which regulate the expression of genes encoding immune-response 
peptides and proteins (Hetru and Hoffmann, 2009). Dorsal and DIF are homologous to 
c-Rel, p65 and RelB and are found in association with inhibitory Cactus, which is 
most similar to IκBα (Huguet et al., 1997).  Dif is important in immunity while dorsal 
plays an essential role in development (Hultmark, 2003).  Relish has an N-terminal 
RH domain and C-terminal ankyrin repeats and is homologous to mammalian p100 
and p105 precursor proteins (Hultmark, 2003).  Two signalling pathways are 
responsible for the activation of these Rel/NF-κB transcription factors, the toll 
pathway and the immune deficiency (Imd) pathway (Figure 1.3).  The Toll pathway is 
generally activated in response to gram positive bacteria and fungal pathogens while 
the Imd pathway is activated in response to gram negative bacterial  
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Figure 1.3 Drosophila Toll and Imd pathways  
The presence of gram positive bacteria or fungal pathogens initiates a proteolytic 
cascade resulting in the cleavage of pro-Spaetzle.  Cleaved Spaetzle binds and 
activates Toll leading to the recruitment of the dMyD88/Tube complex. This recruits 
Pelle which is subsequently activated.  This triggers downstream phosphorylation of 
Cactus by an unknown kinase and its ubiquitin-dependent proteosomal degradation.  
Free Dif then translocates to the nucleus and up-regulates the expression of 
antimicrobial peptides.  PGN binds directly to the PGRP-LC leading to the 
recruitment of Imd.  This triggers the recruitment of FADD and DREDD which cleave 
Imd revealing a IAP association domain.  Interaction of Imd with dIAP2 catalyses the 
K63-linked polyubiquitination of Imd.  This leads to downstream activation of TAK1 
which phosphorylates dJNK and the dIKK complex.  The dIKK complex 
phosphorylates Relish which is subsequently cleaved to release its C-terminal ankyrin 
repeats.  The N-terminal region of Relish translocates to the nucleus and up-regulates 
the expression of anti-microbial peptides.  dJNK activates dAP-1 which can regulate 
the transcription of immune-related genes. 
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infection (Hetru and Hoffmann, 2009).  There are striking similarities in these signal 
transduction pathways and mammalian TLR-signalling pathways and they contain 
many homologous signalling intermediates.  For this reason, Drosophila has proved to 
be a useful model organism for studying innate immune signalling pathways. 
 
 1.6.1 The Toll signalling pathway  
  
 The Toll signalling pathway is activated by peptidoglycan (PGN) found in the 
cell walls of gram positive bacteria and fungal β-(1,3)-glucan (Michel et al., 2001).  
These ligands are not recognised directly by the Toll receptor but instead are sensed 
by secreted peptidoglycan recognition proteins (PGRPs) and β-glucan recognition 
protein (GNBP) which initiate proteolytic cascades resulting in the cleavage of the 
cytokine Spaetzle.  Cleaved Spaetzle binds to the Toll receptor which triggers Toll 
dimerization, initiating the intracellular signalling cascade (Weber et al., 2003).  Like 
TLRs, Toll receptors have extracellular LRRs and an intracellular TIR domain.  
Dimerization of Toll creates a platform for the recruitment of intracellular signalling 
adaptors.  Drosophila MyD88 (dMyD88) is recruited to the receptor via interaction 
with its TIR domain (Horng and Medzhitov, 2001).  When dMyD88 is recruited to the 
receptor it is in association with Tube.  Tube and MyD88 interact through homotypic 
associations of their DDs.  Tube then recruits Pelle to the complex, again through 
association of DDs (Sun et al., 2002).  Pelle is the Drosophila orthologue of IRAK 
and is a protein kinase. Recruitment of Pelle to the receptor complex triggers its 
activation.  This leads to subsequent phosphorylation of Cactus by an unknown kinase 
leading to its ubiquitinination and proteosomal degradation (Belvin and Anderson, 
1995).  The freed transcription factor, Dif, then translocates to the nucleus and 
regulates gene expression (Bergmann et al., 1996).  Dif activates the transcription of 
genes encoding antimicrobial peptides such as Defensin, Drosomycin, Cecropin and 
Metchnikowin (Aggarwal and Silverman, 2008). 
 
1.6.2 The Imd signalling pathway  
 
The Imd signalling pathway is triggered in response to gram negative bacteria 
and results in the activation of Relish.  Gram negative bacterial PGN binds directly to 
a transmembrane receptor PGRP-LC which has an extracellular PGN recognition 
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domain and intracellular signalling domain (Kaneko et al., 2005).  Upon ligand 
binding PGRP-LC recruits the death domain containing adaptor protein, Imd, to the 
receptor (Georgel et al., 2001).  This protein is similar to mammalian RIP1.  Imd then 
recruits Drosophila Fas associating protein with a DD (dFADD) (Naitza et al., 2002), 
which in turn recruits the Drosophila Caspase-8 homologue, Death related ced-
3/Nedd2-like protein DREDD (Leulier et al., 2000).  This triggers dFADD- and 
DREDD-dependent cleavage of Imd which reveals a highly conserved IAP binding 
motif (IBM) which binds Drosophila inhibitor of apoptosis protein 2 (dIAP2) 
(Paquette et al., 2010).  Cleaved Imd is then rapidly K63-ubiquitinated.  dIAP is a 
RING finger protein which most likely functions as an E3 ligase in this process.  
Notably, Ubc13 and Uev1A are also likely to be involved (Paquette et al., 2010).  This 
then leads to subsequent activation of TAK1.  TAK1 is found in association with the 
homologue of mammalian TAB2 which binds to K63-linked polyubiquitin chains 
(Kleino et al., 2005).  TAK1 activation triggers downstream activation of relish and 
JNK (Zhuang et al., 2006).  Activation of dJNK leads to subsequent activation of 
dAP1.  Relish activation requires the IKK complex which is made up of Drosophila 
homologues of IKKβ and IKKγ (Silverman et al., 2000, Rutschmann et al., 2000).  
Activated IKK phosphorylates Relish on key serine residues.  This results in the 
proteosomal-independent processing of Relish into an active transcription factor.  This 
requires cleavage of Relish after which the N-terminal region translocates to the 
nucleus and regulates gene expression.  This process is likely to require DREDD 
(Hetru and Hoffman, 2009).  Relish up-regulates the expression of genes encoding 
antimicrobial peptides such as Diptericins, Cecropins, Drosocin and Attacins 
(Hoffmann and Reichhart 2002).    
 
1.7   Cactin 
 
In 2000 Lin et al. used Cactus as bait in a yeast two hybrid screen and 
identified a novel Cactus-interacting protein termed Cactin.  They overexpressed 
dCactin in a sensitised Cactus background.  These Cactus
A2 
heterozygous flies display 
a weak ventralizing phenotype.  Interestingly, dCactin enhanced this weak 
ventralizing phenotype and increased embryonic lethality (Lin et al., 2000).  This 
suggested that dCactin may affect the stability of Cactus, leading to increased 
degradation of Cactus and increased nuclear translocation of Dorsal (Lin et al., 2000).  
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Cactus is also found in association with Dif which is an important component of 
innate immune signalling in Drosophila.  Due to the similarities observed between the 
Drosophila Toll signalling and TLR signalling cascades it was proposed that the 
human homologue of Cactin may have a similar role in TLR-signalling pathways and 
may target IκBα.  For this reason the human homologue of Cactin was cloned in our 
laboratory.  Interestingly, it appears that the function of Cactin is different than that of 
its Drosophila counterpart.  While dCactin appears to positively regulate the nuclear 
targeting of Dorsal, early studies in our laboratory indicated that hCactin negatively 
regulates the activation of NF-κB and IRFs. Given the importance of negative 
regulators in tempering these pathways to prevent hyperinflammatory responses, this 
thesis explored the modulatory potential of hCactin in innate immune signalling 
pathways.    
 
1.8 Aims of the project  
 
The overall objectives of this study were to: 
 
 Confirm that Cactin is a negative regulator of NF-κB, IRF3 and IRF7 and 
characterise the underlying mechanism(s)  
 
 Determine if Cactin is regulated by TLR-ligands or pro-inflammatory stimuli 
 
 Determine the role of Cactin in MAPK activation 
 
 Identify Cactin-interacting proteins in an attempt to further clarify the  
molecular mechanism(s) underlying the regulatory effects of Cactin. 
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Chapter 2 
 
 
 
Materials and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1 Materials 
 
2.1.1 Reagents 
 
Reagent       Supplier 
Agar        Sigma 
Agarose        Promega 
Agarose, low melting point     Sigma 
Alexa488       Invitrogen 
Alexa594       Invitrogen 
Ampicillin       Sigma 
Antibodies (monoclonal) against human- 
  -Actin                Sigma 
  FLAG M2                  Sigma 
  HA.11      Covance 
                        Myc-Tag (9B11)               Cell Signaling  
  Myc-Tag (71D10)    Cell Signaling                                              
Antibodies (polyclonal) against human- 
   ASCC1     Sigma 
                         C23 (Nucleolin)                                             Santa Cruz 
   ERK1/2     Cell Signaling 
   GFP      Santa Cruz 
   Phospho-ERK1/2    Cell Signaling  
   JNK      Cell Signaling 
   Phospho-JNK     Cell Signaling 
 IRF3      Cell Signaling  
                         Phospho-IRF-3                                              Cell Signaling 
                         IκBα                                                               Santa Cruz 
   Phospho-serine               Abcam 
   p38      Cell signaling 
   phospho-p38     Cell signaling  
   p65 (C-20)     Santa Cruz 
   p65      Cell Signaling 
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    phospho-p65     Cell Signaling 
  TBK1      Cell Signaling  
  Phospho-TBK1     BD    
APS        Sigma 
ASCC1 cDNA clone in CMV expression vector  OriGene    
Blasticidin S       InVivo 
Boric Acid       Sigma 
Bovine serum albumin     Sigma 
Bradford reagent dye      Bio-Rad 
Bromophenol blue       Sigma 
Chamber slides       Nunc 
Chloroform                                                                             Sigma 
Chloroquine       Sigma 
CIP         New England Biolabs 
Coelenterazine      Insight Biotech. 
DEPC-treated water      Ambion 
DMEM       Invitrogen 
DMSO        Sigma 
DNA ladder (1Kb) & Loading dye (6X)   Promega 
dNTPs        Promega 
DTT        Sigma 
E.coli - TOP 10 competent cells    Invitrogen 
EDTA        Sigma 
EMSA buffer kit      Licor Biosciences 
Ethanol                                                                                   Sigma 
Ethidium bromide      Sigma 
FBS        Invitrogen 
Glacial acetic acid      Merck 
Glycerol       Sigma 
Glycine       Sigma 
Goat Serum       Vector Laboratories 
GoTaq Flexi DNA Polymerase    Promega 
High speed plasmid midi kit     Qiagen 
HEPES       Sigma 
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Hoescht stain       Sigma 
Human HEK 293 cell line                                                 InVivo  
Hydrochloric acid      Merck 
Hygrogold       InVivo 
Igepal                                                                                      Sigma 
IL-1β (human)      Cell signaling 
IRDye 800CW Goat Anti-Rabbit                                           Licor Biosciences 
IRDye 680 Donkey Anti-Mouse                                             Licor Biosciences 
Isopropanol         Sigma 
Kanamycin        Sigma 
L-glutamine        Invitrogen 
Lipofectamine 2000       Invitrogen 
Lipopolysaccharide       Alexis 
Luciferase substrate       Promega 
Lymphoprep        Axis-Shield 
Magnesium Chloride       Sigma 
-Mercaptoethanol      Sigma 
Methanol        BDH 
Microlon 96-well plates      Greiner 
MMLV Reverse Transcriptase     Promega 
Morpholinos                                                                            Gene Tools 
Nitrocellulose        Schleicher&Schuell 
NF-κB IRDye Labelled Oligonucleotides     Licor Biosciences 
OptiMEM                                                                                Invitrogen 
PAK1IP1-HA        Genescript 
Paraformaldehyde        Sigma 
Para-p-phenylendiamine      Sigma 
PBS         Oxoid 
pcDNA 3.1/Zeo       Invitrogen 
Penicillin / Streptomycin / Glutamine    Invitrogen 
PMSF         Sigma 
Poly(I:C)        InVivo   
Polybrene                                                                                 Sigma 
31 
Poly-L-Lysine       Sigma 
Ponceau        Sigma 
Prestained molecular weight marker     Fermentas 
Protease inhibitor mixture     Roche 
Protease inhibitor mixture (EDTA free)    Roche 
Protein A/G-agarose      Santa Cruz 
Proteinase K                                                                           Sigma 
Protogel                  National Diagnostics 
Puromycin                                                                              Sigma 
QIAquick gel extraction kit     Qiagen 
Random primers      Invitrogen 
Reverse Transcription System                                                Promega 
RNase Zap       Ambion 
RPMI                  Invitrogen 
SB203580       Cell Signaling 
SDS        Sigma 
shRNA       Sigma 
siRNA                    Invitrogen 
Scrambled siRNA      Invitrogen 
Skim milk powder      Marvel 
Sodium chloride (NaCl)     Sigma 
Sodium Deoxycholate (C24H39O4Na)    Sigma 
Sodium hydroxide (NaOH)     Sigma 
Sodium orthovanadate (Na3VO4)    Sigma 
Sulphuric acid       Sigma 
SensiMix SYBR Low-ROX-kit    Bioline 
Synthetic oligonucleotides     MWG Biotech 
TEMED       Sigma 
Tissue culture ware      Greiner 
TK Renilla       Promega 
Tri reagent                                                                              Sigma 
Tris-base       Sigma 
Tris-HCl       Sigma 
Triton-X       Sigma 
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Trypsin/EDTA      Invitrogen 
Tryptone       DIFCO 
Tween-20       Sigma 
Vectashield       Vector Laboratories 
Whatmann paper                                       AGB  
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2.1.2 Gifts 
 
Cell lines: 
 HEK293 cells and HEK293 stably expressing TLR3 or TLR4 - Prof. Douglas 
T. Golenbock (The University of Massachusetts Medical School, Worcester, 
Massachusetts 01605, USA). 
 THP-1 cell line – Prof. Catherine Godson (School of Medicine and Medical 
Science, Conway Institute, UCD, Dublin, Ireland). 
 U373 cell line – Dr. Sinead Miggin (Biology Department, NUI Maynooth, 
Ireland). 
 
Constructs: 
 Flag-tagged pFLAG-CMV2-TRIF. IRF-3/7 Gal4 reporter constructs, IFN-β-
luciferase reporter constructs – Dr. Kate Fitzgerald (The University of Massachusetts 
Medical School, Worcestor, Massachusetts 01605, USA) 
 Flag-tagged  MyD88 – Dr M. Muzio (Mario Negri Institute, Milan, Italy) 
 IRF3-Flag,– Dr. Marion Butler (National University of Ireland, Maynooth) 
 pFR-luciferase Gal4 reporter construct – Dr. Andrew Bowie (Trinity College 
Dublin, Ireland) 
 NF-B-luciferase reporter construct – Prof. Luke O’Neill (Trinity College 
Dublin, Ireland) 
 GFP-tagged IκBL – Dr. Ross McManus (Trinity College Dublin, Ireland) 
 PRDI-III-, PRDII- and PRDIV-luciferase reporter constructs - Dr. Sinead 
Miggin (Biology department, NUI Maynooth, Ireland) 
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2.2 Methods 
 
2.2.1  Mammalian cell culture 
 
     2.2.1.1  HEK 293 and U373 adherent cell lines  
 
 The human embryonic kidney (HEK) 293 cells that stably express the TLR3 
and TLR4 receptors and U373 cells were maintained in Dulbecco’s Modified Eagle 
Medium (DMEM), which was supplemented with 10 % (v/v) foetal bovine serum 
(FBS), 100 U/ml penicillin and 100 g/ml streptomycin. Cells were maintained in a 
37ºC humidified atmosphere with 5 % CO2. Cells were passaged every 2 to 3 days 
using 1 % (w/v) Trypsin/ethylenediaminetetraacetic acid (EDTA) solution in 
phosphate-buffered saline (PBS). G418 (500 g/ml), blasticidin (100 μg/ml) and/or 
hygrogold (10 μg/ml) was used to select for the stably transfected TLR cell lines. 
HEK293 T (for SV40 large T antigen) cells were also used. This cell line was cultured 
in the same conditions as above in the absence of a selective agent. 
 
  2.2.1.2  THP-1 suspension cells 
 
 THP-1 suspension cells were grown in Roswell Park Memorial Institute 
(RPMI) medium supplemented with 2 mM L-Glutamine,  10 % (v/v) FBS, penicillin 
(100 U/ml) and streptomycin (100 μg/ml). Cells were maintained at 37ºC in a 
humidified atmosphere with 5 % CO2. Cells were passaged every 3-4 days. 
 
 
2.2.2  Transient transfection of mammalian HEK293 cells 
 
2.2.2.1  Transfection of cells for luciferase reporter assay  
 
 HEK293-TLR3 and -TLR4 cells were seeded at 1.5 x 10
5 cells/ml (200 μl 
DMEM/well) in 96-well plates and allowed to adhere for 24 h to approximately 60 % 
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confluency. Cells were transfected using Lipofectamine 2000. For each well to be 
transfected, 25 l of OptiMEM (Invitrogen) was mixed with the DNA. DNA mixes 
were made up for the appropriate luciferase construct as outlined in section 2.2.4. 
Lipofectamine 2000 (0.4 μl) was diluted in OptiMEM (25 l) per sample and the 
reaction was mixed gently and left at room temperature for 5 min. After incubation, 
the Lipofectamine/OptiMEM solution was added to the DNA/OptiMEM mix (total 
volume 50 l per well to be transfected) and the combined reaction was mixed gently 
and incubated at room temperature for 20 min. The transfection mixture was then 
added to each well and mixed gently by tapping the side of the plate. Each 
experimental condition was represented in triplicate. Cell lysates were generated and 
used to measure luciferase activity. 
 
2.2.2.2   Transfection of cells for Western blot analysis 
 
 HEK293 T, TLR3 or TLR4 cells were seeded at 1.5 x 10
5 
cells/ml in 6-well 
plates (3 ml DMEM/well). Cells were grown for 24 h to approximately 60 % 
confluency. For each well of a 6-well plate to be transfected, DNA (2 g) was diluted 
in OptiMEM (250 l) (Invitrogen) and mixed gently. Lipofectamine 2000 (4 l) was 
then diluted in OptiMEM (250 l) and incubated at room temperature. After 5 min 
incubation, the diluted DNA was combined with the diluted Lipofectamine 2000, 
mixed gently, and incubated at room temperature for 20 min. Medium (1 ml) was 
removed from each well before adding the DNA-Lipofectamine complexes (500 l). 
For co-immunoprecipitation experiments, constructs encoding potential interacting 
partners were transfected at a ratio 1:1. After 24 h, cell lysates were generated for co-
immunoprecipitation studies (section 2.2.7). Lysates were analysed using SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting (section 2.2.8) 
 
   
2.2.2.3 Transfection of cells for ChIP analysis 
 
HEK293 TLR4 cells were seeded at 3.5 x 10
5 
cells/ml in 10 cm petri dishes (10 
ml DMEM/dish). Cells were grown for 24 h to approximately 60 % confluency. For 
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each dish to be transfected, DNA (8 g) was diluted in OptiMEM (1 ml) (Invitrogen) 
and mixed gently. Lipofectamine 2000 (8 l) was then diluted in OptiMEM (1 ml) and 
incubated at room temperature. After 5 min incubation, the diluted DNA was 
combined with the diluted Lipofectamine 2000, mixed gently, and incubated at room 
temperature for 20 min. Medium (2 ml) was removed from each dish before adding 
the DNA-Lipofectamine complexes (2 ml). After 24 h, cells were crosslinked and 
lysates were generated for ChIP analysis (section 2.2.11.1) 
 
 
2.2.3  Propagation of DNA 
 
 2.2.3.1 Rapid transformation of competent E.coli cells 
 
 Commercially available TOP 10 competent E.coli bacterial cells were used for 
propagation of plasmids of interest.  Aliquots (1 μl) of plasmids (100 ng DNA) were 
added to TOP10 cells (5 μl). DNA was mixed gently with cells by pipetting gently up 
and down and then incubated on ice for 30 min. The plasmids were allowed to enter 
the bacterial cells by heat shocking the mixture at 42
 o
C for 45 seconds. The cells 
become permeable to allow easy entry of the plasmid. Samples were subsequently  
cooled on ice for 2 min making the cells once again impermeable. The transformed 
cells were then incubated in 1 ml Luria Bertoni (LB) broth (1 % (w/v) tryptone, 0.5 % 
(w/v) yeast extract, 85 mM NaCl) at 37
 o
C on a shaker at 220 rpm for 1 h. Bacterial 
cells were centrifuged at 9000 rpm for 3 min and 850 μl supernatant was removed. 
The pellet was resuspended in the remaining LB broth and plated out onto LB agar 
plates (LB broth with 1.5 % (w/v) agar) containing ampicillin or kanamycin (both 50 
μg/ml) depending on the antibiotic resistance of the plasmid of interest. Plates were 
inverted and incubated overnight at 37
 o
C. Plates were then stored at 4
 o
C. 
 
2.2.3.2  Large scale preparation of DNA from E. coli 
 
 A starter culture of LB broth (2 ml) containing the relevant antibiotic (50 
μg/ml) was inoculated with a single transformed E.coli colony and incubated at 37oC  
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Figure 2.1 Cactin construct 
The Cactin-c-myc construct used for transient expression of Cactin in HEK293 cells.  
The expression vector pcDNA3.1 encodes an ampicillin resistence gene used for 
selection of transformed bacterial cells. 
 
 
 
 
 
 
 
 
 
Cactin
pCMV
ampr
pcDNA3.1
myc
with shaking at 220 rpm for 6-8 h. This was then added to a larger volume of LB broth 
(100 ml) containing the relevant antibiotic and incubated at 37
o
C overnight shaking at 
220 rpm. Large plasmid preparations were made using the Qiagen high speed plasmid 
midi kit. The bacterial cells were centrifuged at 3000 rpm for 40 min and the 
supernatant was discarded and the plasmid DNA was extracted as outlined in the 
manufacturer’s handbook. DNA was quantified using a cary spectrophotometer. After 
diluting the DNA appropriately in Tris-EDTA (TE) buffer, pH 8.0, (10 mM Tris-HCl, 
1 mM EDTA) the absorbance of the solution was measured at 260 nm and 280 nm. 
All samples used had an optical density (OD)260/OD280 ratio in the range of 1.7 to 1.9. 
Ratios below 1.7 or above 1.9 indicated RNA or protein contamination, respectively. 
The concentration was calculated using the formula: 
 
  g/ml DNA = 50 g/ml/OD260 x (OD260 measured) x (dilution factor). 
 
 
2.2.4  Luciferase assays 
 
 HEK293 TLR3 and TLR4 cells were seeded at 1.5 x 10
5
 cells/ml in 96-well 
plates (200 l DMEM/well) and grown for 24 h. All transfections were performed 
using Lipofectamine 2000 transfection reagents (as described in section 2.2.2.1). 
Details of the constructs transfected are given below. 24 h post-transfection, the 
medium was removed from the cells and reporter lysis buffer (100 l, Promega) was 
added to each well using a multi-channel pipette. The plate was then wrapped in 
aluminium foil and placed on a rocker for 30 min at room temperature before being 
placed at -80
o
C for a minimum of 1 h. After thawing at room temperature, aliquots (40 
l) of each were assayed for firefly luciferase activity using firefly luciferase substrate 
(40 l, Promega), while Renilla luciferase activity was assayed using coelenterazine 
(0.1 g/ml in 40 l PBS). Luminescence was monitored with a Glomax microplate 
luminometer (Promega). 
 
 
 
38 
2.2.4.1 NF-κB assay 
 
 To measure activation of the NF-κB pathway, cells were transfected with NF-
κB-regulated firefly luciferase reporter plasmid (80 ng), constitutively expressed 
Renilla-luciferase reporter construct phRL-TK (20 ng) and varying amounts of 
expression constructs (detailed in figure legends). The total amount of DNA was 
equalised using pcDNA3.1. 
 
2.2.4.2 IFN assays 
 
 The activation of the IFN- promoter was assessed by transfecting the cells 
with an IFN-promoter-regulated luciferase construct (80 ng), IFNα promoter-
regulated luciferase construct (80 ng), PRDI-III-regulated luciferase construct (80 ng), 
PRDII-regulated luciferase construct (80 ng) or PRDIV-regulated luciferase construct 
(80 ng) and phRL-TK (20 ng) and varying amounts of expression constructs (detailed 
in figure legends). The total DNA concentration was equalised using pcDNA3.1. 
  
2.2.4.3 IRF3 assay 
 
 To measure the activation of IRF3, cells were transfected with pFR-Luc (60 
ng), the trans-activator plasmid pFA-IRF3 (IRF3 fused downstream of the yeast Gal4 
DNA binding domain, 30 ng), phRL-TK (20 ng) and varying amounts of expression 
constructs (detailed in figure legends). The total DNA concentration was equalised 
using pcDNA3.1.   
 
2.2.4.4 IRF7 assay 
 
 To measure the activation of IRF7, cells were transfected with pFR-Luc (60 
ng), the trans-activator plasmid pFA-IRF7 (IRF7 fused downstream of the yeast Gal4 
DNA binding domain, 25 ng), phRL-TK (20 ng) and varying amounts of expression 
constructs (detailed in figure legends). The total DNA concentration was equalised 
using the pcDNA3.1.  
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2.2.4.5 c-Jun assay 
 
 To measure the activation of c-Jun, cells were transfected with pFR-Luc (60 
ng), the trans-activator plasmid pFA-Jun (activation domain of c-Jun fused 
downstream of the yeast Gal4 DNA binding domain, 30 ng), phRL-TK (20 ng) and 
varying amounts of expression constructs (detailed in figure legends). The total DNA 
concentration was equalised using the pcDNA3.1. 
 
 
2.2.5 siRNA studies 
 
 Pre-designed siRNA targeting Cactin was purchased from Invitrogen (sense 
sequence: 5' – UCUUGAAGUGCUCUGCCUCCUUCUC -3') and a corresponding 
scrambled siRNA was designed (sense sequence 5' – 
GAGAAGGAGGCAGAGCACUUCAAGA - 3') and purchased from Invitrogen. 
 
2.2.5.1 Transfection of siRNA  
 
 HEK293 TLR3 cells were seeded at 1.5 x 10
5 
cells/ml in 6-well plates (3 ml 
DMEM/well). Cells were grown for 24 h to approximately 60 % confluency.  The 
appropriate amount of Cactin siRNA or scrambled siRNA (for a final concentration of 
25 nM/well) was diluted in OptiMEM (250 μl). Lipofectamine 2000 (4 μl) was diluted 
in OptiMEM (250 μl) per sample, and the reaction was mixed gently and left at room 
temperature for 5 min. After the incubation, the Lipofectamine/OptiMEM solution 
was added to the siRNA mix (total volume 500 l per well to be transfected) and the 
combined reaction was mixed gently and incubated at room temperature for 20 min. 
500 l sample was added to each well and mixed gently by rocking the plate back and 
forth. Cells were incubated for 48 h prior to generation of extracts for Western 
immunoblotting (2.2.8) or extraction of RNA for quantitative real-time PCR (2.2.9). 
 
 
 
40 
2.2.6 shRNA studies 
 
Cactin-specific shRNA 5’- AGGTCAGATTCAGAGGAAGAG -3’,  
IκBL-specific shRNA   
5’CCGGGCCTCCCATGAAACCCAGGAACTCGAGTTCCTGGGTTTCATGGGA
GGCTTTTTG – 3’ and a control shRNA (CT) were purchased from Sigma. The 
shRNA CT  is a non-targeting shRNA vector that will activate the RNA-induced 
silencing complex (RISC) and the RNAi pathway, but it does not target any human or 
mouse genes. The short-hairpin sequence contains 5 base pair mismatches to any 
known human or mouse gene. (See Fig. 2.2 for the map of the plasmid). 
 
2.2.6.1 Transfection of shRNA for luciferase assays 
 
 HEK293 TLR3 or TLR4 cells were seeded at 1.5 x 10
5
 cells/ml in 96-well 
plates (200 μl DMEM/well). Cells were grown for 24 h to approximately 60 % 
confluency. DNA mixes were made up for the appropriate luciferase construct as 
outlined in section 2.2.4. Cactin-specific shRNA (100 ng), IκBL-specific shRNA (100 
ng) or shRNA CT (100 ng) was added to the DNA mix which was subsequently 
diluted in OptiMEM (25 μl) and mixed gently. Lipofectamine 2000 (0.4 μl) was 
diluted in OptiMEM (25 μl) per sample, and the reaction mixed gently and left at 
room temperature for 5 min. After the incubation, the Lipofectamine/OptiMEM 
solution was added to the DNA mix (total volume 50 l per well to be transfected) 
and the combined reaction mixed gently and incubated at room temperature for 20 
min. Sample (50 l) was added to each well and mixed gently by tapping the side of 
the plate. Cells were harvested 48 h post-transfection. 
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Figure 2.2 shRNA Lentiviral Vector map. 
The pLKO.1-puro lentiviral plasmid vector contains the ampicillin and puromycin 
antibiotic resistence genes for selection of inserts in bacterial or mammalian cells 
respectively. 
 
 
 
 
 
2.2.6.2 Transfection of shRNA for expression analysis or 
Western immunoblotting 
 
 HEK293 TLR4 cells were seeded at 1.5 x 10
5 
cells/ml in 6-well plates (3 ml 
DMEM/well). Cells were grown for 24 h to approximately 60 % confluency. Cactin-
specific shRNA (1 μg), IκBL-specific shRNA (1 μg) and shRNA CT (1 μg) was 
diluted in OptiMEM (250 μl). Lipofectamine 2000 (4 μl) was diluted in OptiMEM 
(250 μl) per sample, and the reaction mixed gently and left at room temperature for 5 
min. After the incubation, the Lipofectamine/OptiMEM solution was added to the 
DNA mix (total volume 500 l per well to be transfected) and the combined reaction 
mixed gently and incubated at room temperature for 20 min. During this incubation 1 
ml of DMEM was removed from each well.  500 l sample was added to each well 
and mixed gently by rocking the plate back and forth.  Cells were incubated for 48 h 
prior to generation of extracts for Western immunoblotting (2.2.8) or extraction of 
RNA for quantitative real-time PCR (2.2.9). 
 
 
2.2.7 Co-immunoprecipitations (CoIPs) 
 
 HEK293 TLR4 cells were transfected with Lipofectamine 2000 as previously 
described in section 2.2.2.2 with equal amounts (2 μg) of expression constructs 
encoding the potential interaction partners. Cell extracts were generated on ice or at 
4
o
C as follows. Cells were first washed with pre-chilled 1X PBS (1 ml) then lysed 
with pre-chilled CoIP lysis buffer (50 mM Tris-HCl, pH 7.5, containing 150 mM 
NaCl, 0.5 % (v/v) igepal and 50 mM NaF, with 1 mM Na3VO4, 1 mM dithiothreitol 
(DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF) and protease inhibitor mixture 
(leupeptin (25 g/ml), aprotinin (25 g/ml), benzamidine (1 mM), trypsin inhibitor 
(10 g/ml)) for 30 min on a rocker at 4oC. Lysates were scraped into pre-chilled 1.5 
ml eppendorf tubes and centrifuged at 12,000 g for 10 min at 4
o
C. Supernatants were 
removed to fresh tubes (a sample retained for whole cell lysate analysis) and 
incubated for 30 min with mouse or rabbit immunoglobulin (Ig) G (1 μg) (depending 
on the primary antibody) and Protein A/G agarose beads (10 μl) on a rotator at 4 oC. 
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Samples were centrifuged at 1000 g for 5 min at 4
o
C to pellet beads with non-
specifically bound protein and supernatants were removed to fresh pre-chilled tubes. 
Samples were incubated overnight with primary antibody (1 μg). The following day 
Protein A/G agarose beads (20 μl) were added to each sample and they were again 
incubated at 4
o
C overnight. The subsequent day samples were centrifuged at 16,000 g 
for 1 min. The supernatant was removed and the beads were washed with CoIP lysis 
buffer (500 μl) and subject to re-centrifugation. This step was repeated four times. 40 
μl of 1X sample buffer (0.125 M Tris-HCl, pH 6.8, containing 20 % (w/v) glycerol, 4 
% (w/v) SDS, 1.4 M β-mercaptoethanol and 0.0025 % (w/v) bromophenol blue) was 
added to the beads for 30 min at RT. Samples were centrifuged at 16,000 g for 2 min 
and the supernatant was subsequently boiled at 100
o
C for 10 min and analyzed using 
SDS polyacrylamide gel electrophoresis and western blotting (section 2.2.8). 
 
 
2.2.8  Western blot analysis 
 
2.2.8.1 SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) 
 
 SDS-PAGE was conducted according to the method of Laemmli (Laemmli 
1970), as modified by Studier (Studier 1973). Samples and appropriate prestained 
(26.6-180 kDa) protein markers were loaded into separate wells. Electrophoresis was 
performed at 80 V through a 5 % SDS polyacrylamide stacking gel and then through a 
10 % SDS polyacrylamide resolving gel at 110 V for 1-1.5 h, depending on the size of 
the proteins being electrophoresed. 
 
2.2.8.2 Immunoblotting 
 
 Following separation by electrophoresis, the proteins were transferred 
electrophoretically to nitrocellulose membranes in a wet transfer unit at 150 V for 1.5 
h using Whatmann and nitrocellulose pre-soaked in cold transfer buffer (25 mM Tris 
Base, 0.2 M glycine and 20 % (v/v) methanol) for 10 min. Following transfer, non-
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specific binding was blocked by incubating the nitrocellulose membranes at room 
temperature for 1 h (or overnight) in TBS (20 mM Tris-HCl pH 7.5, containing 0.05 
% (v/v) Tween 20 and 0.5 M NaCl) containing 5 % (w/v) skimmed milk powder. The 
membranes were then washed 3 times for 5 min each in TBS prior to incubation at 
4
o
C overnight with the primary antibodies diluted in TBS containing 5 % (w/v) 
skimmed milk powder or BSA. The membranes were subsequently subjected to 5 x 10 
min washes in TBS prior to incubation with secondary antibody (1:5000 dilution) 
specific for the primary antibody in question (anti-rabbit or anti-mouse) in TBS 
containing 5 % (w/v) skimmed milk powder for 1.5 h in the dark at room temperature. 
The membranes were then washed a further 5 times for 10 min each in TBS in the 
dark. The immunoreactive bands were detected using Odyssey Infrared Imaging 
System from Licor Bioscience, according to the instructions of the manufacturer. 
 
1
o 
antibody   Dilution   2
o 
antibody* 
 
ASCC1    1:500     mouse 
-actin    1:5000     mouse 
c-Myc                1:1000     mouse 
Erk1/2    1:1000     rabbit 
Phospho Erk1/2  1:1000     rabbit 
Flag               1:1000     mouse 
GFP                                         1:500                                        rabbit 
HA    1:1000     mouse  
IκBα                                        1:500                                        rabbit 
JNK    1:1000     rabbit 
Phospho-JNK   1:1000     rabbit 
IRF-3                   1:1000                rabbit 
p38    1:1000     rabbit 
Phospho-p38   1:1000     rabbit 
Phospho-IRF-3                       1:1000                                      rabbit 
p65     1:1000     rabbit  
Phospho-p65   1:1000     rabbit 
Phospho-Serine  1:200     rabbit 
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Nucleolin (C23)                      1:500                                        rabbit 
TBK1    1:1000     rabbit 
Phospho-TBK1  1:250     rabbit 
 
 
* All secondary antibodies were used at a dilution of 1:5000.   
 
 
2.2.9  Isolation of RNA and cDNA synthesis 
 
2.2.9.1 Isolation of total RNA from HEK293, THP-1 and 
U373 cells  
 
 In order to minimise RNA degradation, a number of precautions were taken 
throughout the following procedures. All water and salt based solutions were treated 
with diethylpyrocarbonate (DEPC) (0.2 % v/v). All plasticware was certified RNase-
free. Before commencing, equipment was wiped with “RNase Zap”, an RNase 
decontamination solution. Gloves were worn at all times and regularly changed.  Total 
RNA was isolated using the Tri Reagent (Sigma) as per manufacturer’s instructions. 
The amount of isolated RNA was quantified by measuring the absorbance at 
wavelengths of 260 nm and 280 nm on a spectrophotometer, where an absorbance of 1 
unit at 260 nm is ~ 40 μg/ml.  Pure RNA preparations have an OD260/OD280 ratio of 
1.6-1.8.  Extracted RNA was stored at -80
o
C. 
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2.2.9.2 Synthesis of first strand cDNA from messenger RNA    
(mRNA) 
 
 1 g of RNA was placed in nuclease-free microcentrifuge tubes and incubated 
for 10 min at 70
o
C. The mixture was then chilled on ice and centrifuged briefly. The 
following components were then added: 
 
Moloney Murine Leukemia Virus reverse transcriptase (MMLV RT)  0.25 l 
dNTPs (10 mM)        2 l 
5X MMLV Buffer        4 l 
RNasin (40 U/l)        0.5 l 
Random Primers (0.5 μg/μl)                  1 l 
Nuclease-Free Water                                                                                      to 20 μl 
 
The reaction mixture was incubated for 10 min at RT allowing the primers to anneal 
to the RNA. Next, the reaction was incubated at 42°C for 1 h. MMLV RT was then 
deactivated by heating to 95
o
C for 5 min followed by cooling to 0-5
o
C for 5 min. 
Generated cDNA was stored at 4
o
C for short-term storage or -20
o
C for long-term 
storage. 
 
 2.2.10  Quantitative Real Time PCR  
 
 Cells were seeded (1.5 x 105 cells/ml; 3 ml) into 6-well plates and grown for 
24 h to approximately 60 % confluency.   In some cases, cells were transfected, as 
previously described in section 2.2.5.1 and 2.2.6.2 and/or stimulated with Poly(I:C) 
(25 μg/ml) or LPS (100 ng/ml) for various time periods.  Cells were washed with 1X 
PBS (1 ml) and RNA was extracted, as described in section 2.2.9.1.  cDNA was then 
generated as described in section 2.2.9.2.  Samples were assayed by quantitative real 
time PCR for levels of IFNβ, Cactin or IκBL cDNA using SensiMix SYBR Low-ROX 
kit (Bioline).  PCR was conducted with the CFB-322001G Opticon thermal cycler 
(Bio-Rad Laboratories).  Reactions were performed using pre-validated primers 
(Eurofins MWG Operon).  The sequence of primers used were as follows: 
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Cactin   Forward   5’ TACACCAACACCGACAACCC 3’ 
   Reverse   5’ TTCAGCTCCTTCTCCTCCAG 3’ 
IFNβ     Forward   5’ GACCAACAAGTGTCTCCTCCAAA 3’ 
   Reverse  5’ CTCCTCAGGGATGTCAAAGTTCA 3’ 
IκBL  Forward   5’ GCCTACACCGATTTCTTCC 3’ 
  Reverse  5’ CCTCCTCTTCAGCAGAATCC 3’ 
HPRT   Forward   5’ GGTGAAAAGGACCCCACGAA 3’ 
  Reverse  5’ GGCGATGTCAATAGGACTCCAGAT 3’ 
 
 Accumulation of gene-specific PCR products was measured continuously by 
means of fluorescence detection over 40 cycles.  Samples were initially heated for 10 
min at 95
o
C.  This was followed by 10 seconds at 95
o
C, 10 seconds at 59
o
C and 1 min 
at 72
o
C for 40 cycles.  Gene expression was calculated relative to the endogenous 
control and analysis was performed using the 2
-∆∆CT
 method. 
 
 
2.2.11 Chromatin ImmunoPrecipitation (ChIP) 
 
2.2.11.1 X-ChIP 
 
 HEK293 TLR4 cells were seeded at 3.5 x 10
5 
cells/ml in 10 cm petri dishes 
(10 ml DMEM/dish) and
 
grown to approximately 60 % confluency. They were then 
transfected with or without myc-tagged hCactin and HA-tagged p65 as previously 
described in section 2.2.2.3. 24 h post-transfection cells were cross-linked by adding 
37.5 % (v/v) formaldehyde/10 % (v/v) methanol stock directly to the culture medium 
to a final concentration of 1 %. After 10 min incubation at 37°C, medium was 
removed and the cells washed three times in ice-cold PBS. Cells were collected in 
PBS and centrifuged at 8000 x g at 4°C for 5 min. Cells were lysed for 5 min in 500 μl 
L1 buffer (50 mM Tris-HCl pH 8.0, containing 0.2 mM EDTA, 0.1 % (w/v) igepal 
and 10 % (w/v) glycerol). Nuclei were pelleted by centrifugation at 8000 x g for 5 min 
at 4°C. The supernatant constituting the cytoplasmic fraction was removed and the 
nuclei were resuspended in 500 μl buffer L2 (50 mM Tris pH 8.0, containing 5 mM 
EDTA, 1 % (w/v) SDS). After 10 min incubation on ice, chromatin was sheared by 
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sonication. Four 12 s pulses were applied per sample using a Sanyo Soniprep 150 at 
half of the total power. Samples were incubated on ice for a minimum of 1 min 
between pulses. Lysis buffer was periodically monitored for SDS precipitation. SDS 
was redissolved by warming the tube by hand. Following sonication, nuclear debris 
was removed by centrifugation at 8000 x g at 4°C. An aliquot was retained as an input 
sample to normalize PCR reactions and analyze shearing efficiency. The remaining 
sample was divided into two aliquots, which were diluted ten-fold in dilution buffer 
(50 mM Tris pH 8.0, containing 0.5 % (w/v) igepal, 0.2 M NaCl and 5 mM EDTA). 
These samples were precleared for 3 h by rotation at 4°C with 40 µl of a 50 % 
suspension of salmon sperm-saturated protein A-agarose (ssProtein A). Samples were 
then centrifuged for 2 min at 1000 x g to pellet ssProtein A. The supernatant was 
removed to a fresh tube and incubated overnight with rocking at 4°C with 2 µg anti-
p65 antibody or rabbit IgG antibody. Immuno-complexes were collected by 
incubation with 20 µl ssProtein A for 1 h at 4°C, followed by centrifugation at 1000 x 
g. The supernatant containing unbound  DNA was removed. A series of washes was 
then performed. Each wash involved resuspension of the immuno-complexes in wash 
buffer and 5 min incubation with rocking at 4°C. Immuno-complexes were washed 
consecutively with low salt wash buffer (20 mM Tris pH 8.0, 0.2 mM EDTA, 0.1 % 
(w/v) SDS, 1 % (w/v) igepal, 0.15 M NaCl), high salt wash buffer (20 mM Tris pH 
8.0, 0.2 mM EDTA, 0.1 % (w/v) SDS, 1 % (w/v) igepal, 0.5 M NaCl), 0.5 M LiCl and 
twice with TE buffer. After each wash, immune-complexes were pelleted by 
centrifugation at 1000 x g for 2 min at 4°C.   
 
 
2.2.11.2 PCR analysis of immunoprecipitated DNA 
 
 DNA was eluted from immune-complexes by incubation for 15 min with 
extraction buffer (1X TE with 2 % (w/v) SDS). During the incubation, tubes were 
gently agitated at regular intervals to maintain immune-complexes in suspension. 
Reversion of protein-DNA cross-linking was achieved by incubating immuno-
precipitated and input samples overnight at 65°C.  DNA was incubated with 
proteinase K at 50
o
C
 
for 2 h.  DNA was extracted using the Qiaquick purification kit 
(Qiagen) according to the manufacturer’s instructions. In order to monitor chromatin 
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shearing, an aliquot of each input sample was electrophoresed in an agarose gel. DNA 
used for PCR had an average size of 650 bp.  
 
The conditions for standard PCR were as follows:  
 
DNA template                                              5 µl  
Forward and reverse primers (at 100pmol)  1.25 μl 
25 mM MgCl2                                               2 µl 
dNTP mix                                          2 µl 
GoTaq Flexi DNA Polymerase (5 U/µl)        0.25 µl 
5X Green GoTaq Flexi Buffer  5 µl 
PCR-grade water                                          to 25 µl 
 
Samples were initially heated to 95°C for 2 min. This was followed by 40 cycles of 
95°C for 30 s, 63°C for 30 s and 72°C for 30 s. Samples were then incubated at 72°C 
for 10 min and then stored at 4°C. The sequences of primers used are as follows: 
IL-8 promoter 5’- GGAAGTGTGATGACTCAGGTTTGC -3’ 
                        5’- GATGGTTCCTTCCGGTGGTTTCTTC -3’ 
 
2.2.11.3 Agarose gel electrophoresis 
 
 Agarose gels were prepared by suspending agarose (0.8-1 % (w/v)) in TAE 
(0.484 % (w/v) Tris base, 0.1 % (v/v) glacial acetic acid, 0.2 M EDTA). This was 
heated in a microwave until the agarose had completely dissolved, and was then 
cooled to less than 50
o
C. Ethidium bromide (5 g/ml) was added and the agarose 
poured into the gel tray. Following solidification, agarose gels were electrophoresed in 
TAE (1X). Samples were mixed with loading dye (0.017 % (w/v) xylene cyanol, 
0.017 % (w/v) bromophenol blue and 5 % (w/v) glycerol). Samples were run with 
molecular size markers, with a 100 bp ladder.  Gels were run at 110 V for 30 min. 
Nucleic acids were visualised under UV light (254 nm) and images acquired using the 
Syngene G box gel documentation system (Frederick, MD, USA). 
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2.2.12  Immunofluorescence 
 
 HEK293 TLR3/TLR4 cells were seeded at 1.5 x 10
5 
cells/ml in 4 well chamber 
slides (Lab-Tek) (800 l DMEM/well) or on Poly-L-lysine coated coverslips in 6 
well-plates (3 ml DMEM/well) and grown for 24 h to approximately 60 % confluency. 
Cells were transfected using Lipofectamine 2000 with plasmids as detailed in the 
figure legends. Medium was removed and the cells were gently washed with 1X PBS, 
being careful not to disrupt the cells. The cells were then fixed by addition of 4 % 
(v/v) paraformaldehyde (500 l). After 30 min incubation at RT the paraformaldehyde 
was removed and the cells were washed with PBS.  500 μl Hoescht (1:1000 diluted in 
PBS) was added to each well.  After 20 min incubation the Hoescht was removed and 
the cells were washed four times with PBS before removing the chamber walls. A 
single drop of Vectashield hard-set mounting medium was applied to each well. 
Coverslips were then mounted and sealed on the sides with nail varnish, before being 
wrapped in tinfoil and stored at 4
o
C.  
 Alternatively, after fixing with paraformaldehyde cells were incubated with 
0.2 % Triton X (500 μl) for 20 min.  Cells were then gently washed with PBS.  Cells 
were then incubated in 10 % goat serum for 2 h at room temperature to block non-
specific binding.  Cells were probed overnight with anti-myc (1:500), anti-flag (1:500) 
or anti-ASCC1 (1:500) antibodies at 4
o
C.  The following day cells were washed 3 
times for 5 min with PBS and then probed with anti-rabbit Alexa-Floura 488 (1:250) 
and/or anti-mouse Alexa-Floura 594 (1:250) antibodies as deemed appropriate in 5 % 
goat serum with Hoescht (1:1000) for 1.5 h at room temperature.  Cells were then 
gently washed 6 times for 10 min with PBS.   The Poly-L-Lysine coated coverslips 
were then removed from the 6 well plates and mounted on slides with a drop of anti-
fade mounting media (50 % (v/v) glycerol, 0.5X PBS, 2 μg/μl para-p-
phenylendiamine).  Coverslips were sealed on the sides with nail varnish, before being 
wrapped in tinfoil and stored at 4
o
C. 
  Confocal images were captured using the 40 x or 63 x objective lens on the 
Olympus FluoView FV1000 confocal laser scanning microscope equipped with the 
appropriate filter sets. Acquired images were analysed using the Olympus FV-10 
ASW imaging software. 
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2.2.13  Lentiviral shRNA-Cactin infection and stable cell lines 
 
2.2.13.1 Lentiviral production 
 
 HEK293 T cells were seeded at 2 x 10
5 
cells/ml in 6-well plates (3 ml 
DMEM/well) and grown for 24 h to approximately 80 % confluency. The cells were 
transfected as in section 2.2.2.2. The DNA mixture contained packaging plasmid (900 
ng), envelope plasmid (100 ng) and the sh-pLKO.1 vector (1 μg). hCactin sh-RNA 
sequences were as follows: 
hCactin shRNA 1  5’- CAGGGATACAAGTTCAACATC -3’ 
hCactin shRNA 2  5’- AGGTCAGATTCAGAGGAAGAG -3’ 
A control shRNA (CT) was also used in the transfection. It is a non-targeting shRNA 
vector that will activate the RNA-induced silencing complex (RISC) and the RNAi 
pathway, but it does not target any human or mouse genes. The short-harpin sequence 
contains 5 base pair mismatches to any known human or mouse gene. The shRNA 
hCactin and shRNA control plasmids were purchased from Sigma (Fig. 2.2 for the 
map of the plasmid). To remove the transfection reagent, the media was changed 24 h 
post-transfection and replaced with fresh high serum (30 %) growth media. The cells 
were then incubated for 24 h. The media containing lentivirus were harvested ~ 40 h 
post-transfection and transferred to a polypropylene tube for storage at -20°C. The 
media was replaced with fresh high serum (30 %) growth media and the cells were 
incubated for 24 h. The virus was harvested one more time and after the final harvest 
the packaging cells were discarded.  
 
2.2.13.2 Lentiviral infection 
                                                                    
 THP-1 and U373 cells were seeded at 2 x 10
5 
cells/ml in 6-well plates (3 
ml/well RPMI or DMEM, respectively). U373 cells were incubated overnight prior to 
infection to allow the cells to adhere. The growth media was then removed and 
replaced with fresh media containing polybrene (8 μg/ml) and 600 μl of virus. The 
plates were incubated at 37
o
C. The media was removed 24 h post-infection and 
replaced with fresh growth media containing puromycin (10 μg/ml) to select for cells 
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transduced with shRNA. The polyclonal population of cells were cultured for 2-3 
weeks and used for EMSA and Western Blot experiments. 
 
 
2.2.14 Electrophoretic mobility shift assay (EMSA) 
 
 EMSA was used to detect the presence of DNA-binding proteins in nuclear 
extracts from lenti-viral transduced THP-1 cells, siRNA-transfected HEK293 TLR3 
cells and transfected HEK293 TLR4 cells. NF-ĸB Infrared Dye labelled 
oligonucleotides were purchased from Licor Biosciences while Infrared Dye labelled 
oligonucleotides for IFNβ were purchased from MWG. 
 
  2.2.14.1 Preparation of sub-cellular fractions 
 
 HEK293 TLR3 cells were transfected with siRNA as described in section 
2.2.6.1. and treated with Poly(I:C) (25 μg/ml).  HEK293 TLR4 cells were transfected 
as described in section 2.2.2.2 with various expression vectors as detailed in the figure 
legends. Cells were washed with 1 ml of ice cold PBS.  Cells were then detached with 
1 ml of hypotonic buffer (10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.5 
mM dithiothreitol (DTT) and 0.5 mM PMSF). Alternatively THP-1 cells previously 
transduced with shRNA were grown in 6-well plates and stimulated with LPS (100 
ng/ml).  Cells were centrifuged, washed with 1 ml of ice cold PBS and resuspended in 
1 ml hypotonic buffer.  All cells were pelleted in hypotonic buffer by centrifugation at 
21000 x g for 10 min, and then lysed for 10 min on ice in hypotonic buffer A (30 μl) 
containing 0.1 % (w/v) Igepal. Lysates were centrifuged at 21000 x g for 10 min. The 
resulting supernatants constituted cytosolic extracts and were stored at -20ºC in fresh 
microcentrifuge tubes. The remaining pellets were resuspended in 25 μl of Buffer C 
(20 mM HEPES pH 7.9, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 25 % (w/v) 
glycerol and 0.5 mM PMSF) and incubated on ice for 15 min. Incubations were then 
centrifuged at 21000 x g for 10 min. The supernatants were then removed into new 
tubes and 75 μl of Buffer D (10 mM HEPES pH 7.9, 50 mM KCl, 0.2 mM EDTA, 20 
% glycerol, 0.5 mM PMSF and 0.5 mM DTT) was added. Such samples constituted 
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nuclear extracts. Protein concentrations were determined by the method of Bradford 
and assayed for protein-DNA binding activity as outlined in the following sections. 
 
2.2.14.2 Determining protein concentration – Method of  
Bradford 
 
 Protein content of BSA standards and cell extracts was measured by the 
method of Bradford (Bradford 1976). Standards and extracts (10 l) were diluted in 
water and mixed with aliquots (190 l) of Bradford protein reagent (Bio-Rad), diluted 
1:5 in distilled water, by pipetting up and down. A blank was prepared using the same 
dilution of water. Absorbance was measured for each sample in a 96-well plate at 590 
nm using ELx800
TM
 microplate reader with Gen5 Data Analysis Software. Six protein 
standards of BSA (10, 8, 6, 4, 2 and 0 μg/μl) were made and used to construct a 
standard curve which was subsequently used to determine protein concentration of the 
cell extracts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  . 
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2.2.14.3 Incubation of nuclear extracts with NF-ĸB and 
PRDI-III Infrared Dye labelled oligonucleotides 
 
 
 Nuclear extracts (5μg of protein), generated as described in section 2.2.14, 
were incubated with the following reaction mix: 
 
10x Binding Buffer (100 nM Tris, 500 mM KCl, 10 mM DTT; pH 7.5) 2 μl 
Poly (dI-dC) 1 μg/μl in 10 mM Tris, 1 mM EDTA; pH 7.5   1 μl 
25 mM DTT         2 μl 
1 mM MgCl2          1 μl 
NF-ĸB/PRDI-III  IRDye labelled oligonucleotides    1 μl 
          7 μl 
Nuclear extracts (5 μg of protein)       … 
Water               to 20 μl 
 
NF-ĸB consensus oligonucleotide: 
 
5’ - AGTTGAGGGGACTTTCCCAGGC - 3’ 
3’ - TCAACTCCCCTGAAAGGGTCCG - 5’ 
 
 
PRDI-III consensus oligonucleotide 
 
 
5’ – GTAAATGACATAGGAAAACTGAAAGGGAGAAGTGAAAGTGG – 3’ 
 
3’ – CATTTACTGTATCCTTTTGACTTTCCCTCTTCACTTTCACC – 3’ 
 
54 
Incubations were performed for 1 h at room temperature in the dark. Poly (dI-dC) was 
added to prevent non-specific binding of proteins to the oligonucleotide probe and 
thereby to reduce background. Following incubation, orange loading dye (2 μl) was 
added and the incubations were then subjected to electophoresis for 2 h at 90 V in a 
non-denaturing 4 % (w/v) polyacrylamide gel. Gels were run in 0.5 x TBE buffer. 
Gels were then removed from glass plates and visualised using Odyssey Infrared 
Imaging System from Licor Biosciences.  
 
 
2.2.15  Statistical Analysis 
Data are expressed relative to untreated cells transfected with empty vector, and are 
the mean +/- standard error of the mean of triplicate determinations from three 
independent experiments.  For statistical comparisons between two groups, paired 
Student’s t-test (one tail) was used.  A p value of < 0.05 was considered significant 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
55 
  
 
 
 
Chapter 3 
 
 
 
The role of Cactin in NF-κB signalling: probing the 
underlying mechanism of inhibition 
 
 
 
 
 
 
 
 
 
 
 
 3.1 Introduction 
 
The transcription factor NF-κB is activated by a range of signalling pathways.  
Toll Like Receptors (TLRs) recognise conserved microbial motifs and respond by 
activating transcription factors such as NF-κB.  The IL-1 Receptor (IL-1R) and TNF 
Receptor family activate NF-κB in response to endogenous proinflammatory stimuli.  
NOD1 and NOD2 are cytoplasmic receptors for microbial ligands and are another 
example of receptors that can trigger the activation of NF-κB (Philpott and Girardin, 
2004).  NF-κB regulates the expression of a wide variety of genes involved in both 
innate and adaptive immunity.  These genes include proinflammatory cytokines and 
chemokines, adhesion molecules, stress response proteins and anti-apoptotic proteins 
(Li and Verma, 2002).  In the unstimulated cell, NF-κB is predominantly cytoplasmic 
and is found in association with members of the Inhibitory (I)-κB family.  The various 
signalling pathways that lead to NF-κB activation all result in the phosphorylation of 
the IκB proteins, marking them as targets for ubiquitination and subsequent 
degradation by the proteosome.  This allows for NF-κB to bind to motifs in the 
promoter regions of its target genes and thus regulate gene expression.  Members of 
the NF-κB, or Rel, family of transcription factors share a conserved N-terminal rel 
homology (RH) domain.  This domain mediates dimerisation of Rel/NF-κB family 
members, their nuclear translocation and binding to DNA (Ghosh et al., 1998).  The 
Rel/NF-κB family currently has five mammalian members; p65 (RelA), NF-κB1 (p50 
and precursor p105), NF-κB2 (p52 and precursor p100), c-Rel and RelB (Albert and 
Baldwin, 1996).  RelB, c-Rel and p65 also possess a C-terminal transactivation 
domain.  Rel subunits form homo- or heterodimers and the most common combination 
found is a p65/p50 heterodimer.  p50 and p52 homodimers cannot activate 
transcription directly but do, however, have the ability to repress it (Hayden and 
Ghosh, 2004). 
 Dysregulation of NF-κB can lead to various autoimmune and inflammatory 
diseases and so these pathways are tightly regulated.  ST2 (suppression of 
tumorigenicity 2) is a TIR domain containing receptor which sequesters MyD88 and 
Mal and thereby inhibits TLR4 and IL-1R signalling to NF-κB (Brint et al., 2004).  
IRAK-M is a member of the IRAK family which is expressed in monocytes and 
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macrophages and negatively regulates TLR-signalling.  IRAK-M prevents the 
dissociation of IRAK1 and IRAK4 from MyD88, thereby preventing their association 
with downstream regulators of the pathway (Kobayashi et al., 2002). A20 is another 
negative regulator of NF-κB which functions by interfering with the ubiquitination of 
receptor interacting protein (RIP), an essential mediater of TNFR signalling, and TNF 
receptor associated factor (TRAF)6 (Wertz et al., 2004, Boone et al., 2004).   
Suppressor of cytokine signalling 1 (SOCS1) is a member of the cytokine-induced 
SOCS family which inhibits LPS mediated NF-κB activation (Akira and Takeda, 
2004).   
 In Drosophila the Toll signalling pathway triggers the activation of Rel 
transcription factors.  Three such transcription factors have been identified in 
Drosophila; Dorsal, Dif and Relish.  Like their mammalian counterparts, these 
transcription factors all contain a conserved RH domain which mediates dimerisation, 
DNA-binding and interaction with IκB-inhibitor proteins (Govind, 1999).   Following 
nuclear translocation Rel transcription factors bind to κB sites in genes controlling 
many biological processes including early development and immune response.  The 
components of the Toll pathway are evolutionarily conserved and most have 
homologues in the mammalian TLR-signalling pathway.  In Drosophila Rel 
transcription factors are sequestered in the cytoplasm through their association with 
Cactus, the human orthologue of which is IκBα.  Cactus is phosphorylated following 
Toll activation, allowing for the Rel transcription factor to translocate to the nucleus 
and regulate gene expression.  In 2000, Cactus was used as bait in a yeast-2-hybrid 
screen which led to the discovery of a novel Cactus-interacting protein termed Cactin 
(Lin et al., 2000).  dCactin was overexpressed in females with cactus haplo-
insufficient phenotype which displays weak ventralisation.  Overexpression of dCactin 
enhanced this weak ventralising phenotype suggesting that dCactin may function as a 
positive regulator of Dorsal nuclear translocation by affecting the stability of Cactus 
protein (Lin et al., 2000).  Due to the similarities of the insect Toll signalling pathway 
and mammalian TLR signalling and given that IκBα, the human homologue of Cactus, 
is vital to controlling NF-κB activation and inflammation, we were keen to investigate 
if human Cactin can regulate innate immune signalling.  Prior to this study the human 
homologue of Cactin was cloned in the author’s laboratory and previous studies 
indicated that Cactin inhibits NF-κB activation.   
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3.1.1  Specific aims of chapter 3 
 
1. Confirm that Cactin is a negative regulator of NF-κB activation. 
 
2. Uncover a possible mechanism by which Cactin exerts its inhibitory effects on 
NF-κB.   
 
3. Examine if, like other negative regulators of TLR-signalling, Cactin is 
regulated by proinflammatory stimuli. 
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3.2 Results 
 
3.2.1 Cactin acts as a negative regulator of the NF-κB pathway 
 
Drosophila Cactin was first discovered in a yeast-two hybrid screen using 
Cactus as bait (Lin et al., 2000).  Cactus is the Drosophila  orthologue of human IκBα 
which is a regulator of NF-κB.  Thus, human Cactin was initially probed for its effects 
on the NF-κB pathway.  In order to investigate this, HEK293 cells stably transfected 
with TLR3 and TLR4 were employed.  These cells were transfected with increasing 
concentrations of an expression plasmid encoding myc-tagged Cactin and assessed for 
their ability to induce a co-transfected NF-κB regulated luciferase gene in response to 
various stimuli.  Overexpression of Cactin significantly inhibited the activation of NF-
κB in response to the TLR4 ligand LPS (Figure 3.1A) and the TLR3 ligand Poly(I:C) 
(Figure 3.1B).  Overexpression of Cactin also inhibited the activation of NF-κB in 
response to the endogenous proinflammatory stimulus IL-1β (Figure 3.1C).  When the 
TIR-domain containing adaptor protein MyD88 was used to drive NF-κB activation 
Cactin displayed similar inhibitory effects (Figure 3.1D).  These results are consistent 
with previous findings from the laboratory suggesting that Cactin is a negative 
regulator of the NF-κB pathway. 
Because the above studies were performed using cells engineered to express 
TLRs it was necessary to demonstrate a role for Cactin in a more physiologically 
relevant system. It was also hoped to complement the above overexpression studies 
and assess the effects of suppressing endogenous expression of Cactin on the NF-κB 
pathway.  Thus, cells that naturally express TLRs were employed.  THP-1 is a human, 
acute monocytic, leukemia cell line that naturally express TLR4 and respond to LPS 
while U373 human astrocytoma cells express TLR3 and TLR4 and respond to both 
LPS and Poly(I:C).  These cells are not easily transfected and so they were transduced 
with lentiviral particles containing a plasmid encoding Cactin-specific shRNAs in 
order to suppress Cactin expression.  Cells were also transduced with a plasmid 
encoding a control shRNA that does not target Cactin or any other human gene.  
These plasmids also encode a puromycin resistance gene allowing for selection of 
cells that have been stably transduced with the constructs.  In the absence of an 
available antibody for Cactin protein, quantitative realtime PCR was used to confirm 
knockdown of endogenous Cactin in these cells lines.  THP-1 cells exhibited 80 % 
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knockdown of endogenous Cactin (Figure 3.2A) while Cactin expression in U373 
cells was decreased by an average of 50 % (Figure 3.2B). 
THP-1 cells, previously transduced with control or Cactin-specific shRNA 
were treated for various time points with LPS.  Nuclear extracts were generated and 
then assayed for NF-κB activation by electrophoretic mobility shift assay (EMSA) 
using an oligonucleotide encoding a consensus binding site for NF-κB.  THP-1 cells 
transduced with Cactin specific shRNA displayed, stronger and more prolonged 
activation of NF-κB compared with those transduced with the control shRNA (Figure 
3.3). The protein-DNA complexes observed contained the Rel subunits p65 and c-Rel 
as confirmed by supershift analysis.  It is also worth noting that THP-1 and U373 cells 
transduced with Cactin shRNA demonstrated greatly enhanced expression of IL-8 and 
TNF-α, most likely due to potentiation of NF-κB activation.  These findings 
demonstrate a functional role for Cactin in regulating activation of NF-κB in these cell 
lines.  
The ability of Cactin to regulate the phosphorylation of p65 was next 
examined.  U373 cells transduced with Cactin specific shRNA and control shRNA 
were treated with LPS for various time points.  Samples were harvested in SDS-PAGE 
sample buffer and subjected to Western immunoblotting.  Surprisingly, knockdown of 
endogenous Cactin did not lead to increased levels of phospho-p65 as detected by 
immunoblotting using an anti-phospho-p65 antibody (Figure 3.4).  As we previously 
demonstrated that knockdown of endogenous Cactin led to increased activation of NF-
κB by EMSA this suggests that Cactin may be exerting its negative effects 
downstream of p65 phosphorylation and possibly at the nuclear level. 
 
3.2.2  Cactin is localised in the nucleus and its nuclear localisation is important 
for manifesting its inhibitory effects on NF-κB 
 
 Given the likely action of Cactin at the nuclear level the subcellular 
localisation of Cactin was examined by confocal microscopy.  HEK293 cells were 
transfected with GFP-tagged Cactin.  Cells were fixed and stained with hoescht to 
visualise the nuclei.  Cactin was found to be expressed exclusively in the nucleus 
(Figure 3.5A).  Bioinformatic analysis of Cactin using a protein family and domain 
database, PROSITE, predicts two bipartite nuclear localisation sequences (NLSs) in 
the N-terminal region.  In order to assess the importance of nuclear localisation for the 
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inhibitory effects of Cactin, a truncated form of Cactin was cloned which lacks both 
nuclear localisation sequences (Figure 3.5B).  The C-terminal 200 residues of Cactin 
are highly conserved and, in Drosophila, are responsible for interaction with Cactus.  
This conserved C-terminal region is intact in the truncation mutant.  However, the 
conserved mid region of Cactin which contains coiled-coil domains is disrupted by the 
truncation.  In order to confirm that truncated Cactin is expressed in the cytoplasm 
HEK293 cells were transfected with GFP-tagged truncated Cactin. Again, the cells 
were fixed and stained with hoescht to allow for visualisation of the nuclei.  Truncated 
Cactin was found to be localised in the cytoplasm (Figure 3.5C). 
 The inhibitory effects of truncated Cactin were then compared with that of the 
full length protein.  HEK293 TLR4 cells were transfected with increasing 
concentrations of plasmids encoding myc-tagged truncated Cactin and myc-tagged 
Cactin.  Transfected cells were then assayed for the activation of a co-transfected NF-
κB regulated luciferase gene.  In response to the TLR4 ligand LPS, full length Cactin 
exhibited statistically significant inhibitory effects when only 30 ng of plasmid was 
transfected while truncated-Cactin only exhibited inhibitory effects when higher 
concentrations of the plasmid were used (Figure 3.6A).  Similarly, in response to the 
endogenous pro-inflammatory stimulus IL-1β full length Cactin showed statistically 
significant inhibitory effects at all concentrations while truncated Cactin was 
ineffective (Figure 3.6B).  Finally in cells co-transfected with MyD88, full length 
Cactin again proved a more powerful inhibitor of NF-κB as it exhibited significant 
effects when the lowest concentration of plasmid DNA was transfected and more 
significant effects than truncated Cactin when higher concentrations of plasmid were 
used (Figure 3.6C).  These results indicate that the nuclear localisation of Cactin is 
important for manifesting its regulatory effects on the NF-κB pathway. 
 
3.2.3 Cactin does not bind to a consensus NF-κB-binding motif and does not co-
immunoprecipitate with p65 
   
Given that Cactin appears to exert its negative effects downstream of p65 
phosphorylation and is expressed in the nucleus it seemed plausible that Cactin itself 
might bind to DNA thus preventing NF-κB from binding to the promoter regions of 
the various genes it regulates.  In order to investigate this possibility, HEK293 cells 
were transfected with plasmids encoding HA-tagged p65 and myc-tagged Cactin.  
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HA-tagged p65 was used as a positive control for DNA-binding.  Nuclear lysates were 
generated and incubated with an oligonucleotide encoding a consensus binding site for 
NF-κB. Overexpressed p65 translocates to the nucleus in the absence of a stimulus 
and so the p65-DNA complex was detected by electrophoretic mobility shift assay 
(EMSA) (Figure 3.7).  The specificity of this band was confirmed by supershift 
analysis (Figure 3.7B) and by the use of a specific competitor for NF-κB (Figure 
3.7A).  Nuclear lysates from cells transfected with myc-tagged Cactin were also 
assessed for DNA-binding activity.  However, no protein-DNA complexes were 
detected indicating that Cactin cannot bind to the consensus NF-κB binding site 
excluding the binding of Cactin to the NF-κB motif as a possible mechanism to 
explain the inhibitory effects of Cactin on NF-κB. 
Next we investigated if Cactin interacts directly with the NF-κB subunit p65, 
thus preventing it from binding to DNA and upregulating gene expression.  In order to 
investigate this proposal, HEK293 cells were co-transfected with myc-tagged Cactin 
and HA-tagged p65.  Cell lysates were generated and immunoprecipitated with an 
anti-myc antibody.  No p65-HA was detected in immunoprecipitates although it was 
detected in the appropriate whole cell lysates and myc-tagged Cactin was also 
detected in the immunoprecipitates (Figure 3.8).  This suggests that Cactin and the 
NF-κB subunit p65 do not interact so again this is unlikely to be the mechanism by 
which Cactin negatively regulates NF-κB.  Similarly, no interaction was detected 
between Cactin and the NF-κB subunits c-Rel or RelB. 
 
3.2.4 Cactin prevents p65 from binding to DNA 
 
 Although Cactin does not bind to DNA or interact directly with p65 it was still 
plausible that Cactin could prevent p65 from binding to DNA by some other 
mechanism.  In order to investigate if this is the case HEK293 TLR4 cells were co-
transfected with plasmids encoding myc-tagged Cactin and HA-tagged p65.  Nuclear 
lysates were generated and assessed for DNA binding activity.  Again overexpressed 
p65 displayed the ability to bind DNA in the absence of a stimulus by EMSA and the 
specificity of this band was confirmed with the use of a specific competitor for NF-
κB.  Interestingly in nuclear lysates from cells transfected with both HA-tagged p65 
and myc-tagged Cactin there was significantly less p65 bound to the oligonucleotide 
than in lysates from cells expressing p65 alone (Figure 3.9A). HA-tagged p65 was 
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detected in both nuclear lysates (Figure 3.9B). This suggests that Cactin inhibits the 
NF-κB subunit p65 at the level of DNA-binding. 
 The inhibition of p65 binding to its cognate DNA sequence by Cactin would 
predict that the latter could reduce the transactivation potential of p65. To test this 
hypothesis  HEK293 TLR4 cells were transfected with increasing concentrations of a 
plasmid encoding myc-tagged Cactin and assessed for the regulatory effects of Cactin 
on  p65-HA-induced expression of the co-transfected NF-κB-regulated luciferase 
gene.  Cactin inhibited p65-induced expression of NF-κB-regulated luciferase in a 
statistically significant manner (p < 0.05) (Figure 3.10). Finally, ChIP analysis was 
carried out to confirm that Cactin could block p65 binding to a target promoter in an 
in vivo setting.  Again HEK293 TLR4 cells were transfected with plasmids encoding 
p65-HA and Cactin-myc.  Nuclear lysates were generated, sonicated, and 
immunoprecipitated with anti-p65 or anti-IgG antibodies.  PCR analysis was then 
performed using primers to specifically amplify a region of the IL-8 promoter that 
contains an NF-κB binding site.  As expected the IL-8 promoter fragment was 
amplified in immunoprecipitates from cells expressing p65-HA.  The IL-8 promoter 
was not, however, amplified from immunoprecipitates from cells expressing both 
Cactin-myc and p65-HA, although IL-8 was detected in corresponding Input sample, 
indicating that Cactin can prevent p65 from binding to the IL-8 promoter (Figure 
3.11). 
 
3.2.5 There is some regulation of Cactin mRNA in response to LPS and 
Poly(I:C) 
 
Given that Cactin inhibits NF-κB activation we were interested to see if the 
expression of Cactin can be regulated by NF-κB as part of autoregulatory system.  
Firstly, we investigated if the expression of Cactin, at the mRNA level, changes 
following stimulation with the the TLR ligands LPS and Poly(I:C).  HEK293 TLR3 
cells were treated for various time points with Poly(I:C) while HEK293 TLR4 cells 
were treated with LPS.  RNA was then extracted and converted to cDNA. Realtime 
PCR was carried out to quantify the amount of Cactin cDNA at each time point.  
There were only very small changes in levels of Cactin mRNA in response to 
Poly(I:C) stimulation.  There were no statistically significant changes observed but a 
similar trend was seen each time (Figure 3.12A).  In response to LPS there was a more 
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significant increase in Cactin mRNA following 5 h stimulation (Figure 3.12B).  This 
suggests that there is also some transcriptional regulation of Cactin following NF-κB 
activation. 
 
3.2.6 The expression of Cactin is stabilised by IL-1β, LPS and Poly(I:C) 
 
As only modest changes were detected in the mRNA levels of Cactin 
following LPS and Poly(I:C) stimulation we next investigated if Cactin is regulated at 
the protein level.  To investigate this HEK293 TLR4 or TLR3 cells were transfected 
with myc-tagged Cactin and treated for various time-points with the different stimuli.  
IL-1β, LPS and Poly(I:C) all triggered the stabilisation of Cactin, as visualised by 
Western Immunoblotting with an anti-myc antibody (Figure 3.13).  This regulation of 
expression was also visualised by fluorescent microscopy.  HEK293 TLR4 cells were 
transfected with GFP-tagged Cactin and stimulated with LPS.  At time zero the cells 
were fixed and stained with hoescht to allow for visualisation of the nuclei.  In non-
stimulated cells Cactin is expressed in localised nuclear dots. Following LPS-
stimulation GFP-Cactin appears more intense and now covers the entire nucleus, no 
longer in localised dots (Figure 3.14).   
 
3.2.7 The stabilisation of Cactin in response to IL-1β and Poly(I:C) is 
dependent on NF-κB activation 
 
In order to investigate if this regulation of Cactin is dependent on NF-κB 
activation a plasmid encoding a mutated form of IκBα was employed.  IκBα-Super 
Repressor (SR) has a mutated serine residue and cannot be phosphorylated, and 
therefore is not ubiquitinated or degraded, and can suppress NF-κB activation.  
HEK293 cells were co-transfected with a plasmid encoding myc-tagged Cactin and 
with or without a plasmid encoding IκBα-SR.  Cells were then treated with IL-1β.  
Again the expression of Cactin was stabilised following IL-1β stimulation.  
Intriguingly, in cells expressing the IκBα-SR this stabilisation of expression was not 
observed (Figure 3.15).  This indicates that the regulation of Cactin is dependant on 
NF-κB activation. 
Next we investigated if the regulation of Cactin in response to Poly(I:C) 
stimulation is also due to NF-κB activation.  HEK293 TLR3 cells were co-transfected 
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with a plasmid encoding myc-tagged Cactin and with or without a plasmid encoding 
IκBα-SR and treated for various time-points with Poly(I:C).  Stabilisation of Cactin 
expression was observed following Poly(I:C) stimulation.  Once more this regulation 
was prevented by the overexpression of the NF-κB repressor (Figure 3.16).  These 
results indicate that Cactin is regulated by NF-κB. 
 
3.2.8 Cactin is not ubiquitinated in response to LPS stimulation 
 
The stabilisation of Cactin may be due to post-translational modification 
following NF-κB activation. Thus, we wanted to investigate what these modifications 
might be.  Ubiquitination plays a very important role in TLR-signalling as many of the 
signalling intermediates of the pathway are activated by ubiquitination.  For this 
reason we first wanted to examine if Cactin is ubiquitinated following LPS 
stimulation.  To do this HEK293 TLR4 cells were co-transfected with plasmids 
encoding myc-tagged Cactin and HA-tagged ubiquitin.  Transfected cells were then 
treated with LPS.  Cell lysates were generated and immunoprecipitated using an anti-
myc antibody and probed for the presence of HA.  There was no ubiquitin-HA 
detected in immunoprecipitates although it was detected in the corresponding whole 
cell lysates (Figure 3.17).  Also, Cactin-myc was detected in the immunoprecipitates 
indicating that the immunoprecipitation process was successful.  It is worth noting that 
it may appear from the whole cell lysates that Cactin is having some effect on global 
ubiquitination, however the observed effect is possibly due to competition for the 
transcription machinery of the cell.  The above findings indicate that Cactin is not 
ubiquitinated and therefore the stabilisation of expression must be due to some other 
form of modification and mechanism. 
 
3.2.9 Cactin is phosphorylated following IL-1β stimulation 
 
Next we investigated if Cactin is phosphorylated following NF-κB activation.  
HEK293 TLR4 cells were transfected with a plasmid encoding myc-tagged Cactin and 
treated for various time-points with IL-1β.  Cell extracts were generated, split and 
incubated with and without Calf Intestinal Alkaline Phosphatase (CIP) for 1 h at 37
o
C. 
CIP can be used to catalyse the hydrolysis of phosphate groups from phosphorylated 
serine, tyrosine and threonine residues in proteins.  The extracts were then subjected 
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to Western blotting. Stabilisation of Cactin was observed in extracts from cells treated 
with IL-1β when samples were incubated without CIP.  Interestingly the same 
stabilisation was not observed when the same extracts had been incubated with CIP 
(Figure 3.18).  These results suggest that the stabilisation of Cactin following IL-1β 
stimulation is due to phosphorylation. 
To confirm these findings another approach was taken in which HEK293 
TLR4 cells were transfected with either myc-tagged Cactin or empty vector 
pcDNA3.1. Cell lysates were generated and interacting proteins were dissociated.  The 
lysates were then immunoprecipitated using an anti-myc antibody.  The 
immunoprecipitates were probed for the presence of phosphorylated serine residues 
which were detected in immunoprecipitates from cells expressing Cactin-myc.  The 
strongest phosphorylation was observed 10 minutes after IL-1β stimulation (Figure 
3.19).  Therefore Cactin is phosphorylated at one of more serine residues following 
NF-κB activation.  Immunoprecipitates were also probed for the presence of 
phosphorylated tyrosine and threonine residues but none were detected.     
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Figure 3.1 Cactin inhibits LPS, Poly(I:C), IL-1β and MyD88-mediated activation 
of NF-κB 
HEK293 cells stably transfected with TLR4 or TLR3, were cotransfected with 
plasmids encoding NF-κB-regulated firefly luciferase (80 ng) and constitutively 
expressed TK Renilla (20 ng) and with or without plasmids encoding myc-tagged 
Cactin (30, 60 or 90 ng) or MyD88 (50 ng).  Empty vector (EV) pcDNA3.1 was used 
to normalise the amount of total DNA transfected.  Transfected cells were left 
overnight and then treated with (A) LPS (100 ng/ml), (B) Poly(I:C) (25 μg/ml) or (C) 
IL-1β (10 ng/ml) for 24 h.  Cell lysates were generated and assayed for firefly and 
Renilla luciferase activity.  Data are presented as the mean +/- S.E.M of triplicate 
determinations from three independent experiments.  * p<0.05, ** p<0.01 paired t-
test. 
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Figure 3.2  Knockdown of endogenous Cactin by lentiviral vector-encoded 
shRNA in THP-1 and U373 cell lines 
(A) THP-1 and (B) U373 cells stably transduced with Control or Cactin specific-
shRNA were cultured in the presence of puromycin (10 μg/ml).  Total RNA was 
extracted and cDNA was generated using RT-PCR.  Samples were subsequently 
assayed by quantitative real-time PCR for levels of Cactin.  Gene expression was 
calculated relative to the housekeeping gene HPRT and analysis was performed using 
the 2
-∆∆CT
 method.  Data represent the mean +/- S.E. of three independent 
experiments.   
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Figure 3.3   Cactin-specific shRNA augments LPS-induced activation of NF-κB in 
THP-1 cells 
THP-1 cells stably transduced with Control and Cactin-specific shRNA were grown in 
6-well plates for 24 h.  Cells were then treated with LPS (100 ng/ml) for the indicated 
time periods.  Nuclear extracts were generated and assayed for binding to a 
fluorescently labelled oligonucleotide encoding a consensus NF-κB-binding motif by 
EMSA.  Nuclear extracts from cells stimulated for 1 h with LPS were pre-incubated 
with anti-p65 and c-rel or non-specific IgG antibody before assaying NF-κB-DNA 
binding activity.  Immunoreactivity was visualised using the Odyssey Infrared 
imaging system.  Results shown are indicative of two independent experiments. 
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Figure 3.4 Knockdown of endogenous Cactin does not affect phosphorylation of 
p65 in U373 cells 
U373 cells stably transduced with Control or Cactin-specific shRNA were grown in 6-
well plates for 24 h.  Cells were then stimulated with LPS (100 ng/ml) for the 
indicated time periods.  Cells were harvested in SDS-PAGE sample buffer and lysates 
were resolved by SDS-PAGE.   Western blotting was carried out probing with anti-
phospho-p65, anti-p65 and anti-β-actin antibodies.  Blots shown are representative of 
two independent experiments. 
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Figure 3.5 Cactin is localised in the nucleus while the truncated Cactin mutant is 
expressed in the cytoplasm 
HEK293 TLR4 cells were transfected with (A) GFP-tagged Cactin or (C) GFP-tagged 
truncated Cactin (800 ng).  Cells were fixed 24 h post-transfection, stained with 
hoescht, and mounted in anti-fade medium.  Confocal images were captured using 
Olympus FluoView FV1000 confocal laser scanning microscope equipment.  Data 
analysis was performed using the Olympus FV-10 ASW imaging software. (B) 
Schematic representation of full length and truncated Cactin with location of nuclear 
localisation sequences (NLS)s depicted. 
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Figure 3.6  Full length Cactin is a more powerful inhibitor of LPS, IL-1β and 
MyD88-mediated activation NF-κB than truncated Cactin 
HEK293 cells stably transfected with TLR4 were co-transfected with plasmids 
encoding NF-κB regulated firefly luciferase (80 ng) and constitutively expressed TK 
Renilla (20 ng) and with or without plasmids encoding Cactin-myc (30, 60 or 90 ng), 
truncated Cactin-myc (30, 60 or 90 ng) or MyD88 (50 ng).  Empty vector (EV) 
pcDNA3.1 was used to normalise the amount of total DNA transfected.  Transfected 
cells were left overnight and then treated with (A) LPS (100 ng/ml) or (B) IL-1β (10 
ng/ml) for 24 h.  Cell lysates were assayed for firefly and Renilla luciferase activity. 
Data are presented as the mean +/- S.E.M. of triplicate determinations from three 
independent experiments. * p<0.05, **p<0.01; ligand stimulated cells transfected with 
EV compared with ligand stimulated cells transfected with Cactin/T-Cactin. 
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Figure 3.7  Cactin does not bind to a consensus NF-κB-binding motif 
HEK293 cells were transfected with empty vector (EV) pcDNA3.1 (1 μg), p65-HA (1 
μg) or Cactin-myc (1 μg).  Nuclear lysates were generated and assayed for binding to 
a fluorescently labelled oligonucleotide containing a consensus NF-κB-binding motif 
by EMSA.  (A) Nuclear extracts from cells transfected with p65-HA and Cactin-myc 
were preincubated with an unlabelled oligonucleotide encoding the same binding 
motif, specific competitor (SC), or an oligonucleotide encoding an unrelated DNA 
sequence, non-specific competitor (NC), before assaying for DNA binding activity.  
(B) Nuclear extracts from cells transfected with p65-HA and Cactin-myc were 
preincubated with anti-HA, anti-myc or non-specific IgG antibodies before assaying 
for DNA binding activity.  Results are representative of two independent experiments. 
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Figure 3.8  Cactin does not interact with p65 
HEK293 TLR4 cells were transfected with or without myc-tagged Cactin (2 μg) and 
HA-tagged p65 (2 μg).  pcDNA3.1 was used to normalise the amount of total DNA 
transfected.   Cell extracts were generated 24 h post transfection and were 
immunoprecipitated with an anti-myc antibody.  Immunoprecipitates and whole cell 
lysates (WCL) were subjected to Western immunoblotting using anti-HA and anti-
myc antibodies.  Immunoreactivity was visualised using the Odyssey infrared imaging 
system. Blots shown are representative of two independent experiments. 
 
 
 
 
 
- +          - +        Cactin-myc
- - +          +        p65-HA
IP: myc
IB: HA
IB: myc
WCL
IB: HA
IB: myc
- 100
- 70
- 70
- 100
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9  Cactin inhibits p65 binding to a consensus NF-κB binding site 
HEK293 TLR4 cells were transfected with plasmids encoding myc-tagged Cactin (1 
μg) and HA-tagged p65 (1 μg).  Empty vector (EV) pcDNA3.1 was used to normalise 
the amount of total DNA transfected.  24 h post transfection nuclear extracts were 
generated and (A) assayed for binding to a fluorescently labelled oligonucleotide 
encoding a consensus NF-κB-binding motif by EMSA. Nuclear extracts from cells 
transfected with p65-HA were preincubated with an unlabelled oligonucleotide 
encoding the same binding motif, specific competitor (SC), or an oligonucleotide 
encoding an unrelated DNA sequence, non-specific competitor (NC), before assaying 
for DNA binding activity.  (B) Nuclear lysates were also subjected to Western blotting 
using anti-myc and anti-HA antibodies.  Results shown are representative of two 
independent experiments. 
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Figure 3.10  Cactin inhibits p65-mediated activation of NF-κB 
HEK293 TLR4 cells were co-transfected with plasmids encoding NF-κB-regulated 
firefly luciferase (80 ng) and constitutively expressed TK Renilla (20 ng) and with or 
without plasmids encoding Cactin-myc (30, 60 and 90 ng) and p65-HA (50 ng).  
Empty vector pcDNA3.1 was used to normalise the total amount of DNA transfected.  
24 h post transfection cell lysates were generated.  Lysates were assayed for firefly 
and Renilla luciferase activity.  The data presented are mean +/- S.E.M of triplicate 
determinations from a representative of three independent experiments. * p < 0.05, 
paired t-test. 
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Figure 3.11 Cactin inhibits binding of p65 to the IL-8 promoter 
HEK293 TLR4 cells were transfected with HA-tagged p65 (8 μg) and myc-tagged 
Cactin (8 μg).  Empty vector pcDNA3.1 was used to normalise the amount of total 
DNA transfected.   Sonicated nuclear lysates were immunoprecipitated with anti-p65 
or non-immune IgG antibodies.  Immunoprecipitated DNA was analysed for the 
presence of specific IL-8 promoter fragments by PCR.  Input DNA was removed from 
the sonicated nuclear lysates before immunoprecipitation and was also analysed for 
the presence of IL-8 promoter.  Results are representative of two independent 
experiments. 
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Figure 3.12  Regulation of  Cactin mRNA expression by LPS and Poly(I:C) 
stimulation 
(A) HEK293 TLR3 were treated with Poly(I:C) (25 μg/ml) while (B) HEK293 TLR4 
cells were treated with LPS (100 ng/ml) for the indicated time periods.  Total RNA 
was extracted and cDNA was generated using RT-PCR.  Samples were subsequently 
assayed by quantitative real-time PCR for levels of Cactin.  Gene expression was 
calculated relative to the housekeeping gene HPRT and analysis was performed using 
the 2
-∆∆CT
 method.  Data represent the mean +/- S.E. of three independent 
experiments.  * p<0.05, **p<0.01 paired t-test. 
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Figure 3.13 IL-1β, LPS and Poly(I:C) regulate protein expression levels of Cactin 
HEK293 cells stably transfected with TLR4 or TLR3 were transfected with a plasmid 
encoding myc-tagged Cactin (2 μg) or empty vector pcDNA3.1 (2 μg).  The cells were 
stimulated with (A) IL-1β (10 ng/ml), (B) LPS (100 ng/ml) or  (C) Poly(I:C) (25 
μg/ml) for the indicated time periods.  Cell lysates were generated and subjected to 
Western blotting using anti-myc and anti-β-actin antibodies.   Results are indicative of 
three independent experiments. 
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Figure 3.14 The expression pattern of Cactin is regulated by LPS 
HEK293 TLR4 cells were transfected with GFP-tagged Cactin (1 μg).  Transfected 
cells were left overnight and then treated for the indicated time-points with LPS (100 
ng/ml).  Cells were then fixed, stained with hoescht, and mounted in anti-fade media.  
Slides were visualised using fluorescent microscopy.  Results shown are a 
representative of three independent experiments. 
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Figure 3.15  Regulation of Cactin in response to IL-1β is dependent on NF-κB 
activation 
HEK293 TLR4 cells were transfected with myc-tagged cactin (2 μg) and with or 
without IκBα Super Repressor (SR) (2 μg).  pcDNA3.1 was used to normalise the 
amount of total DNA transfected.  Transfected cells were left overnight and then 
treated with IL-1β (10 ng/ml) for the indicated time periods.  Cell lysates were 
generated and subjected to Western blotting using anti-myc, anti-IκBα and anti-β-actin 
antibodies.  Blots shown are representative of three independent experiments. 
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Figure 3.16  Regulation of Cactin in response to Poly(I:C) is dependent on NF-κB 
activation 
HEK293 TLR3 cells were transfected with myc-tagged Cactin (2 μg) and with or 
without IκBα-Super Repressor (SR) (2 μg).  pcDNA was used to normalise the 
amount of total DNA transfected.  Transfected cells were left overnight and then 
treated with or without Poly(I:C) (25 μg/ml) for the indicated time periods.  24 h post 
transfection cell lysates were generated and subjected to Western blotting using anti-
myc, anti-IκBα and anti-β-actin antibodies.  Results shown are indicative of three 
independent experiments. 
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Figure 3.17  Cactin is not ubiquitinated following LPS stimulation 
HEK293 TLR4 cells were co-transfected with or without myc-tagged Cactin (1 μg) 
and HA-tagged ubiquitin (3 μg).  pcDNA3.1 was used to normalise the total amount 
of DNA transfected.  Transfected cells were left overnight and then treated with or 
without LPS (100 ng/ml) for the indicated time periods.  Lysates were generated and 
immunoprecipitated with an anti-myc antibody.  Immunoprecipitaes and whole cell 
lysates were subjected to Western blotting using anti-HA and anti-myc antibodies. 
Blotts shown are representative of three independent experiments.  
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Figure 3.18 Cactin is phosphorylated following IL-1β stimulation 
HEK293 TLR4 cells were transfected with Cactin-myc (2 μg).  The cells were left 
overnight and then treated with IL-1β for the indicated time periods.  Lysates were 
generated 24 h post transfection.  Cell lysates were split and then incubated with or 
without CIP at 37
o
C for 1 h.  Lysates were then resolved by SDS-PAGE and subjected 
to Western blotting using anti-myc and anti-β-actin antibodies.  Immunoreactivity was 
visualised using the Odyssey infrared imaging system.  Blots shown are representative 
of three independent experiments. 
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Figure 3.19 Cactin is serine phosphorylated following IL-1β stimulation 
HEK293 TLR4 cells are transfected with myc-tagged Cactin (2 μg) or empty vector 
(EV) pcDNA3.1 (2 μg).  Transfected cells were left overnight and then treated with 
IL-1β (10 ng/ml) for the indicated time periods.  Cell lysates were generated and 
incubated at 95
o
C for 5 min with 0.5% SDS to dissociate interacting proteins.  Lysates 
were then immunoprecipitated with an anti-myc antibody.  Immunoprecipitates and 
whole cell lysates were then subjected to Western immunoblotting with anti-phospho-
serine, anti-myc and anti-β-actin antibodies.  Blots shown are representative of two 
independent experiments. 
 
 
 
 
 
 
 
0     10’ 20’ 40’ 1h   6h    0    10’ 20’ 40’ 1h   6h         IL-1β
EV Cactin
IP: myc
IB: Phospho-Serine
IB: myc
WCL
IB: myc
IB: β-actin
100 -
100 -
100 -
35 -
Phospho-serine
3.3 Discussion  
 
Given that Drosophila Cactin appears to positively regulate the translocation 
of the Rel transcription factor dorsal to the nucleus it may appear surprising that the 
human orthologue acts as a negative regulator of NF-κB activation.  However, 
homology does not always correspond to conserved function (Jensen, 2001).  Cactin 
inhibits the activation of NF-κB in response to a variety of stimuli including the TLR4 
and TLR3 ligands LPS and Poly(I:C) and the pro-inflammatory cytokine IL-1β.  The 
effects of Cactin are also independent of cell-type as the inhibitory effects of Cactin 
were observed in HEK, THP-1 and U373 cell lines.  It is worth noting that 
suppression of endogenous Cactin in THP-1 cells led to more prolonged activation of 
NF-κB in response to LPS.  This suggests that Cactin may function as an endogenous 
control system, designed to prevent prolonged activation of NF-κB in response to 
inflammatory stimuli.  Constitutive activation of NF-κB is associated with a number 
of diseases including rheumatoid arthritis, multiple sclerosis and asthma (Li and 
Verma, 2002), highlighting the importance of negative regulators such as Cactin in 
controlling innate immune signalling.   
Cactin was first observed in 1999 as an antigen in patients with renal cell 
carcinoma and was termed NY-REN-24 (Scanlon et al., 1999).  Cactin is also 
differentially expressed in patients with multiple myeloma (Davies et al. 2003).  
Furthermore, the gene for Cactin maps closely to a microsatellite marker, D19S216, a 
site which is defective in uterine cancers (Lee et al., 1998).  This is not entirely 
unexpected given that Cactin is a regulator of NF-κB which upregulates pro-survival 
genes and has been implicated in many Cancers.  Interestingly dysregulation of Rel 
transcription factors leads to the production of melanotic tumours in Drosophila and 
unpublished findings from Prof. Ruth Stewards laboratory indicate that larvae from 
transgenic flies expressing a dCactin-RNAi construct develop melanotic tumours  
(http://waksman.rutgers.edu/Waks/Steward/steward.html). Such studies in conjunction 
with the regulatory effects of Cactin on the NF-κB pathway suggests that Cactin may 
play a regulatory role in tumourogenesis and cancer.   
dCactin interacts with Cactus, the homologue of human IκBα and modulates 
Rel transcription factor activation (Lin et al., 2000).  In contrast, human Cactin 
appears to function downstream of IκBα.  Phosphorylation and degradation of the 
IκBs is not sufficient for maximal NF-κB response (Oeckinghaus and Ghosh, 2009).  
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The subunits of NF-κB are also subject to post-translational modifications including 
phosphorylation, acetylation and ubiquitination (Perkins, 2006).  This is another point 
at which the activation of NF-κB can be controlled.  Interestingly, Cactin did not 
affect the phosphorylation of p65 indicating that Cactin targets the pathway 
downstream of this NF-κB subunit modification.  Cactin is localised to the nucleus 
and the nuclear localisation appears to be important for manifesting its inhibitory 
effects.  These findings led us to ask the question, can Cactin target NF-κB DNA-
binding?  Overexpressed p65 translocates to the nucleus where it binds κB sites in 
target genes in the absence of a proinflammatory stimulus.  This allowed us to 
investigate if Cactin can inhibit p65 at the level of DNA-binding.  EMSA was initially 
employed to show that Cactin can inhibit p65 binding to a consensus DNA-binding 
motif.  A more physiologically relevant model system, using  ChIP analysis, was also 
used to show that Cactin can inhibit p65 binding to the IL-8 promoter.  
Many inhibitors of NF-κB are regulated by proinflammatory stimuli and thus 
establish a self-regulatory control system.  Sterile α and HEAT-armadillo motifs 
(SARM) is a TIR domain containing adaptor which negatively regulates TLR 
signalling.  The expression of SARM is strongly enhanced by LPS stimulation (Carty 
et al., 2006).   The negative regulator A20 also increases in expression in response to 
LPS and TNF (Opipari et al., 1990).  Another example is SOCS1 protein which is 
induced by cytokine stimulation (Akira and Takira, 2004).  Cactin is induced by LPS 
stimulation.  Higher levels of Cactin mRNA were detected in cells treated for 5 h with 
LPS, quantified by real-time PCR.  Furthermore, Cactin appears to be stabilised by IL-
1β, LPS and Poly(I:C) stimulation due to post-translational modification.  Cactin 
appears to be serine phosphorylated in response to pro-inflammatory signals and this 
seems to be associated with increase protein stability. Furthermore this stabilisation is 
dependent on NF-κB activation.  Again this is not unusual as NF-κB upregulates the 
transcription of many genes, including genes encoding its own inhibitors, such as 
IκBα.  This again demonstrates that Cactin may function as an endogenous haulting 
mechanism for NF-κB activation.  NF-κB might upregulate the expression of the gene 
encoding the protein kinase responsible for Cactin phosphorylation.  Alternatively 
NF-κB activation might induce a phosphotase inhibitor leading to increased 
phosphorylation of Cactin. 
This chapter demonstrates that Cactin is a negative regulator of NF-κB by 
inhibiting its DNA-binding activity.  Cactin is also a powerful negative regulator of 
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IRF3 and IRF7.  It was interesting to determine if Cactin inhibits the activation of 
these transcription factors by a similar mechanism and this forms the content of the 
next chapter. 
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Chapter 4 
 
 
 
Exploring the role of Cactin in IRF3 and IRF7 
regulation and characterising the effect of Cactin on 
TLR-mediated MAPK activation 
 
 
 
 
 
 
 
 
 4.1 Introduction 
 
In addition to NF-κB, TLR-signalling also regulates members of the Interferon 
Regulatory Factor (IRF) family of transcription factors. The IRF family consist of 
nine members which all possess an N-terminal DNA binding domain (DBD) and a C-
terminal IRF association domain (IAD) (Savitsky et al., 2010).  IRFs regulate the 
expression of Type 1 interferons (IFNs) which are multifunctional secreted proteins 
involved in antiviral defence, immune activation and cell growth and regulation 
(Goodbourn et al., 2000).  Type I IFNs are encoded by one IFNβ gene and several 
IFNα genes.  The IRF family members IRF3 and IRF7 have been extensively studied 
in the context of Type I IFN regulation in response to viral infection (Taniguchi et al., 
2001).  IRF3 is expressed at high constitutive levels in most cells and is expressed 
predominantly in the cytoplasm.  Viral or bacterial infection leads to specific 
phosphorylation of a serine/threonine cluster in the C-terminal region of IRF3 which 
promotes dimerisation, nuclear translocation and association with co-activators CBP 
and p300 (Yoneyama et al., 1998).  IRF3 can then bind to the IFNβ promoter with the 
co-operation of other transcription factors such an NF-κB and induce the early phase 
of IFNβ production.  This leads to the subsequent activation of the transcription factor 
complex IFN-stimulated gene factor 3 (ISGF3), made up of signal transducer and 
activator of transcription (STAT)1, STAT2 and IRF9 (Taniguchi et al., 2001).  IRF7 is 
expressed at much lower levels in most cells but is strongly induced by ISGF3 (Genin 
et al., 2003).  IRF7 is also phosphorylated in its C-terminal region which promotes 
dimersation, with itself or with IRF3, and translocation to the nucleus.  IRF3 and IRF7 
then cooperate to amplify IFNα and IFNβ production in the late phase of the IFN 
response.   
 TLR3 is located on the membrane of endosomes and phagosomes and 
recognises viral double stranded dsRNA derived from dsRNA viruses or as replication 
intermediates from ssRNA viruses (Akira et al., 2006).  Upon recognition of dsRNA 
TLR3 recruits the adaptor protein TRIF to the receptor.  TRIF can then associate with 
TRAF3 which activates inducible IKK (IKK-i) and TRAF family member-associated 
NF-κB activator (TANK)-binding kinase 1 (TBK1).  Both kinases have been show to 
directly phosphorylate and activate IRF3 and IRF7 (Sharma et al., 2003).  TLR3 
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stimulation also leads to TRIF-dependent NF-κB activation through activation of 
receptor interacting protein (RIP)1 (Meylan et al., 2004).  In conjunction with 
MyD88-mediated NF-κB activation, TLR4 also utilises the adaptor protein TRIF to 
activate IRF3 and IRF7 in response to bacterial LPS (Fitzgerald et al., 2003).  Once 
activated, IRF3 and IRF7 bind to regulatory elements in the IFNβ promoter.  The 
IFNβ promoter contains four overlapping positive regulatory domains (PRDs).  PRD1 
and PRDIII are closely related to the IFN-stimulated response element (ISRE), found 
in genes transduced by Type I IFNs, and are bound by members of the IRF family, 
including IRF3 and IRF7.   PRDII is bound and activated by NF-κB and PRDIV is 
regulated by ATF-2 homodimers or ATF-2/c-Jun heterodimers.  These transcription 
factors interact with each other and also with CBP/p300 and high-mobility-group 
protein (HMG) to form a multiprotein transcription-promoting complex called an 
enhanceasome (Maniatis et al., 1998).   
 TLR-signalling can also lead to the activation of Mitogen-activated protein 
kinases (MAPKs).  MAPKs are evolutionary conserved enzymes which transduce 
extracellular signals into cellular responses. MAPKs are controlled by complex 
signalling cascades and regulate a wide range of cellular processes including cell 
proliferation, apoptosis, differentiation, cell migration and gene expression.   There 
are three groups of mammalian MAPKs, extracellular signal-related kinases (ERK)s, 
p38 proteins and Jun amino-terminal kinases (JNK)s (English et al., 1999).  MAPK 
activation involves a three-tiered signalling cascade involving a MAPK, a MAPK 
kinase (MAPKK, MKK or MEK) and a MAPKK kinase (MAPKKK or MEKK).  
ERK1 and ERK2 have been linked to cell proliferation but also have roles in other 
processes.  JNK1/2 and 3 are activated in response to environmental stresses and are 
implicated in apoptosis, cell transformation and cytokine biosynthesis (English et al., 
1999).  JNK phosphorylates and activates c-Jun which, along with the ATF2 or c-Fos, 
forms the transcription factor AP-1.  AP-1 plays a role in the regulation of 
inflammation (Krishnan et al., 2007).   p38 MAPKs can also be activated by stress or 
bacterial infection and have roles in processes such as cytokine biosynthesis, muscle 
differentiation and B cell proliferation (English et al., 1999).  p38 is also involved in 
the activation of subunits of AP-1 (Krishnan et al., 2007) 
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4.1.1  Specific aims of chapter 4 
 
1. Given that previous studies from the lab indicated that Cactin is a negative 
regulator of IRF3 and IRF7 this chapter aimed to dissect the underlying 
mechanism(s) involved. 
  
2. Determine if this inhibition has a functional effect on the production of type 1 
IFNs. 
 
3. Investigate if Cactin regulates MAPK activation. 
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4.2 Results 
 
4.2.1 Cactin inhibits IRF3 and IRF7 activation 
 
In response to viral and bacterial infection IRF3 and IRF7 regulate the 
expression of Type I IFNs.  Type I IFNs encode powerful antiviral molecules and also 
have an important role in bridging innate and adaptive immunity by upregulating co-
stimulatory molecules on antigen-presenting cells (Moynagh, 2005).  TLR3 
recognises dsRNA and activates IRF3 and IRF7, while TLR4 activates IRFs in 
response to bacterial LPS.  In order to investigate if Cactin regulates the activation of 
IRF3 and IRF7 in response to viral and bacterial infection, HEK293 cells stably 
transfected with TLR3 and TLR4 were used.  Cells were transfected with plasmids 
encoding pFA-IRF3 or pFA-IRF7 in conjunction with a pFR luciferase reporter 
plasmid and increasing concentrations of a plasmid encoding myc-tagged Cactin.  
Cactin significantly inhibited the activation of IRF3 and IRF7 in response to the 
synthetic double dsRNA Poly(I:C) in HEK293 TLR3 cells (Figure 4.1A, Figure 4.1B).  
This inhibitory effect is not stimulus specific as Cactin also significantly impaired the 
activation of IRF3 and IRF7 in response to LPS stimulation in HEK293 TLR4 cells 
(Figure 4.1C, Figure 4.1D).   
Because Cactin exhibited such potent inhibitory effects on IRF3 and IRF7 it 
was important to exclude the possibility that Cactin was preventing gene expression 
from the pFA plasmids.  HEK293 TLR3 cells were thus co-transfected with the pFA-
IRF3 plasmid and a myc-tagged Cactin plasmid.  Cells were also treated in the 
presence or absence of Poly(I:C).  The co-expression of Cactin failed to affect the 
expression levels of pFA-IRF3 (Figure 4.2).  This indicates that Cactin regulates the 
activation of IRF3 rather than preventing the expression of IRF3 from the the plasmid.  
Because the above studies were carried out in cells engineered to express TLRs it was 
necessary to assess if Cactin exhibited the same inhibitory effect in cells naturally 
expressing TLRs.  U373 astocytoma cells naturally express TLR3 and respond to 
Poly(I:C).  U373 cells previously transduced with control and Cactin-specific shRNA 
were treated with Poly(I:C) and assessed for phosphorylation of TBK1 as an index of 
TLR3 signalling since TBK1 is the kinase responsible to IRF3 and IRF7 
phosphorylation.  Interestingly U373 cells transduced with Cactin shRNA showed 
increased basal phophorylation of TBK1 compared with cells expressing the control 
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shRNA (Figure 4.3).  This suggests that the pathway may be constitutively active in 
these cells.  Interestingly, suppression of Cactin had no effect on Poly(I:C) induced 
phosphorylation of TBK1.  It is worth noting that suppression of Cactin in U373 cells 
led to increased expression of the IRF responsive gene RANTES, thus confirming the 
inhibitory effects of Cactin in these cells (Atzei et al., 2010). 
 
4.2.2 Cactin inhibits IFNβ gene expression 
 
Since IRFs regulate the expression of Type I IFNs, the effects of Cactin on 
IFNβ gene expression was next assessed.  HEK293 TLR3 cells were transfected with 
plasmids encoding myc-tagged Cactin or empty vector (EV) pcDNA3.1 and 
stimulated with Poly(I:C).  Real-time PCR was performed to quantify the amount of 
IFNβ mRNA transcribed.  Over-expression of Cactin significantly inhibited IFNβ 
induction following 6 h stimulation with Poly(I:C) (Figure 4.4).  In order to 
complement the above findings that used overexpression approaches, the effects of 
Cactin suppression on Poly(I:C) induction of IFNβ was next assessed.  HEK293 cells 
were thus transfected with Cactin specific siRNA.  Real-time PCR confirmed that 
there is ~ 55% knockdown of endogenous Cactin in cells transfected with Cactin-
specific siRNA compared with cells transfected with a scrambled control (Figure 4.5).  
Suppression of endogenous Cactin in HEK293 TLR3 cells augmented the induction of 
IFNβ mRNA following stimulation with Poly(I:C) (Figure 4.6). This confirms the 
earlier findings indicating a functional role for cactin in regulation of IRFs and 
induction of IFNβ. 
 Given the inhibitory effects of Cactin on IRFs and IFNβ expression Cactin was 
next probed for its regulation of the IFNβ promoter. HEK293 TLR3 cells were 
transfected with a reporter plasmid encoding a luciferase gene regulated by the IFNβ-
promoter in the absence or presence of a plasmid encoding Cactin-myc. Cactin 
significantly inhibited Poly(I:C) mediated IFNβ activation (Figure 4.7A). The IFNβ 
promoter contains four overlapping PRD domains.  PRDI and PRDIII are bound and 
regulated by IRFs, while PRDII is activated by NF-κB and PRDIV is bound by ATF-
2/c-Jun.  In order to investigate which domain of the IFNβ promoter are subject to 
regulation by Cactin, HEK293 TLR3 cells were transfected with PRDI-III-Luc, 
PRDII-Luc and PRDIV-Luc reporter plasmids in the presence or absence of Cactin-
myc.  Interestingly, Cactin failed to inhibit Poly(I:C)-induced activation of PRDII.  
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Indeed there was increased Poly(I:C) activation of PRDII in cells transfected with 
Cactin compared with cells transfected with Empty vector (Figure 4.7B).  Cactin did, 
however, inhibit Poly(I:C) mediated activation of PRDI-III and to a lesser extent 
PRDIV (Figure 4.7B).  These results indicate that Cactin negatively regulates IFNβ 
activation by targeting IRFs and inhibiting IRF-mediated activation of the IFNβ 
promoter.    
 
4.2.3 Cactin does not inhibit IRF3 phosphorylation or prevent the translocation 
of IRF3 or IRF7 to the nucleus. 
 
Because the activation of the IRF pathway requires phosphorylation of IRF3 
which subsequently dimerises and translocates to the nucleus, Cactin was next 
assessed for its ability to regulate IRF3 phosphorylation.  HEK293 TLR3 cells were 
transfected with Cactin-specific siRNA and a scrambled siRNA control.  Interestingly 
suppression of Cactin did not augment Poly(I:C) mediated IRF3 phosphorylation as 
detected by Western blotting using an anti-phospho-IRF3 antibody (Figure 4.8).   In 
fact, there was decreased phosphorylated IRF3 detected in cells transfected with 
Cactin specific siRNA.  This indicates that Cactin may exert its inhibitory effects 
downstream of IRF3 phosphorylation and so it was next investigated if Cactin inhibits 
IRF3 translocation to the nucleus.  HEK293 TLR3 cells were thus co-transfected with 
plasmids encoding IRF3-flag and Cactin-myc.  Following 30 min stimulation with 
Poly(I:C), cells were fixed and stained with anti-flag and anti-myc antibodies.  Cells 
were also stained with hoescht to visualise the nuclei.  IRF3-flag was detected in the 
nucleus of Poly(I:C) stimulated cells as visualised by confocal microscopy (Figure 
4.9).  Interestingly, IRF3-flag was also detected in the nucleus of Poly(I:C) stimulated 
cells expressing Cactin-myc (Figure 4.9).  This suggests that Cactin does not inhibit 
the translocation of IRF3 to the nucleus. Similarly, when cells were transfected with 
plasmids encoding IRF7-flag and Cactin-myc, IRF7-flag was detected in the nucleus 
of Poly(I:C) stimulated cells and this was still apparent in cells expressing Cactin-myc 
(Figure 4.10).  The above findings indicate that Cactin is functioning downstream of 
phosphorylation and translocation of IRF3 and IRF7 to the nucleus and so this 
prompted us to investigate if Cactin manifests its inhibitory effects on IRFs within the 
nucleus. 
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4.2.4 The nuclear localisation of Cactin is essential for manifesting its inhibitory 
effects on IRF3 and IRF7 
 
In order to determine if the nuclear localisation of Cactin is important for its 
negative regulation of IRFs a truncated-Cactin mutant was employed.  Truncated-
Cactin lacks a NLS and is expressed exclusively in the cytoplasm (see Figure 3.5 in 
previous chapter).  HEK293 TLR3 or TLR4 cells were transfected with increasing 
concentrations of plasmids encoding Cactin-myc or truncated-Cactin-myc and pFA-
IRF3 or pFA-IRF7 and pFR-regulated firefly luciferase.   Truncated Cactin had 
modest inhibitory effects on Poly(I:C), LPS, and TRIF-mediated IRF3 and IRF7 
activation but the inhibitory effects were greatly reduced when compared with full-
length Cactin (Figure 4.11).  This suggests that the regulatory effects of Cactin on 
IRFs are heavily dependent on its nuclear localisation.   
 
4.2.5 Cactin does not co-immunoprecipitate with IRF3 or IRF7. 
 
As Cactin appears to manifest its inhibitory effects in the nucleus we then 
investigated if Cactin interacts directly with IRF3 and IRF7 and affects their ability to 
bind DNA.  HEK293 TLR3 cells were co-transfected with plasmids encoding IRF3-
flag and Cactin-myc.  Cells were then treated with Poly(I:C) to stimulate IRF3 
phosphorylation and translocation to the nucleus to allow for possible interaction with 
Cactin.  Lysates were generated and immunoprecipitated with an anti-myc antibody.  
IRF3-flag was not detected in immunoprecipitates from cells expressing Cactin-myc 
and IRF3-flag, although IRF3-flag was detected in the corresponding whole cell lysate 
(Figure 4.12).  HEK293 TLR3 cells were also transfected with plasmids encoding 
IRF7-flag and Cactin-myc.  Again, cells were stimulated with Poly(I:C) to stimulate 
IRF7 phosphorylation and translocation to the nucleus.  Lysates were 
immunoprecipitated, using an anti-flag antibody.  Cactin-myc failed to co-
immunoprecipitate with IRF7-flag although it was detected in the whole cell lysate 
(Figure 4.13).  This suggests that Cactin does not interact directly with IRF3 or IRF7 
hinting at an indirect mechanism of action. 
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4.2.6 Suppression of Cactin leads to increased binding of IRF3 to PRDI-III of the 
IFNβ promoter 
 
Nuclear lysates from HEK293 TLR3 cells transfected with Cactin-specific 
siRNA and a scrambled siRNA control were subjected to Western immunoblotting 
using an anti-IRF3 antibody.  Suppression of Cactin did not augment Poly(I:C) 
mediated nuclear translocation of IRF3 to the nucleus.  However, higher levels of 
IRF3 were detected in nuclear lysates from cells transfected with Cactin-specific 
siRNA, compared to cells transfected with a scrambled control, following 24 h 
stimulation with Poly(I:C), presumably due to increased binding of IRF3 to its target 
promoter (Figure 4.14).  Nucleolin/C23 was used as a loading control for nuclear 
lysates.  In order to determine if Cactin prevents IRF3 from binding to the IFNβ 
promoter, HEK293 TLR3 cells were transfected with siRNA specific for Cactin and a 
scrambled siRNA control.  Nuclear lysates were generated and incubated with an 
oligonucleotide encoding PRDI-III of the IFNβ promoter.  Interestingly, there was 
stronger and more prolonged activation of PRDI-III following Poly(I:C) stimulation in 
cells suppressing endogenous Cactin (Figure 4.15).  Supershift analysis indicates the 
presence of IRF3 in the protein-DNA complexes.  The above findings indicate that 
Cactin inhibits IRF3 at the level of DNA-binding and knockdown of Cactin leads to 
more prolonged binding of  IRF3 to the IFNβ promoter. 
 
4.2.7 Cactin inhibits IRF7-induced IFNα expression and affects the stability of 
IRF7 protein 
 
Given the regulatory effects of Cactin on IRF3, Cactin was next assessed for 
its regulation of IRF7 activity. HEK293 TLR3 cells were transfected with a plasmid 
encoding a luciferase reporter gene regulated by the IFNα-1 promoter and with or 
without plasmids encoding Cactin-myc and IRF7-flag.  Cactin significantly inhibited 
IRF7-induced activation of IFNα-luc (Figure 4.16).  These findings suggest that 
Cactin targets IRF7 in addition to IRF3.  IRF7 is subject to post-translational 
modifications including phosphorylation and ubiquitination following Poly(I:C) 
stimulation (Ning et al., 2011) which regulates its expression.  To examine the effect 
of Cactin on IRF7 protein expression, HEK293 TLR3 cells were transfected with a 
plasmid encoding flag tagged IRF7 and with or without Cactin-specific siRNA or a 
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plasmid encoding myc-tagged Cactin.  Interestingly, suppression of Cactin led to 
stabilization of IRF7-flag in unstimulated cells (Figure 4.17A).  Furthermore, over-
expression of Cactin inhibited poly(I:C) mediated stabilisation of IRF7-flag (Figure 
4.17B).  These results further confirm that Cactin negatively regulates IRF7. 
 
4.2.8 Cactin positively regulates the activation of the MAPKs JNK, p38 and 
ERK1/2 
 
As part of the above studies, interrogating the effects of Cactin on IFNβ 
expression, it was noted that Cactin, whilst showing strong regulatory potential on 
IRFs and the PRDI-III region of the IFNβ promoter, it also showed some modest 
regulation of the PRDIV domain. Given that the latter is driven by AP-1 complexes 
that are regulated by MAPK signalling the susceptibility of the MAPK pathways to 
Cactin was next probed.  JNK phosphorylates and activates the AP-1 subunit c-jun 
and so to investigate if Cactin regulates JNK signalling HEK293 cells were 
transfected with plasmids encoding pFA-Jun and pFR-regulated firefly luciferase.  
MEKK1 was also over-expressed in these cells as a positive control to drive the 
activation of c-Jun.  Intriguingly over-expression of Cactin enhanced MEKK1 
activation of c-Jun (Figure 4.18).  To examine if Cactin regulates JNK activation in a 
physiologically relevant system U373 cells previously transduced with Cactin-specific 
shRNA or a non-specific shRNA control were employed.  Samples were generated 
from Poly(I:C) stimulated cells and subjected to Western immunoblotting.  There 
were decreased levels of phospho-JNK detected in cells suppressing endogenous 
Cactin (Figure 4.19).  Furthermore, there were also decreased levels of phospho-p38 
and phospho-ERK1/2 detected in cells transduced with Cactin-specific shRNA 
compared with cells transduced with a control shRNA (Figure 4.19).  These data 
indicate that Cactin can act  as a positive regulator of JNK, p38 and ERK1/2 activation 
in response to TLR3 stimulation. We next examined if such a role for Cactin in 
regulating MAPK activation extends to the TLR4 pathway. 
 U373 cells transduced with Cactin-specific and control shRNA were treated 
with LPS for various time-points and the levels of phospho-ERK1/2, p38 and JNK 
were again visualised by Western Immunoblotting.  Interestingly, similar levels of 
phosphorylated ERK1/2, p38 and JNK were detected in cells suppressing endogenous 
Cactin (Figure 4.20).  This suggests that the effects of Cactin on these MAPKs may be 
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stimulus specific.  These results were confirmed using densitometry analysis (Figure 
4.21). 
 
4.2.9 p38 positively regulates IRF3 and IRF7 activation 
 
As Cactin was displaying such strong regulatory effects on Poly(I:C) induced 
p38 phosphorylation it seemed necessary to investigate if phosphorylation of p38 is 
required for Cactin to manifest its inhibitory effects.  To investigate this, HEK293 
TLR3 cells were transfected with pFA-IRF3 and pFR-regulated luciferase constructs.  
Cells were also transfected with a plasmid encoding a dominant negative mutant of 
p38 (∆p38).  Interestingly overexpression of ∆p38 inhibited Poly(I:C) mediated IRF3 
activation (Figure 4.22A).  Furthermore, pre-treatment of cells with the p38 inhibitor 
SB 203580 inhibited Poly(I:C)-mediated IRF3 activation (Figure 4.22B).  Similarly, 
overexpression of ∆p38 inhibited Poly(I:C) induced activation of IRF7 as did 
treatment with SB 203580 (Figure 4.23).  As phosphorylation of p38 promotes the 
activation of IRF3 and IRF7, this indicates that phosphorylation of p38 is not 
important for Cactin’s inhibitory effects on IRFs. 
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Figure 4.1  Cactin inhibits Poly(I:C) and LPS-mediated activation of IRF3 and 
IRF7 
HEK293 TLR3 or TLR4 cells were cotransfected with plasmids encoding (A, C) 
pFA-IRF3 (30 ng) or (B, D) pFA-IRF7 (25 ng), pFR-regulated firefly luciferase (60 
ng) and constitutively expressed TK Renilla luciferase (20 ng) in the absence or 
presence of a plasmid encoding myc-tagged Cactin (30, 60 or 90 ng).  Empty vector 
pcDNA3.1 was used to normalise the total amount of DNA transfected.  24 h post-
transfection cells were treated overnight with (A, B) Poly(I:C) (25 μg/ml) or (C, D) 
LPS (100 ng/ml). Lysates were generated and assayed for firefly and Renilla 
luciferase activity. Results shown are the mean +/- S.E.M. of triplicate determinations 
from three independent experiments.  * p < 0.05, paired t-test, ligand stimulated cells 
transfected with Cactin compared with ligand stimulated cells transfected with EV. 
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Figure 4.2 Cactin does not affect expression levels of pFA-IRF3 
HEK293 TLR3 cells were transfected with plasmids encoding pFA-IRF3 (2 μg) and 
Cactin-myc (2 μg).  Empty vector pcDNA3.1 was used to normalise the total amount 
of DNA transfected.  24 h post transfection cells were treated with or without 
Poly(I:C) (25 μg/ml) for 1 h.  Lysates were generated and subjected to Western 
Immunoblotting using anti-IRF3 and anti-myc antibodies.  Immunoreactivity was 
visualised using the Odyssey Infrared imaging system.  Results shown are 
representative of two independent experiments. 
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Figure 4.3  Effect of Cactin knockdown on phosphorylation of TBK1 in U373 
cells 
U373 cells stably transduced with Control shRNA and Cactin specific shRNA were 
treated with Poly(I:C) (10 μg/ml) for the indicated time periods.  Cells were lysed in 
SDS-PAGE sample buffer and samples subjected to  Western blotting using anti-
phospho-TBK1, anti-TBK1 and anti-β-actin antibodies.  Immunoreactivity was 
visualised using the Odyssey Infrared imaging system.  Results shown are indicative 
of three independent experiments.  
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Figure 4.4  Overexpression of Cactin inhibits Poly(I:C) induction of IFNβ 
HEK293 TLR3 cells were transfected with myc-tagged Cactin (2 μg) or Empty Vector 
(EV) pcDNA3.1 (2 μg).  24 hours post-transfection cells were treated with Poly(I:C) 
(25 μg/ml) for the indicated time periods. Total RNA was extracted and cDNA was 
generated using RT-PCR.  Samples were subsequently assayed by quantitative real-
time PCR for levels of IFNβ.  Gene expression was calculated relative to the 
housekeeping gene HPRT and analysis was performed using the 2
-∆∆CT
 method.  Data 
represent the mean +/- S.E. of three independent experiments. * p < 0.05, paired t-test, 
Poly(I:C) stimulated cells expressing Cactin compared with ligand stimulating cells 
transfected with EV. 
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Figure 4.5  Cactin-specific siRNA suppresses endogenous Cactin expression in 
HEK293 cells 
HEK293 TLR3 cells were transfected with Cactin specific siRNA or scrambled 
siRNA (25 nM).  Total RNA was extracted and cDNA was generated using RT-PCR.  
Samples were subsequently assayed by quantitative real-time PCR for levels of 
Cactin.  (A) Gene expression was calculated relative to the housekeeping gene HPRT 
and analysis was performed using the 2
-∆∆CT
 method.  Data represent the mean +/- S.E. 
of three independent experiments.  (B) Real-time products were separated by gel 
electrophoresis.  Results shown are representative of three independent experiments. 
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Figure 4.6  Suppression of endogenous Cactin augments Poly(I:C) induced IFNβ 
HEK293 TLR3 cells were transfected with Cactin specific and scrambled siRNA (25 
nM).  Cells were treated for the indicated time-points with Poly(I:C) (25 μg/ml).  
Total RNA was extracted 48 h post-transfection and cDNA was generated by RT-
PCR.  Samples were then assayed by real-time PCR for levels of IFNβ.  Gene 
expression was calculated relative to the housekeeping gene HPRT and analysis was 
performed using the 2
-∆∆CT
 method.  Data represent the mean +/- S.E. of three 
independent experiments.  * p < 0.05, paired t-test, Poly(I:C) stimulated cells 
transfected with Cactin siRNA compared with cells transfected with scrambled siRNA 
control. 
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Figure 4.7  Cactin inhibits Poly(I:C)-mediated IFNβ activation and inhibits the 
activation of PRDI-III and PRDIV but not PRDII of the IFNβ promoter 
HEK293 TLR3 cells were co-transfected with plasmids encoding (A) IFNβ luciferase 
reporter plasmid (80 ng) or (B) PRDI-III, PRDII and PRDIV luciferase reporter 
plasmids (80 ng) and constitutively expressed TK Renilla (20 ng) and were transfected 
with plasmids encoding Cactin-myc (90 ng) or Empty Vector (EV) pcDNA3.1 (90 
ng).  Transfected cells were left overnight and then treated with Poly(I:C) (25 μg/ml) 
for 24 h.  Lysates were generated and assayed for firefly and Renilla luciferase 
activity.  Data presented and the mean +/- S.E.M. of triplicate determinations from 
three independent experiments. * p < 0.05, ** p < 0.01, paired t-test, Poly(I:C) 
stimulated cells expressing Cactin compared with Poly(I:C) stimulated cells 
transfected with EV. 
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Figure 4.8  Effect of  Cactin knockdown on  IRF3 phosphorylation 
HEK293 TLR3 cells were transfected with Cactin specific and scrambled siRNA (25 
nM). 24 h post-transfection cells were treated with the indicated time periods with 
Poly(I:C) (25 μg/ml).  Lysates were generated and subjected to Western 
Immunoblotting using anti-phospho-IRF3, anti-IRF3 and anti-β-actin antibodies.  
Immunoreactivity was visualised using the Odyssey Infrared imaging system.  Blots 
shown are a representative of three independent experiments. 
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Figure 4.9  Overexpression of Cactin does not prevent the translocation of IRF3 
to the nucleus 
HEK293 TLR3 cells were co-transfected with plasmids encoding Flag-tagged IRF3 (2 
μg) and myc-tagged Cactin (2 μg). pcDNA3.1 was used to normalise the total amount 
of DNA transfected. 24 h post transfection cells were treated with or without Poly(I:C) 
(25 μg/ml) for 30 min. Cells were fixed, stained with hoescht, anti-flag and anti-myc 
antibodies and mounted in anti-fade medium.  Confocal images were captured using 
the Olympus FluoView FV1000 confocal laser scanning microscope. Data analysis 
was performed using the Olympus FV-10 ASW imaging software. Results shown are 
representative of two independent experiments. 
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Figure 4.10  Overexpression of Cactin does not prevent nuclear translocation of 
IRF7  
HEK293 TLR3 cells were co-transfected with flag-tagged IRF7 (2 μg) and myc-
tagged Cactin (2 μg). 24 h post-transfection cells were treated with Poly(I:C) (25 
μg/ml) for 30 min.  Cells were fixed, stained with anti-flag and anti-myc antibodies, 
stained with hoescht and mounted in anti-fade medium.  Confocal images were 
captured with the Olympus FluoView FV1000 confocal laser scanning microscope 
and data analysis was performed using the Olympus FV-10 ASW imaging software.  
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Figure 4.11 Nuclear localisation of Cactin is important for manifesting its 
inhibitory effects on IRF3 and IRF7 
HEK293 TLR3 or TLR4 cells were co-transfected with (A, C, E)  pFA-IRF3 (30 ng) 
or (B, D, F) pFA-IRF7 (25 ng), pFR-regulated firefly luciferase (60 ng) and 
constitutively expressed TK Renilla (20 ng) and transfected with or without plasmids 
encoding myc-tagged Cactin (30, 60 or 90 ng), myc-tagged truncated Cactin (30, 60 or 
90 ng) and TRIF (50 ng).  Empty vector (EV) pcDNA3.1 was used to normalise the 
amount of DNA transfected. Cells were treated with and without (A, B) Poly(I:C) (25 
μg/ml) or (C, D) LPS (100 ng/ml) overnight.  Lysates were generated and assayed for 
firefly and Renilla luciferase activity.  Data are the mean +/- S.E.M. for triplicate 
determinations from three independent experiments. * p < 0.05, ** p < 0.01, paired t-
test, ligand stimulated or TRIF expressing cells transfected with Cactin or T-Cactin 
compared with ligand stimulated or TRIF expressing cells transfected with EV. 
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Figure 4.12  IRF3 does not co-immunoprecipitate with Cactin 
HEK293 TLR3 cells were co-transfected with flag-tagged IRF3 (2 μg) and myc-
tagged Cactin (2 μg). Empty vector pcDNA 3.1 was used to normalise the total 
amount of DNA transfected.  Transfected cells were left overnight and then treated for 
30 min with Poly(I:C) (25 μg/ml).  Lysates were generated and immunoprecipitated 
with an anti-myc antibody.  Immunoprecipitaes and whole cell lysates (WCL)s were 
subjected to Western immunoblotting with anti-flag and anti-myc antibodies.  
Immunoreactivity was visualised with the Odyssey Infrared imaging system.  Results 
shown are representative of three independent experiments.  
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Figure 4.13 Cactin does not co-immunoprecipitate with IRF7 
HEK293 TLR3 cells were co-transfected with myc-tagged Cactin (2 μg) and flag-
tagged IRF7 (2 μg).  Empty vector pcDNA3.1 was used to normalise the total amount 
of DNA transfected.  Transfected cells were left overnight and then treated with 
Poly(I:C) (25 μg/ml) for 30 mins.  Lysates were generated and then 
immunoprecipitated with an anti-flag antibody.  Immunoprecipitates and whole cell 
lysates (WCL)s were subjected to Western Immunoblotting using anti-myc and anti-
flag antibodies.  Immunoreactivity was visualised with the Odyssey Infrared imaging 
system.  Blots shown are indicative of three independent experiments. 
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Figure 4.14  Suppression of endogenous Cactin leads to increased nuclear levels 
of IRF3 in response to  Poly(I:C) 
HEK293 TLR3 cells were transfected with Cactin specific and scrambled siRNA (25 
nM).  24 h post-transfection cells were treated for the indicated time-periods with 
Poly(I:C) (25 μg/ml).  Nuclear lysates were generated and subjected to Western 
immunoblotting using anti-IRF3 and anti-Nucleolin antibodies.  Immunoreactivity 
was visualised using the Odyssey Infrared imaging system.  Blots shown are 
indicative of two independent experiments. 
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Figure 4.15 Suppression of endogenous Cactin expression augments IRF3 
binding to the IFNβ promoter 
HEK293 TLR3 cells were transfected with Cactin specific and scrambled siRNA (25 
nM).  24 h post-transfection cells were treated with Poly(I:C) (25 μg/ml) for the 
indicated time periods.  Nuclear lysates were generated and assayed for binding to an 
oligonucleotide encoding PRDI-III of the IFNβ promoter by EMSA.  Lysates from 
cells treated with Poly(I:C) for 2 h and transfected with Cactin specific siRNA were 
incubated with an anti-IRF3 antibody or non specific IgG before assaying for DNA-
binding activity.  Immunoreactivity was visualised using the Odyssey Infrared 
imaging system.  Results shown are representative of three independent experiments.  
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Figure 4.16 Cactin inhibits IRF7-induced activation of the IFNα-1 promoter 
HEK293 TLR3 cells were co-transfected with plasmids encoding an IFNα-1 firefly 
luciferase reporter plasmid (80 ng) and constitutively expressed TK Renilla luciferase 
(20 ng) and with or without plasmids encoding myc-tagged Cactin (90 ng) and flag 
tagged IRF7 (50 ng).  Empty Vector (EV) pcDNA3.1 was used to normalise the total 
amount of DNA transfected. Lysates were generated 24 h post transfection and 
assayed for firefly and Renilla luciferase activity.  Data shown are the mean +/- 
S.E.M. of triplicate determinations from three independent experiments. * p < 0.05, 
paired t-test, IRF7 transfected cells expressing Cactin compared with IRF7 expressing 
cells transfected with EV. 
 
 
 
 
 
 
 
  
 
0
50
100
150
200
250
300
EV Cactin
IF
N
a
lp
h
a
 F
o
ld
 I
n
d
u
c
ti
o
n
EV
IRF7
*
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17  Cactin regulates protein levels of  IRF7 
(A) HEK293 TLR3 cells were co-transfected with Cactin specific and scrambled 
siRNA (25 nM) and a plasmid encoding flag-tagged IRF7 (2 μg).  (B) HEK293 TLR3 
cells were co-transfected with a plasmid encoding flag-tagged IRF7 (2 μg) and with or 
without a plasmid encoding myc-tagged Cactin (2 μg).  Empty Vector (EV) 
pcDNA3.1 was used to normalise the total amount of DNA transfected.  Transfected 
cells were left overnight and then treated for the indicated time points with Poly(I:C) 
(25 μg/ml).  Lysates were generated 48 h post-transfection and subjected to Western 
immunoblotting using anti-flag, anti-β-actin and anti-myc antibodies.  
Immunoreactivity was visualised using the Odyssey Infrared imaging system.  Blots 
shown are representative of three independent experiments. 
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Figure 4.18  Cactin positively regulates c-Jun activation 
HEK293 TLR4 cells were co-transfected with plasmids encoding pFA-jun (30 ng), 
pFR-regulated firefly luciferase (60 ng) and constitutively expressed TK Renilla 
luciferase (20 ng) and with or without plasmids encoding myc-tagged Cactin (30, 60 
and 90 ng) and MEKK1 (20 ng).  Empty Vector (EV) pcDNA3.1 was used to 
normalise the total amount of DNA transfected.  Lysates were generated 24 h post 
transfection and assayed for firefly luciferase activity and normalised for transfection 
efficiency using Renilla luciferase activity. Data are presented as the mean +/- S.E.M. 
of triplicate determinations from three independent experiments. ** p < 0.01, paired t-
test, MEKK1 expressing cells transfected with Cactin compared with MEKK1 
expressing cells transfected with EV. 
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Figure 4.19  Knockdown of Cactin inhibits TLR3-induced MAPK signalling in  
U373 cells  
U373 cells previously transduced with control and Cactin specific shRNA were 
treated for the indicated time periods with Poly(I:C) (10 μg/ml).  Cells were harvested 
in SDS-PAGE sample buffer and subjected to Western immunoblotting using anti-
phospho-ERK1/2, anti-ERK1/2, anti-phospho-p38, anti-p38, anti-phospho-JNK, anti-
JNK and anti-β-actin antibodies.  Immunoreactivity was visualised using the Odyssey 
Infrared imaging system.  Results shown are representative of two independent 
experiments. 
 
 
p-ERK1/2 
ERK1/2 
p-p38 
p38 
p-JNK 
JNK 
β-actin 
0    15’ 30’ 1h   4h   24h   0    15’ 30’ 1h   4h  24h     Poly(I:C)
CT shRNA Cactin shRNA
- 35
- 35
- 35
- 35
- 35
- 55
- 55
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20  Suppression of endogenous Cactin fails to affect LPS mediated 
phosphorylation of ERK1/2, p38 and JNK in U373 cells. 
U373 cells previously transduced with control and Cactin specific shRNA were 
treated for the indicated time periods with LPS (100 ng/ml).  Cells were harvested in 
SDS-PAGE sample buffer and subjected to Western immunoblotting using anti-
phospho-ERK1/2, anti-ERK1/2, anti-phospho-p38, anti-p38, anti-phospho-JNK, anti-
JNK and anti-β-actin antibodies.  Immunoreactivity was visualised using the Odyssey 
Infrared imaging system.  Results shown are representative of two independent 
experiments. 
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Figure 4.21  Densitometry analysis of western blots seen in Figure 4.19 and 
Figure 4.20. 
Levels of phospho-ERK1/2, phospho-p38 and phospho-JNK were determined by 
densitometry and normalised to the amount of total ERK1/2, p38 or JNK and relative 
to the amount detected in non-treated samples.   Densitometry was performed using 
ImageJ software. 
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Figure 4.22  p38 positively regulates IRF3 activation 
(A)  HEK293 TLR3 cells were co-transfected with plasmids encoding pFA-IRF3 (30 
ng), pFR-regulated firefly luciferase (60 ng) and constitutively expressed TK Renilla 
(20 ng) and with or without plasmids encoding myc-tagged Cactin (90 ng) and a 
dominant negative mutant of p38 (∆p38) (50 ng).  Transfected cells were left 
overnight and then treated with Poly(I:C) (25 μg/ml) for 24 h.  (B)  HEK293 TLR3 
cells were co-transfected with plasmids encoding pFA-IRF3 (30 ng), pFR-regulated 
firefly luciferase (60 ng) and constitutively expressed TK Renilla (20 ng).  Cells were 
pre-treated with various concentrations of SB 203580 prior to stimulation with 
Poly(I:C) (25 μg/ml) for 24 h.  Lysates were generated and assayed for firefly and 
Renilla luciferase activity.  Data presented are the mean +/- S.E.M. of triplicate 
determinations from three independent experiments. * p < 0.05, ** p < 0.01, *** p < 
0.001, paired t-test, (A) Ligand stimulated cells transfected with EV compared with 
ligand stimulated cells transfected with Cactin and/or ∆p38 and (B) Ligand stimulated 
cells pretreated with SB 203580 compared with ligand stimulated cells pre-treated 
with DMSO. 
A
B
0
1
2
3
4
5
6
7
8
9
0 1 5 20
SB 203580 uM
IR
F
3
 F
o
ld
 I
n
d
u
c
ti
o
n
- Poly(I:C)
+ Poly(I:C)
*
* *
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
EV Δp38 EV Δp38
EV Cactin
IR
F
3
 F
o
ld
 I
n
d
u
c
ti
o
n
- Poly(I:C)
+ Poly(I:C)
** **
***
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.23  p38 positively regulates IRF7 activation 
(A)  HEK293 TLR3 cells were co-transfected with plasmids encoding pFA-IRF7 (25 
ng), pFR-regulated firefly luciferase (60 ng) and constitutively expressed TK Renilla 
(20 ng) and with or without plasmids encoding myc-tagged Cactin (90 ng) and a 
dominant negative mutant of p38 (∆p38) (50 ng).  Transfected cells were then treated 
with Poly(I:C) (25 μg/ml) for 24 h.  (B)  HEK293 TLR3 cells were co-transfected 
with plasmids encoding pFA-IRF7 (25 ng), pFR-regulated firefly luciferase (60 ng) 
and constitutively expressed TK Renilla (20 ng). Cells were pretreated with various 
concentrations of SB 203580 for 1 h prior to stimulation with Poly(I:C) (25 μg/ml) for 
24 h.  Lysates were generated and assayed for firefly and Renilla luciferase activity.  
Data presented are the mean +/- S.E.M. of triplicate determinations from three 
independent experiments. * p < 0.05, *** P < 0.001, paired t-test, (A) Ligand 
stimulated cells transfected with EV compared with ligand stimulated cells transfected 
with Cactin and/or ∆p38 and (B) Ligand stimulated cells pretreated with SB 203580 
compared with ligand stimulated cells pre-treated with DMSO. 
A
B
0
5
10
15
20
25
30
35
0 1 5 20
SB 203580 uM
IR
F
7
 F
o
ld
 I
n
d
u
c
ti
o
n
- Poly(I:C)
+ Poly(I:C)
*** ***
0
2
4
6
8
10
12
14
16
18
EV Δp38 EV Δp38
EV Cactin
IR
F
7
 F
o
ld
 I
n
d
u
c
ti
o
n
- Poly(I:C)
+ Poly(I:C)
*
*
*
4.3 Discussion  
 
The production of Type I IFNs is essential for mounting an efficient immune 
response to invading pathogens.  However dysregulation of the pathways controlling 
Type I IFN expression can contribute to the development of autoimmune and 
autoinflammatory disorders such as Rheumatoid arthritis (RA) (Ivashkiv and Hu, 
2003) and systemic lupus erythamatosis (SLE) (Hu et al., 2008).  The activation of 
Type I IFNs is tightly regulated at various stages to avoid the development of 
autoimmune disorders and also to prevent undue stress in uninfected cells.  For 
example, the half-life of IFN-induced IRF7 is only 0.5-1 h, most likely to ensure that 
the production of Type I IFNs is transient (Sato et al., 2000).  Peptidyl-prolyl 
isomerase Pin1 is a negative regulator of Type I IFNs and ubiquitinates activated 
IRF3, marking it as a target for proteosomal degradation (Saitoh et al., 2006).  Some 
members of the IRF family, IRF2 and IRF8, bind to ISREs and negatively regulate 
gene expression (Goodbourn et al., 2000). The present studies now suggest that Cactin 
is a novel negative regulator of Type I IFNs. 
 Consistent with previous findings from the lab the data here indicates that 
Cactin is a powerful negative regulator of IRF3 and IRF7 activation.  This inhibitory 
effect was found to be stimulus and cell type independent as Cactin negatively 
regulated the activation of IRF3 and IRF7 in response to Poly(I:C) and LPS in 
HEK293 cells and suppression of endogenous Cactin led to increased expression of 
RANTES in U373 cells.  Importantly this study showed that Cactin negatively 
regulates IFNβ induction.  Over-expression of Cactin inhibited Poly(I:C) induced 
IFNβ while suppression of endogenous Cactin enhanced IFNβ expression.  
Interestingly, Cactin has no effect on the phosphorylation of IRF3 or translocation of 
IRF3 or IRF7 to the nucleus.  However, suppression of Cactin leads to increased 
binding of IRF3 to PRDI-III of the IFNβ promoter.  Together these results suggest that 
Cactin inhibits IRFs at the level of DNA binding.  This is consistent with findings 
from the previous chapter indicating that Cactin inhibits NF-κB-DNA binding.  Indeed 
nuclear localisation was shown to be critical for Cactin to manifest its inhibitory 
effects on IRF3 and IRF7 as a truncated-Cactin mutant failed to manifest the same 
inhibitory effects on LPS, Poly(I:C) and TRIF-mediated IRF3 and IRF7 activation.  
Interestingly, this inhibition was not achieved through direct binding of Cactin to 
IRF3.  It is possible that Cactin interacts with other IRF3 binding proteins.  For 
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example, association of CBP/p300 and IRF3 has been shown to be essential for IRF3-
DNA binding activity (Suhara et al., 2002).  Interference with this association could 
therefore repress the DNA binding activity of IRF3. 
 IRF7 is essential for the induction of IFNα genes.  Notably, Cactin inhibited 
IRF7-induced activation of the IFNα-1 promoter.  This confirms that Cactin also 
targets IRF7.  IRF7 is subject to post-translational modifications including 
phosphorylation and ubiquitination following Poly(I:C) stimulation (Ning et al., 
2011).  K48-linked ubiquitination of IRF7 promotes its proteosomal degradation.  The 
results here indicate that overexpressed IRF7 is degraded in the absence of Poly(I:C) 
in HEK293 cells.  Interestingly, suppression of Cactin expression prevented this 
degredation.  Furthermore, overexpression of Cactin inhibited the Poly(I:C) induced 
stabilisation of Cactin and this is also a contributory mechanism to the inhibitory 
effects of Cactin on IFNβ expression.  The regulatory effects of Cactin on IRF7 are 
particularly interesting due to the role of IRF7 in autoimmune diseases such as SLE, 
psoriasis and systemic sclerosis (SSc) (Sozzani et al., 2010).  This raises the 
possibility of exploiting Cactin for the treatment of these autoimmune diseases.  It 
would be interesting, in the future, to look at the expression levels of Cactin is 
autoimmune diseases such as SLE. 
 As Cactin negatively regulates the activation of a range of transcription factors 
including NF-κB, IRF3 and IRF7 it was important to ensure that such effects were not 
non-specific, reflecting inhibitory effects on global transcription. Importantly, Cactin 
enhanced c-Jun-induced gene expression indicating that Cactin can differentially 
regulate specific transcription factors.  It also suggests that Cactin is a positive 
regulator of JNK activation which was further confirmed when suppression of 
endogenous Cactin decreased Poly(I:C) mediated JNK phosphorylation.  Furthermore, 
Cactin also positively regulates Poly(I:C) mediated phosphorylation of MAPKs p38 
and ERK1/2.  p38 has a role in LPS mediated IRF3 activation in U373 cells (Navarro 
and David, 1999).  p38 is also required for CpG-DNA mediated IRF7 activation in 
plasmacytoid dentritic cell precursors (Takauchi et al., 2002).  This current study 
indicates that p38 is also a positive regulator of Poly(I:C) mediated IRF3 and IRF7 
activation.   This appears to be somewhat of a contradiction as Cactin positively 
regulates the activation of p38 which should lead to increased activation of IRF3.  
However, Cactin inhibits IRF3 at the level of DNA binding and so this inhibition 
would override any upstream affects on MAPK activation.  This also would also 
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explain how Cactin can positively regulate JNK phosphorylation but negatively 
regulates binding of AP-1 heterodimers to PRDIV of the IFNβ promoter.  The positive 
regulation of p38 by Cactin also explains how suppression of endogenous Cactin leads 
to decreased phosphorylation of IRF3 in response to Poly(I:C). 
  In order to explore the mechanism by which Cactin negatively regulates TLR-
signalling it is important to identify novel Cactin-interacting proteins and to 
characterise the functional consequences of these interactions.  Such studies form the 
content of the next chapter.   
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Chapter 5 
 
 
 
Identifying Cactin-interacting proteins and 
determining the functional consequences of these 
interactions 
 
 
 
 
 
 
 
 
 
 
 
 5.1 Introduction 
 
In order to further dissect the mechanism by which Cactin negatively regulates 
TLR-signalling it was necessary to investigate potential protein-interacting partners 
for Cactin.  Prior to this current study Mass Spectrometry analysis was carried out to 
identify proteins that co-immunoprecipitated with Cactin and this approach identified 
several potential Cactin interactors (Table 5.1).  This study was especially interested 
in validating putative interactions with proteins of relevance to pathways that are 
regulated by Cactin. One such interactor was Activating signal cointegrator 1 complex 
subunit 1 (ASCC1).  ASSC1 was identified as a component of the ASC-1 complex 
which regulates NF-κB, AP-1 and serum response factor (SRF) (Jung et al. 2002).  
The ASC-1 complex binds directly to SRF, AP-1 subunit Jun and NF-κB subunits p50 
and p65 and positively regulates transactivation.  ASC-1 is also a transcription 
coactivator of nuclear receptors (Kim et al., 1999).  ASCC1 contains an RNA-binding 
motif termed KH and this domain appears to be essential for its function and 
interaction with other components of the ASC-1 complex (Jung et al., 2002).   
Potential interaction of Cactin and ASCC1 seemed interesting as ASCC1 has been 
shown to enhance NF-κB and AP-1 transactivation and so this study aimed to confirm 
this interaction by co-immunoprecipitation.   
PAK1 interacting protein 1 (PAK1IP1) was another potential Cactin-interactor 
identified by Mass Spectrometry.  The p21-activated kinases (PAKs) are a family of 
serine-threonine protein kinases regulated by small GTPases, CDc42 and Rac (Manser 
et al., 1994).  There are four known isoforms, PAK1-4, which are differentially 
expressed in mammalian cells and regulate diverse cellular functions.  PAK1 has been 
shown to activate the MAPK signalling cascades resulting in JNK and p38 activation 
(Bagrodia et al., 1995).   PAK1 can also activate NF-κB in response to various stimuli 
including LPS (Frost et al., 2000).  PAK proteins all possess an N-terminal 
autoregulatory domain and C-terminal kinase domain and form inactive dimers in 
unstimulated cells.  PAKs are activated by binding of GTPases to the N-terminal 
domain disrupting the dimer and resulting in an active kinase.  PAK1IP1 interacts 
with the N-terminal autoregulatory domain of PAK1 and inhibits PAK1 mediated 
activation of NF-κB and JNK (Xia et al., 2001).  Given that PAK1IP1 and Cactin both 
83 
negatively regulate NF-κB activation we wanted to confirm this possible interaction 
and to determine if these proteins co-operate in order to inhibit NF-κB activation. 
Given that drosophila Cactin was discovered as an interactor of Cactus, we 
decided to investigate if human Cactin interacts with IκBα, or other members of the 
IκB family.  IκB family members all possess five to seven ankyrin repeat motifs 
which mediate interaction with the RHD of Rel/NF-κB proteins (Oeckingus and 
Ghosh, 2009).  In the unstimulated cell, cytoplasmic IκB proteins, IκBα, IκBβ, and 
IκBε are found in association with NF-κB dimers.  The amino terminal of cytoplasmic 
IκBs contains conserved serine and lysine residues which can be phosphorylated and 
ubiquitinated respectively, marking them as targets for K48-linked ubiquitination and 
subsequent proteosomal degradation (Manavalan et al., 2010).  This allows for NF-κB 
to translocate to the nucleus and regulate gene expression.   Nuclear IκBs, including 
IκBζ, IκBNS, IκB-like (IκBL) and Bcl-3 also possess these ankyrin repeats and some 
have been shown to interact directly with NF-κB dimers.  IκBζ inhibits DNA binding 
and transactivation of p65-containing NF-κB complexes but also appears to upregulate 
the expression of some NF-κB-regulated genes (Oeckingus and Ghosh, 2009).  Bcl-3 
has also been shown to both promote and inhibit transcriptional activity (Yammamoto 
and Takeda, 2008).  Nuclear IκBs have been shown to interact with proteins other than 
NF-κB subunits.  For example, IκBζ can interact with and inhibit STAT3 activity (Wu 
et al., 2009).  IκBL has been shown to interact with translation elongation factor 1 α 
and CTP synthase 1 and can also associate directly with mRNA, suggesting a role for 
IκBL in mRNA processing or in regulation of translation (Greetham et al., 2007).  It is 
clear that nuclear IκB proteins are complex regulators of gene expression.  Given that 
Cactin is expressed in the nucleus it was interesting to investigate if Cactin might 
interact with nuclear members of the IκB family thus regulating NF-κB activation.  
Using a combination of the unbiased proteomic-based screening (described above) 
with more targeted analysis of IB proteins, the studies described in this chapter 
hoped to provide an increased understanding of the mechanisms underlying the 
regulatory effects of Cactin by identifying and validating Cactin interactors of 
functional relevance.  
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5.1.1 Specific aims of Chapter 5 
 
1. Validating Cactin interactors detected by Mass Spectrometry analysis. 
 
2. Investigate if Cactin interacts with IκBα or other members of the IκB family. 
 
3. Determine the functional relevance of any interactions detected. 
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5.2 Results  
 
5.2.1 Cactin-myc does not co-immunoprecipitate with PAK1IP1-HA 
 
Proteomic-based analysis, carried out prior to this study, identified PAK1IP1 
as an interactor of Cactin.  HEK293 T cells were transfected with Myc-tagged hCactin 
and cell lysates were immunoprecipitated using anti-IgG mouse or anti-myc 
antibodies. The immunoprecipitates were resolved in a SDS acrylamide gel and both 
lanes in the gel were cut into slices and the proteins were digested with trypsin and 
subjected to nano-electrospray liquid chromatography mass spectrometry
 
(Nano-LC 
MS/MS).  We were keen to confirm this interaction by co-immunoprecipitation.  To 
do this HEK293 TLR4 cells were co-transfected with plasmids encoding HA-tagged 
PAK1IP1 and myc-tagged Cactin.  Lysates were generated and immunoprecipitated 
with an anti-HA antibody.  PAK1IP1-HA was detected in immunoprecipitates from 
cells expressing PAK1IP1-HA indicating that the immunoprecipitation process was 
successful (Figure 5.1). However Cactin-myc was not detectable in 
immunoprecipitates from cells expressing both PAK1IP1-HA and Cactin-myc 
although it was detected in the corresponding whole cell lysates (Figure 5.1).  This 
suggests that PAK1IP1 and Cactin do not interact.  It is worth noting that cells were 
also treated with IL-1β and Poly(I:C)  to assess if any potential interaction could be 
stimulus dependent but again no interaction was detected. 
 
5.2.2 ASCC1 co-immunoprecipitates with Cactin-myc 
 
ASCC1 is another protein that had been identified as a Cactin interactor by our 
proteomic approach.  To confirm this interaction HEK293 TLR4 cells were co-
transfected with plasmids encoding ASCC1 and myc-tagged Cactin.  Lysates were 
generated and immunoprecipitated with an anti-myc antibody.  ASCC1 was detected 
in immunoprecipitates from cells over-expressing ASCC1 and Cactin-myc, indicating 
that there was some interaction between the two proteins (Figure 5.2).  To further 
confirm this interaction by confocal microscopy HEK293 TLR4 cells were transfected 
with plasmids encoding Cactin-myc and ASCC1, fixed and stained with anti-ASCC1 
and anti-myc antibodies.  Cells were also stained with Hoescht to visualise the nuclei. 
ASCC1 was expressed in the cytoplasm and the nuclei of the cells while Cactin-myc 
86 
was again found exclusively in the nucleus (Figure 5.3).  ASCC1 and Cactin-myc co-
localised in some but not all cells which was detected by overlapping red and green 
staining which forms yellow/orange immunoflourescence (Figure 5.3).  It is worth 
noting that similar results were observed when cells were treated with the pro-
inflammatory stimulus IL-1β. 
   In order to investigate the functional relevance of the interaction between 
ASCC1 and Cactin, the ability of ASCC1 to regulate NF-κB, IRF3 and IRF7 was next 
examined.  Over-expression of ASCC1 was found to have no effect on the activation 
of a co-transfected NF-κB-regulated luciferase gene by LPS (Figure 5.4A).  This was 
somewhat surprising as ASCC1 was identified as a component of the ASC-1 complex 
which enhances NF-κB transactivation in HeLa cells (Jung et al., 2002).  The ability 
of ASCC1 to regulate IRF3 and IRF7 was then examined.  HEK293 TLR3 cells were 
transfected with plasmids encoding pFA-IRF3 or pFA-IRF7 and pFR-regulated 
luciferase in the absence or presence of ASCC1.  Interestingly over-expression of 
ASCC1 inhibited Poly(I:C) mediated IRF3 and IRF7 activation (Figure 5.4B, C).  
This is interesting as Cactin is also a negative regulator of IRF3 and IRF7 activation 
and so these two proteins may co-operate in order to inhibit IRFs. However the 
magnitude of inhibition effected by ASCC1 was more modest than Cactin, especially 
in relation to regulation of NF-κB and thus the functional importance of this 
interaction was not further considered in this thesis.     
 
5.2.3 Cactin fails to interact with IκBα but does interact with nuclear IκBL 
  
Given that Drosophila Cactin interacts with Cactus we investigated if Cactin 
interacts with the human homologue of Cactus which is IκBα.  In order to investigate 
this HEK293 TLR4 cells were transfected with a plasmid encoding myc-tagged Cactin 
and subsequently treated with the pro-inflammatory stimulus IL-1β for various time 
periods to see if these proteins interact under inflammatory conditions.  Lysates were 
generated and immunoprecipitated with an anti-myc antibody. Whilst the expression 
of both  Cactin-myc and IκBα was confirmed by Western blotting, IκBα was not 
detected in samples of immunoprecipitated Cactin, even in samples from cells 
previously stimulated with  IL-1β (Figure 5.5).  This is not altogether surprising as 
IκBα is expressed predominantly in the cytoplasm and Cactin-myc displays a nuclear 
localisation.  For this reason, it was then investigated if Cactin interacts with a nuclear 
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member of the IκB family, IκBL.  To do this HEK293 T cells were co-transfected 
with plasmids encoding GFP-tagged IκBL and myc-tagged Cactin.  Lysates were 
generated and immunoprecipitated with an anti-myc antibody.  IκBL-GFP was 
detected in immunoprecipitates from cells expressing IκBL-GFP and Cactin-myc 
indicating that there was interaction between the two proteins (Figure 5.6).    
To further confirm this association HEK293 TLR4 cells were co-transfected 
with plasmids encoding GFP-tagged IκBL and RFP-tagged Cactin.  The cells were 
then fixed and stained with hoescht to visualise the nuclei.  IκBL-GFP and Cactin-
RFP showed very similar nuclear expression patterns.  Co-localisation was apparent in 
many cells as evidenced by the overlapping RFP and GFP formation of yellow/orange 
immunofluorescence (Figure 5.7).  As a control HEK293 T cells were co-transfected 
with plasmids encoding GFP-tagged Cactin and myc-tagged IκBα.  Lysates were 
generated and immunoprecipitated using an anti-myc antibody.  Cactin-GFP was not 
detected in immunoprecipitates from cells expressing both IκBα-myc and Cactin-GFP 
although IκBα-myc was detected in the immunoprecipitates and Cactin-GFP was 
detected in the whole cell lysates (Figure 5.8).  This further confirms that Cactin does 
not interact with IκBα and also that the association seen between IκBL-GFP and 
Cactin-myc is more likely to be a true interaction and not an artefact of expressing 
GFP and myc tagged proteins.  
 
5.2.4 Cactin and IκBL function independently to inhibit NF-κB activation 
 
To investigate the functional relevance of Cactin and IκBL association, the 
ability of IκBL to regulate NF-κB activation was first examined.  To do this HEK293 
TLR4 cells were transfected with or without a plasmid encoding IκBL-GFP and 
assessed for their ability to activate a co-transfected NF-κB-regulated luciferase gene 
in response to IL-1β and LPS stimulation.  IκBL-GFP significantly inhibited IL-1β 
and LPS mediated activation of NF-κB (Figure 5.9).  As Cactin is also a negative 
regulator of NF-κB we were keen to investigate if the association of these two proteins 
is necessary for manifesting the inhibitory effects of both proteins on NF-κB.  In order 
to do this Cactin- and IκBL-specific shRNA was used to suppress endogenous 
expression of these proteins.  Quantitative real-time PCR was used to confirm the 
specific effects of these two shRNAs.  Real-time PCR confirmed ~55% knockdown of 
endogenous IκBL by shRNA in HEK293 TLR4 cells (Figure 5.10A,B) while there 
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was ~50% less Cactin in HEK293 TLR3 cells transfected with Cactin-specific shRNA 
compared to the non-specific shRNA control (Figure 5.10C,D).   
 In order to determine if IκBL is required for Cactin’s negative regulation of 
NF-κB, HEK293 TLR4 cells were transfected with plasmids encoding IκBL-specific 
shRNA or a non-specific shRNA control and assessed for the ability of Cactin-myc to 
inhibit LPS mediated activation of a co-transfected NF-κB-regulated luciferase 
reporter plasmid.  As expected, knockdown of IκBL using shRNA augmented LPS 
activation of NF-κB (Figure 5.11) further confirming its role as a negative regulator of 
NF-κB.  However, over-expression of Cactin-myc inhibited LPS-mediated NF-κB 
activation in cells suppressing IκBL to the same extent as in cells transfected with the 
non-specific shRNA control (Figure 5.11).  This suggests that Cactin inhibits NF-κB 
activation independently of its associated with IκBL.  Next we examined if the 
regulatory effects of IκBL on NF-κB are dependent on its association with Cactin.  To 
do this HEK293 TLR4 cells were co-transfected with plasmids encoding Cactin-
specific shRNA or a non-specific shRNA control, IκBL-GFP or Empty Vector (EV) 
pcDNA3.1 and NF-κB-regulated luciferase.  As before, suppression of endogenous 
Cactin augmented LPS mediated NF-κB activation (Figure 5.13).  Interestingly, there 
was no impairment of the ability of IκBL to inhibit LPS mediated NF-κB activation in 
cells transfected with Cactin-specific shRNA compared with cells transfected with a 
non-specific shRNA control (Figure 5.12).  This indicates that IκBL inhibits NF-κB 
activation independent of Cactin and so the two proteins appear to function 
independently to regulate NF-κB. 
 
5.2.5  IκBL inhibits IRF3 and IRF7 activation 
 
Given that Cactin and IκBL appear to function independently in terms of NF-
κB regulation we decided to investigate if the association of IκBL and Cactin is 
important for the regulation of IRFs.  Firstly, the effects of IκBL on Poly(I:C) 
mediated IRF3 and IRF7 activation was examined.  To do this HEK293 TLR3 cells 
were co-transfected with plasmids encoding pFA-IRF3 or pFA-IRF7 and a pFR-
regulated luciferase gene and with or without a plasmid encoding IκBL-GFP.  Like 
Cactin, IκBL-GFP inhibited the activation of IRF3 and IRF7 in response to Poly(I:C) 
(Figure 5.13).   
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5.2.6 IκBL negatively regulates IFNβ induction 
 
To investigate the functional consequence of IκBL negatively regulating IRF3 
and IRF7 activation, the ability of IκBL to regulate IFNβ induction was next 
examined.  HEK293 TLR3 cells were transfected with plasmids encoding IκBL-
specific shRNA or a non-specific shRNA control.  Cells were then stimulated with 
Poly(I:C) before extracting RNA.  Real-time PCR was performed to quantify the 
amount of IFNβ mRNA transcribed.  In keeping with regulatory effects of Cactin on 
IRF activation, suppression of endogenous IκBL augmented Poly(I:C) induction of 
IFNβ (Figure 5.14).  To further confirm that IκBL inhibits IFNβ induction by targeting 
IRF-mediated activation of the IFNβ promoter HEK293 TLR3 cells were transfected 
with plasmids encoding IκBL-specific shRNA or a non-specific shRNA control and 
assessed for their ability to activate a co-transfected IFNβ-, PRDI-III-, PRDII- or 
PRDIV-regulated luciferase reporter construct.  Suppression of endogenous IκBL 
augmented the activation of the IFNβ promoter in response to Poly(I:C) (Figure 5.15).  
Interestingly IκBL appears to target PRDI-III of the IFNβ promoter as suppression of 
endogenous IκBL augmented Poly(I:C) activation of PRDI-III-luciferase (Figure 
5.15), although the figures did not reach statistical significance.  Suppression of 
endogenous IκBL had no affect on Poly(I:C) mediated PRDII or PRDIV activation.  
Given that Cactin was also found to be a powerful negative regulator of IFNβ 
induction by targeting PRDI-III of the IFNβ promoter it was interesting to determine 
if these proteins co-operate in order to inhibit the activation of IRFs and induction of 
IFNβ.   
 
5.2.7 IκBL has no affect on Poly(I:C) -induced phosphorylation of IRF3  
 
Phosphorylation of IRF3 is essential for its activation as it promotes 
dimerisation and translocation to the nucleus.  In an effort to investigate the effect of 
IκBL on Poly(I:C) mediated IRF3 phosphorylation, HEK293 TLR3 cells were 
transfected with plasmids encoding IκBL-specific shRNA or a non-specific shRNA 
control.  Suppression of endogenous IκBL had no effect on Poly(I:C) mediated IRF3 
phosphorylation as detected by Western immunoblotting using an anti-phospho-IRF3 
antibody (Figure 5.16).  This indicates that, similarly to Cactin, IκBL manifests in 
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inhibitory effects downstream of IRF3 phosphorylation and most likely downstream 
of nuclear translocation.  
 
5.2.8  Cactin and IκBL function independently to inhibit IRF3 and IRF7 
activation 
 
In order to determine if Cactin’s negative regulation of IRF3 and IRF7 
activation is dependent on its interaction with IκBL, HEK293 TLR3 cells were 
transfected with plasmids encoding pFA-IRF3 or pFA-IRF7 and pFR-regulated 
luciferase.  Cells were also transfected with or without plasmids encoding IκBL-
specific shRNA or a non-specific shRNA control and Cactin-myc.  Suppression of 
endogenous IκBL augmented Poly(I:C) mediated IRF3 and IRF7 activation (Figure 
5.17), further confirming the role of IκBL as a negative regulator of IRFs. However 
there was no impairment of Cactin’s ability to inhibit Poly(I:C) mediated IRF3 or 
IRF7 activation in cells suppressing endogenous IκBL (Figure 5.17).  This indicates 
that interaction with IκBL is not essential for Cactin to negatively regulate IRF3 or 
IRF7 activation.  It was still possible, however, that IκBL inhibits IRF3 and IRF7 
activation in a Cactin-dependent manner.  In order to investigate this HEK293 TLR3 
cells were again transfected with plasmids encoding pFA-IRF3 or pFA-IRF7 and 
pFR-regulated luciferase.  Cells were also transfected with or without plasmids 
encoding Cactin-specific shRNA or a non-specific shRNA control and IκBL-GFP.  
Suppression of endogenous Cactin augmented Poly(I:C) mediated IRF3 and IRF7 
activation.  Again there was no impairment of IκBL’s inhibitory effects in cells 
suppressing endogenous Cactin compared with cells transfected with a non-specific 
shRNA control (Figure 5.18).  The above data suggests that IκBL and Cactin function 
independently to negatively regulate IRF3 and IRF7 activation.   
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Table 5.1 List of Cactin interacting proteins identified by Mass Spectrometry and 
listed by IPI number.  
 
protein name Description Gene 
Name 
prot 
score 
IPI00736681.1 predicted: chromosome 19 open reading frame 29 isoform 1. C19orf29 1 
IPI00031508.1 atp-dependent rna helicase dhx8. DHX8 1 
IPI00385143.1 microfibrillar protein 2 (fragment). PTF1A 1 
IPI00005055.3 hypothetical protein flj22965. CXorf56 1 
IPI00022276.3 mitochondrial 28s ribosomal protein s28. MRPS28 1 
IPI00006970.1 mitochondrial 28s ribosomal protein s2. MRPS2 1 
IPI00249529.2 predicted: ip63 protein isoform 1. CEP78 1 
IPI00001757.1 splice isoform 1 of rna-binding protein 8a. RBM8A 1 
IPI00061245.4 mitochondrial 28s ribosomal protein s10. MRPS10 1 
IPI00036742.5 hypothetical protein loc25962 isoform 1. KIAA1429 1 
IPI00219335.9 60s ribosomal protein l3-like. RPL3L 1 
IPI00011875.1 protein red. IK 1 
IPI00411680.6 similar to protein-l-isoaspartate. PCMT1 1 
IPI00643356.1 karp-1-binding protein. CEP170 1 
IPI00643414.1 3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] 
kinase, mitochondria 
BCKDK 1 
IPI00001690.1 cullin-7. CUL7 1 
IPI00297900.4 probable atp-dependent rna helicase ddx10. DDX10 1 
IPI00006379.1 nucleolar protein nop5. NOP5 1 
IPI00219350.1 splice isoform 2 of 28s ribosomal protein s11; mitochondrial 
precursor. 
MRPS11 1 
IPI00305833.3 smu-1 suppressor of mec-8 and unc-52 homolog. SMU1 1 
IPI00395337.1 splice isoform 1 of pre-mrna 3'-end-processing factor fip1. FIP1L1 1 
IPI00007049.1 28s ribosomal protein s18c; mitochondrial precursor. HPSE 1 
IPI00013721.2 serine/threonine-protein kinase prp4 homolog. PRPF4B 1 
IPI00045051.1 transcriptional activator protein pur-beta. PURB 1 
IPI00013180.2 protein g10 homolog. BUD31 1 
IPI00017451.1 splicing factor 3 subunit 1. SF3A1 1 
IPI00030820.1 39s ribosomal protein l47; mitochondrial precursor. MRPL47 1 
IPI00069750.1 fuse-binding protein-interacting repressor isoform a. PUF60 1 
IPI00074690.1 kiaa1839 protein (fragment). RNPC3 1 
IPI00175136.3 rna binding motif protein 15b. RBM15B 1 
IPI00290566.1 t-complex protein 1 subunit alpha. TCP1 1 
IPI00430079.1 splice isoform 2 of phd finger protein 8. PHF8 1 
IPI00514173.1 cyclophilin-33b. PPIE 1 
IPI00554737.1 serine/threonine-protein phosphatase 2a 65 kda regulatory 
subunit a alpha isoform. 
PPP2R1A 1 
IPI00022793.4 trifunctional enzyme beta subunit; mitochondrial precursor. HADHB 1 
IPI00514399.1 ribosomal protein s27. RPS27 1 
IPI00654654.1 mrps33 protein (fragment). MRPS33 1 
IPI00002902.5 nucleolar protein 9. NOL9 1 
IPI00005492.2 wd-repeat protein 5. WDR5 1 
  
 
HEK293 T cells were transfected with Myc-tagged hCactin and cell lysates were 
immunoprecipitated using anti-IgG mouse or anti-myc antibodies. The 
immunoprecipitates were resolved in a SDS acrylamide gel and both lanes in the gel 
were cut into slices and the proteins were digested with trypsin and subjected to nano-
electrospray liquid chromatography mass spectrometry
 
(Nano-LC MS/MS). Proteins 
were identified that were immunoprecipitated with the anti-myc antibody but not the 
the control anti-IgG and the top Protein Prophet (PP) scoring proteins are listed above 
; performed by Dr. Paola Atzei and Dr. Patricia Maguire 
 
 
 
 
IPI00006181.1 eukaryotic translation initiation factor 3 subunit 7. EIF3S7 1 
IPI00020729.1 insulin receptor substrate 4. IRS4 1 
IPI00022373.1 art-4 protein. NOB1 1 
IPI00023086.3 mitochondrial ribosomal protein l15. LYPLA1 1 
IPI00073779.1 28s ribosomal protein s35; mitochondrial precursor. MRPS35 1 
IPI00083708.2 hbxag transactivated protein 2. BAT2D1 1 
IPI00167009.3 cdna flj38620 fis; clone heart2007767; weakly similar to mus 
musculus e-map-115 protein. 
RPRC1 1 
IPI00300659.4 parafibromin. CDC73 1 
IPI00305068.5 u5 snrnp-associated 102 kda protein. PRPF6 1 
IPI00337736.1 splice isoform 2 of kinectin. KTN1 1 
IPI00410067.1 splice isoform 1 of zinc finger ccch type antiviral protein 1. ZC3HAV1 1 
IPI00418403.4 hypothetical protein loc51490. C9orf114 1 
IPI00427242.1 protein c14orf111. FCF1 1 
IPI00434390.1 splice isoform 2 of activating signal cointegrator 1 complex 
subunit 1. 
ASCC1 1 
IPI00549540.3 p21-activated protein kinase-interacting protein 1. PAK1IP1 1 
IPI00550037.2 28s ribosomal protein s15; mitochondrial precursor. MRPS15 1 
IPI00643426.1 ring-finger protein. TOPORS 1 
IPI00300952.3 splice isoform 1 of peptidyl-prolyl cis-trans isomerase-like 3. PPIL3 0.99 
IPI00472102.2 60 kda heat shock protein; mitochondrial precursor. HSPD1 0.99 
IPI00550227.2 Nephrocystin-3 NPHP3 0.99 
IPI00032416.6 splice isoform long of jagged-2 precursor. JAG2 0.99 
IPI00456940.4 ribosomal protein l7; eukaryotic form family protein. RPL7L1 0.98 
IPI00220302.1 splice isoform 1 of wilms' tumor 1-associating protein. WTAP 0.98 
IPI00641770.1 phosphatidylinositol 4-kinase; catalytic; beta polypeptide. PIK4CB 0.97 
IPI00021435.2 26s protease regulatory subunit 7. PSMC2 0.92 
IPI00004459.1 probable dimethyladenosine transferase. DIMT1L 0.92 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1  Cactin-myc does not co-immunoprecipitate with PAK1IP1-HA 
HEK293 TLR4 cells were co-transfected with plasmids encoding myc-tagged Cactin 
(2 μg) and PAK1IP1-HA (2 μg).  Empty vector pcDNA3.1 was used to normalise the 
total amount of DNA transfected.  24 h post transfection lysates were generated and 
immunoprecipitated with an anti-HA antibody.  Immunoprecipitates and whole cell 
lysates (WCL)s were subjected to Western immunoblotting using anti-myc and anti-
HA antibodies.  Immunoreactivity was visualised using the Odyssey Infrared imaging 
system.  Results shown are representative of three independent experiments.  
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Figure 5.2  ASCC1 co-immunoprecipitates with Cactin-myc 
HEK293 TLR4 cells were co-transfected with plasmids encoding myc-tagged Cactin 
(2 μg) and ASCC1 (2 μg).  Empty vector pcDNA3.1 was used to normalise the total 
amount of DNA transfected.  24 h post transfection lysates were generated and 
immunoprecipitated with an anti-myc antibody.  Immunoprecipitates and whole cell 
lysates (WCL)s were subjected to Western immunoblotting using anti-ASCC1 and 
anti-myc antibodies.  Immunoreactivity was visualised using the Odyssey Infrared 
imaging system.  Results shown are indicative of three independent experiments. 
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Figure 5.3  Cactin-myc and ASCC1 co-localise in some cells 
HEK293 TLR4 cells were co-transfected with plasmids encoding myc-tagged Cactin 
(2 μg) and ASCC1 (2 μg).  24 h post-transfection cells were fixed, stained with anti-
myc and anti-ASCC1 antibodies, stained with hoescht and mounted in anti-fade 
medium.  Confocal images were captured with the Olympus FluoView FV1000 
confocal laser scanning microscope and data analysis was performed using the 
Olympus FV-10 ASW imaging software.  Images shown are representative of two 
independent experiments. 
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Figure 5.4  ASCC1 inhibits Poly(I:C)-induced activation of IRF3 and IRF7 but 
has no effect on LPS-induced activation of NF-κB  
HEK293 TLR4 or TLR3 cells were transfected with plasmids encoding (A) NF-κB-
regulated luciferase (80 ng) and constitutively expressed TK Renilla luciferase (20 
ng), (B) pFA-IRF3 (30 ng), pFR-regulated firefly luciferase (60 ng) and constitutively 
expressed TK Renilla luciferase (20 ng) or (C) pFA-IRF7 (25 ng), pFR-regulated 
firefly luciferase (60 ng) and constitutively expressed TK Renilla luciferase ( 20 ng) 
and with or without plasmids encoding ASCC1 (90 ng) or Empty vector (EV) 
pcDNA3.1 (90 ng).  Transfected cells were left overnight and then treated with (A) 
LPS (100 ng/ml) or (B, C) Poly(I:C) (25 μg/ml) for 24 h.  Lysates were generated and 
assayed for firefly and Renilla luciferase activity.  Results shown are the mean +/- 
S.E.M. of triplicate determinations from three independent experiments.  * p < 0.05, 
** p < 0.01, paired t-test, Ligand stimulated cells transfected with ASCC1 compared 
with ligand stimulated cells transfected with EV.  
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Figure 5.5  IκBα does not co-immunoprecipitate with Cactin–myc 
HEK293 TLR4 cells were transfected with a plasmid encoding myc-tagged Cactin (2 
μg) or empty vector pcDNA3.1 (2 μg).  Transfected cells were left overnight and then 
treated for the indicated time periods with IL-1β (10 ng/ml).  Lysates were generated 
and immunoprecipitated with an anti-myc antibody.  Immunoprecipitates and whole 
cell lysates (WCL)s were subjected to Western immunoblotting using anti-IκBα and 
anti-myc antibodies.  Immunoreactivity was visualised using the Odyssey Infrared 
imaging system.  Results shown are representative of three independent experiments.  
 
 
 
 
 
 
- +        +        +       +        +       +         Cactin-myc
- - 15’ 30’ 1h     6h     24h       IL-1β
IP: myc
IB: IκBα
IB: myc
WCL
IB: IκBα
IB: myc
- 35
- 100
- 35
- 100
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6  IκBL co-immunoprecipitates with Cactin-myc 
HEK293 T cells were co-transfected with plasmids encoding myc-tagged Cactin (2 
μg) and GFP-tagged IκBL (2 μg).  Empty vector pcDNA 3.1 was used to normalise 
the total amount of DNA transfected.  24 h post-transfection lysates were generated 
and immunoprecipitated with an anti-myc antibody.  Immunoprecipitates and whole 
cell lysates (WCL)s were subjected to Western immunoblotting using anti-GFP and 
anti-myc antibodies.  Immunoreactivity was visualised using the Odyssey Infrared 
imaging system.  Blots shown are representative of three independent experiments. 
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Figure 5.7  IκBL-GFP co-localises with Cactin-RFP 
HEK293 TLR4 cells were transfected with GFP tagged IκBL (400 ng) and RFP-
tagged Cactin (400 ng).  24 h post transfection cells were fixed and stained with 
hoescht.  Confocal images were captured using the Olympus FluoView FV1000 
confocal laser scanning microscope and data analysis was performed using the 
Olympus FV-10 ASW imaging software.  Results shown are representative of two 
independent experiments. 
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Figure 5.8  Cactin-GFP does not co-immunoprecipitate with IκBα-myc 
HEK293 T cells were co-transfected with GFP tagged Cactin (2 μg) and myc tagged 
IκBα (2 μg).  24 h post transfection lysates were generated and immunoprecipitated 
with an anti myc antibody.  Immunoprecipitates and whole cell lysates (WCL)s were 
subjected to Western immunoblotting using anti-GFP and anti-myc antibodies.  
Images were captured using the Odyssey Infrared imaging system.  Blots shown are 
indicative of three independent experiments.  
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Figure 5.9  IκBL inhibits IL-1β and LPS-induced activation of NF-κB  
HEK293 TLR4 cells were transfected with plasmids encoding NF-κB –regulated 
firefly luciferase (80 ng) and constitutively expressed TK Renilla luciferase (20 ng) 
and with or without a plasmid encoding GFP tagged IκBL (90 ng).  Empty vector 
(EV) pcDNA3.1 was used to normalise the total amount of DNA transfected.  
Transfected cells were left overnight and then stimulated with (A) IL-1β (10 ng/ml) or 
(B) LPS (100 ng/ml) for 24 h.  Lysates were generated and assayed for firefly and 
Renilla luciferase activity.  Data shown are the mean +/- S.E.M of triplicate 
determinations of a representative of three independent experiments.  ** p < 0.01, 
paired t-test, Ligand stimulated cells transfected with IκBL compared with ligand 
stimulated cells transfected with EV. 
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Figure 5.10  shRNA-mediated knockdown of IκBL and Cactin  
HEK293 TLR4 or TLR3 cells were transfected with plasmids encoding (A, B) IκBL-
specific shRNA (1 μg), (C, D) Cactin-specific shRNA (1 μg), or a non-specific 
shRNA control (1 μg).  Total RNA was extracted and converted to cDNA by RT-
PCR.  Real-time PCR was then performed to quantify the amount of (A) IκBL or (C) 
Cactin.  Gene expression was quantified relative to the housekeeping gene HPRT and 
data analysis was performed using the 2
-∆∆CT
 method.  Data represent the mean +/- 
S.E. of three independent experiments.  (B, D) Real-time products were separated by 
gel electrophoresis.  
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5.11  Suppression of endogenous IκBL does not affect the ability of Cactin to 
inhibit LPS-induced activation of NF-κB 
HEK293 TLR4 cells were transfected with plasmids encoding NF-κB-regulated 
luciferase (80 ng) and constitutively expressed TK Renilla luciferase (20 ng),  myc-
tagged Cactin (90 ng) or Empty Vector (EV) pcDNA3.1 (90 ng) and IκBL-specific 
shRNA (100 ng) or a non-specific shRNA control (100 ng).  Transfected cells were 
left overnight and then treated with LPS (100 ng/ml) for 24 h.  Lysates were generated 
and assayed for firefly and Renilla luciferase activity.  Data presented are the mean +/- 
S.E.M. of triplicate determinations from three independent experiments.  * p < 0.05, 
paired t-test, LPS stimulated cells transfected with Cactin compared with LPS 
stimulated cells transfected with EV.  
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Figure 5.12  Suppression of endogenous Cactin does not affect the ability of IκBL 
to inhibit LPS induced activation of NF-κB  
HEK293 TLR4 cells were transfected with plasmids encoding NF-κB-regulated 
luciferase (80 ng) and constitutively expressed TK Renilla luciferase (20 ng), GFP-
tagged IκBL (90 ng) or Empty Vector (EV) pcDNA3.1 (90 ng) and Cactin-specific 
shRNA (100 ng) or a non-specific shRNA control (100 ng).  Transfected cells were 
left overnight and then treated with LPS (100 ng/ml) for 24 h.  Lysates were generated 
and assayed for firely and Renilla luciferase activity.  Data shown are the mean +/- 
S.E.M. of triplicate determinations from three independent experiments.  * p < 0.05, 
paired t-test, LPS stimulated cells transfected with IκBL compared with LPS 
stimulated cells transfected with EV. 
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Figure 5.13  IκBL inhibits Poly(I:C) induced activation of IRF3 and IRF7  
HEK293 TLR3 cells were transfected with plasmids encoding (A) pFA IRF3 (30 ng) 
or (B) pFA-IRF7 (25 ng), pFR-regulated firefly luciferase (60 ng) and constitutively 
expressed TK Renilla luciferase (20 ng) and with or without plasmids encoding GFP-
tagged IκBL (90 ng) or Empty Vector (EV) pcDNA3.1 (90 ng).  Transfected cells 
were left overnight and then treated with or without Poly(I:C) (25 μg/ml) for 24 h.  
Lysates were generated and assayed for firefly and Renilla luciferase activity.  Data 
represent the mean +/- S.E.M. of triplicate determinations from three independent 
experiments.  * p < 0.05, paired t-test, Ligand stimulated cells transfected with IκBL 
compared with ligand stimulated cells transfected with EV. 
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Figure 5.14  Suppression of endogenous IκBL augments Poly(I:C) induction of  
IFNβ 
HEK293 TLR3 cells were transfected with IκBL-specific shRNA (1 μg) or a non-
specific shRNA control (1 μg).  Cells were treated with Poly(I:C) (25 μg/ml) for the 
indicated time-periods.  Total RNA was extracted 48 h post-transfection and 
converted to cDNA by RT-PCR.  Realtime PCR was then carried out to quantify the 
amount of IFNβ in each sample.  Gene expression was quantified relative to the 
housekeeping gene HPRT and data analysis was performed using the 2
-∆∆CT
 method.  
Data presented are the mean +/- S.E. of three independent experiments.  * p < 0.05, ** 
p < 0.01, paired t-test, Cells transfected with IκBL-specific shRNA compared with 
cells transfected with a non-specific shRNA control. 
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Figure 5.15  Suppression of endogenous IκBL augments Poly(I:C)-induced 
activation of  PRDI-III and the IFNβ promoter 
HEK293 TLR3 cells were transfected with plasmids encoding PRDI-III-, PRDII-, 
PRDIV- or IFNβ-regulated firefly luciferase (80 ng) and constitutively expressed TK 
Renilla luciferase (20 ng) and with or without plasmids encoding IκBL-specific 
shRNA (100 ng) or a non-specific shRNA control (100 ng). 24 h post-transfection 
cells were treated with Poly(I:C) (25 μg/ml) overnight.  Lysates were generated 48 h 
post-transfection and assayed for firefly and Renilla luciferase activity.  Data shown 
are the mean +/- S.E.M of triplicate determinations from three independent 
experiments.  ** p < 0.01, paired t-test, Poly(I:C) stimulated cells transfected with 
IκBL-specific shRNA compared with Poly(I:C) stimulated cells transfected with a 
non-specific shRNA control. 
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Figure 5.16  Suppression of endogenous IκBL has no effect on Poly(I:C)-induced 
phosphorylation of IRF3  
HEK293 TLR3 cells were transfected with IκBL-specific shRNA (1 μg) or a non-
specific shRNA control (1 μg).  24 h post-transfection cells were stimulated for the 
indicated time-periods with Poly(I:C) (25 μg/ml).  Cell lysates were generated 48 h 
post-transfection and subjected to Western immunoblotting using anti-phospho-IRF3, 
anti-IRF3 and anti-β-actin antibodies.  Results shown are indicative of three 
independent experiments. 
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Figure 5.17  Cactin inhibits Poly(I:C) mediated IRF3 and IRF7 activation 
independently of IκBL 
HEK293 TLR3 cells were transfected with plasmids encoding (A) pFA-IRF3 (30 ng) 
or (B) pFA-IRF7 (25 ng), pFR-regulated firefly luciferase (60 ng) and constitutively 
expressed TK Renilla luciferase (20 ng) and with or without plasmids encoding myc-
tagged Cactin (90 ng), Empty Vector (EV) pcDNA3.1 (90 ng), IκBL-specific shRNA 
(100 ng) or a non-specific shRNA control (100 ng).  Transfected cells were left 
overnight and then stimulated with Poly(I:C) (25 μg/ml) for 24 h.  Lysates were 
generated and assayed for firefly and Renilla luciferase activity.  Data shown are the 
mean +/- S.E.M. of triplicate determinations from three independent experiments.  * p 
< 0.05, paired t-test, Ligand stimulated cells transfected with Cactin compared with 
ligand stimulated cells transfected with EV. 
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Figure 5.18 IκBL inhibits Poly(I:C) mediated IRF3 and IRF7 activation 
independently of Cactin.   
HEK293 TLR3 cells were transfected with plasmids encoding (A) pFA-IRF3 (30 ng) 
or (B) pFA-IRF7 (25 ng), pFR-regulated firefly luciferase (60 ng) and constitutively 
expressed TK Renilla luciferase (20 ng) and with or without plasmids encoding GFP-
tagged IκBL (90 ng), Empty Vector (EV) pcDNA3.1 (90 ng), Cactin-specific shRNA 
(100 ng) or a non-specific shRNA control (100 ng).  Transfected cells were left 
overnight and then stimulated with Poly(I:C) (25 μg/ml) for 24 h.  Lysates were 
generated and assayed for firefly and Renilla luciferase activity.  Data shown are the 
mean +/- S.E.M. of triplicate determinations from three independent experiments.  * p 
< 0.05, paired t-test, Ligand stimulated cells transfected with IκBL compared with 
ligand stimulated cells transfected with EV. 
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5.3 Discussion 
 
An unbiased proteomic approach in our laboratory had identified ASCC1 as an 
interactor of Cactin and we were keen to validate this interaction by other techniques.  
Some interaction was detected by co-immunoprecipitation and co-localisation of over-
expressed Cactin and ASCC1 was detected in some cells by confocal microscopy.  
This interaction is interesting as ASCC1 has been shown to be essential for ASC-1 
transactivation of AP-1 (Jung et al., 2002) and most likely NF-κB.  As ASCC1 
appears to be an important component of the ASC-1 complex it is possible that 
interaction with Cactin could displace ASCC1 from the complex, thus affecting the 
ability of ASC-1 to regulate NF-κB transactivation.  Further investigation is required, 
however, to determine the importance of ASCC1 and Cactin association.  Mass 
Spectrometry analysis also identified PAK1IP1 as an interactor of Cactin.  However 
this study failed to confirm the interaction by co-immunoprecipitation in both non-
stimulated and ligand treated cells.  This suggests that PAK1IP1 may not be a true 
interactor of Cactin.  According to Mass spectrometry analysis Cactin also interacts 
with proteins involved in RNA processing and a number of DEAD-box (DDX) RNA 
helicases.  This is potentially interesting as a member of the RNA helicase family, 
namely DDX3, has been shown to enhance TBK1 mediated IFNβ induction 
(Schroeder et al., 2008).  However, these interactions need to be further confirmed by 
other methods. 
 We also decided to exploit homology relationships in order to identify 
potential interactors of Cactin.  We initially assessed the ability of Cactin to interact 
with cytoplasmic IκBα.  There was no detectable interaction of Cactin and IκBα in 
non-stimulated cells or after stimulation with pro-inflammatory stimuli.  This is not 
surprising as IκBα is expressed in the cytoplasm while Cactin localises to the nucleus.  
For this reason, we next assessed the ability of Cactin to interact with a nuclear 
member of the IκB family, IκBL.  Interaction between Cactin and IκBL was detected 
by co-immunoprecipitation.  Co-localisation was also observed by confocal 
microscopy and IκBL and Cactin appear to have very similar nuclear expression 
patterns.   Mutation in the gene coding for IκBL has been associated with various 
autoimmune disorders.  For example, the gene for IκBL has been identified as a 
susceptibility gene for RA (Greetham et al., 2007).  Furthermore IκBL gene 
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polymorphism increases the risk of developing SLE and primary Sjogren’s syndrome 
(pSS) (Castiblanco and Anaya, 2008).   
 A role for IκBL in mRNA processing and regulation of translation has 
previously been suggested (Greetham et al., 2007).  We were keen to investigate a role 
for IκBL in innate immune signalling.  Similarly to Cactin, IκBL negatively regulates 
the activation of NF-κB by the TLR ligand LPS and the endogenous pro-inflammatory 
stimulus IL-1β.  Interestingly, the association of Cactin and IκBL does not appear to 
be essential for Cactin or IκBL’s negative regulation of NF-κB.  Cactin displays the 
same inhibitory effects when endogenous IκBL expression is suppressed.  Similarly 
knockdown of endogenous Cactin expression has no effect on IκBL’s inhibitory 
effects.  These findings suggest functional redundancy for Cactin and IκBL in terms of 
NF-κB signalling.  As Cactin is also a powerful inhibitor of IRFs we next assessed the 
ability of IκBL to regulate IRF signalling pathways.  Overexpression of IκBL 
inhibited Poly(I:C) mediated IRF3 and IRF7 activation while suppression of 
endogenous IκBL augmented Poly(I:C) induction of IFNβ.  Intriguingly, like Cactin, 
knockdown of endogenous IκBL had no effect on Poly(I:C) stimulated IRF3 
phosphorylation.  Furthermore, both Cactin and IκBL target PRDI-III of the IFNβ 
promoter and inhibit IFNβ expression.  These results suggest that Cactin and IκBL 
manifest their regulatory effects on IRFs by similar mechanism.  Interestingly these 
two proteins appear to function independently to inhibit IRFs as knockdown of 
endogenous Cactin had not effect on IκBL’s ability to negatively regulate IRF3 and 
IRF7, while knockdown of IκBL similarly did not affect the regulatory effects of 
Cactin.  Again these findings suggest functional redundancy for Cactin and IκBL in 
regulating IRF as well as NF-κB signalling.  It is possible that both Cactin and IκBL 
function as part of a multi-protein complex which regulates transcription factors in the 
nucleus.    
 It is also worth noting that IκBL is encoded in the MHC class III gene region 
of chromosome 6.  Susceptibility loci to several diseases such as Graves disease, 
Crohn’s disease and SLE have been localised to this region of the genome (Matsuzaka 
et al., 2001).  Given that this gene cluster has been associated with autoimmune 
disorders a high throughput yeast two hybrid system was used to identify interaction 
partners for proteins encoded by the MHC class III region (Lehner et al., 2003).  
Interestingly, Cactin was identified as an interaction partner for two of these proteins,  
RD binding protein (RDBP) and leukocyte-specific transcript 1 protein (LST1) 
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(Lehner et al., 2003).  Furthermore, the TNF gene is also located within this region.  
Cactin has been shown to negatively regulate TNF-α mediated NF-κB activation and 
suppression of endogenous Cactin augmented LPS mediated TNF-α expression (Atzei 
et al., 2010).  Given that Cactin targets a number of proteins encoded by the MHC 
class III region, either directly or functionally, it appears that Cactin functions as a key 
regulator of this gene cluster.  This also means that Cactin may prove to be important 
in preventing the development of autoimmune disease as this genomic region has been 
associated with susceptibility to diseases such as RA and SLE. Going forward it will 
be of interest to explore the role of Cactin in autoimmunity.   
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Chapter 6 
 
 
 
Concluding remarks 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.1 Concluding Remarks 
 
 Drosophila is used as a model organism for the study of innate immune 
signalling due to the striking similarities in the Drosophila Toll and Imd pathways and 
mammalian TLR signalling cascades.  Drosophila Cactin was identified as a regulator 
of Drosophila Toll signalling that positively regulated the activation of the Rel/NF-κB 
transcription factor dorsal (Lin et al., 2000).  For this reason the human homologue of 
Cactin was cloned in our laboratory to examine its role in TLR signalling pathways 
but it was found to have a different function than its Drosophila orthologue.  Cactin 
negatively regulates the activation of NF-κB, IRF3 and IRF7.  The aim of this current 
work was to probe the mechanisms underlying the negative regulatory effects of 
Cactin.   
Cactin is expressed exclusively in the nucleus and a truncated mutant of 
Cactin, which lacks both of its NLSs and is expressed in the cytoplasm, showed 
considerably reduced inhibitory effects on NF-κB.   This indicates that the nuclear 
localisation of Cactin is important for its function.  Suppression of endogenous Cactin 
resulted in increased DNA binding activity of NF-κB in response to LPS but had no 
effect on LPS mediated p65 phosphorylation, indicating that Cactin might function 
downstream of this event.  The predominant form of NF-κB is a p65/p50 heterodimer 
(Li and Verma, 2002).  For this reason we focussed our studies on the NF-κB subunit 
p65.  Overexpressed p65 dimerises and translocates to the nucleus where it binds to 
κB sites its target genes.  This occurs in the absence of a stimulus due to the lack of 
IκB proteins to export the p65 dimers to the cytoplasm.  This provided us with a tool 
to determine if Cactin can inhibit p65 transactivation.  This study showed that Cactin 
prevented p65 from binding to a consensus NF-κB-binding motif.  Furthermore, 
Cactin prevented p65 binding to the endogenous IL-8 promoter.  Intriguingly this 
inhibition was not achieved through direct interaction with p65 or by competing with 
p65 for DNA-binding activity.  Notably, p65 is acetylated by p300/CBP and this 
modification is essential for full transcriptional activity (Chen and Greene, 2002).  
Conversely, deacetylation of p65 repressess its DNA binding activity and increases its 
binding affinity for IκBα (Ashburner et al., 2001).  It is possible that Cactin recruits 
the histone deacetylating proteins, HDACs, responsible for p65 deacetylation.  These 
HDACs are also responsible for chromatin remodelling and gene silencing.  
Alternatively Cactin might interact with CBP/p300 and prevent their association with 
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p65, thus preventing its acetylation and DNA binding.  Cactin could also recruit other 
proteins that compete for binding at the NF-κB binding site. 
This study also showed that Cactin is regulated by pro-inflammatory stimuli.  
The regulation of Cactin is both transcriptional and post-translational in response to 
LPS.  Cactin expression was induced following 5 h stimulation with LPS.  However, 
more apparent than this regulation was the stabilization of Cactin protein following 
stimulation of cells with the endogenous pro-inflammatory stimulus IL-1β, and the 
TLR ligands LPS and Poly(I:C).  This stabilisation appears to be due to serine 
phosphorylation of Cactin.  Furthermore, the stabilisation of Cactin was shown to be 
dependent on NF-κB activation as repression of NF-κB prevented its stabilisation.  
The kinase responsible for Cactin phosphorylation might be encoded by an NF-κB-
regulated gene.  Conversely, NF-κB might upregulate the expression of the gene 
encoding the activator of the responsible kinase.  Many negative regulators of TLR 
signalling are regulated by NF-κB activation and represent negative feedback 
mechanisms to ensure the termination of the inflammatory response.  Prolonged 
activation of NF-κB can cause damage to the host and is associated with a range of 
inflammatory and autoimmune diseases.  This highlights the therapeutic potential of 
exploiting the inhibitory effects of Cactin.  Also, because Cactin targets the DNA-
binding activity of NF-κB it can negatively regulate its activation by any stimulus and 
any signalling pathway. 
 Cactin is also a powerful negative regulator of IRF3 and IRF7.  This study 
showed that Cactin inhibits the induction IFNβ in response to Poly(I:C).  Again we 
wanted to dissect the mechanism by which Cactin inhibits the activation of these 
transcription factors.  IRF3 and IRF7 are both phosphorylated which promotes their 
dimerisation and translocation to the nucleus.  Interestingly this study found that 
Cactin had no effect on Poly(I:C) mediated phosphorylation of IRF3.  Nor did it affect 
the translocation of IRF3 or IRF7 to the nucleus.  Suppression of Cactin by siRNA 
technology did, however, lead to increased binding of IRF3 to the IFNβ promoter.  
This suggests that Cactin can also inhibit the DNA-binding activity of IRF3 and this is 
the mechanism by which it inhibits IFNβ induction.  Furthermore, Cactin inhibited the 
transactivation of IRF7 as it prevented its induction of an IFNα-regulated reporter 
plasmid.  Again this inhibition at the level of DNA binding does not involve direct 
interaction of Cactin with either IRF3 or IRF7.  It is possible that Cactin interacts with 
other IRF3 or IRF7 interacting partners to inhibit their DNA binding activity.  For 
96 
example association of CBP/p300 promotes IRF3 acetylation and unmasks its DNA-
binding domain (Lin et al., 1999).  Furthermore this association has been shown to be 
indispensible for IRF3 DNA-binding activity (Suhara et al., 2002). Disruption of this 
interaction would inhibit the DNA binding activity of IRF3.  Histone acetylation by 
CBP/p300 is also important for chromatin remodelling essential for the initiation of 
transcription.  CBP/p300 interaction has also been shown to be important for IRF7-
mediated IFNβ induction (Yang et al., 2004).  However, the association of CBP/p300 
with IRF7 is weaker than that of CBP/p300 and IRF3 (Genin et al., 2009). 
Interestingly, Cactin regulates the stability of IRF7 protein.  The expression of 
IRF7 is tightly regulated both transcriptionally and post-translationally to ensure tight 
regulation of Type 1 IFN responses.  IRF7 is ubiquitinated by TRAF6 which 
positively regulates its activation (Kawai et al., 2004).  A mutant of IRF7 that cannot 
be ubiquitinated lost its transactivational activity (Ning et al., 2008).  Disruption of 
this modification by Cactin, or by a deubiquitinase recruited by Cactin could 
potentially repress its DNA binding activity.  IRF7 is also targeted by SUMO E3 
ligase tripartite motif- containing protein (TRIM)28 which triggers its SUMOylation 
and transcriptional repression (Liang et al., 2011).  Similarly IRF3 is SUMOylated 
and this negatively regulates Type 1 IFN induction (Kubota et al., 2009).  Acetylation 
of IRF7 by pCAF at a specific site also reduces its DNA binding activity by masking 
its DNA-binding domain (Caillaud et al., 2002).  Furthermore RAUL catalyses the 
K48-linked ubiquitination of IRF7 leading to its proteosome-dependent degradation 
(Yu and Hatward, 2010).  IRF7 has a very short half-life which ensures that Type 1 
IFNs are not produced in the absence of viral infection.  Interestingly, RAUL 
suppression leads to the accumulation of IRF7 in HEK293 T cells (Yu and Hayward 
2010).  Similarly, in the present study, more overexpressed IRF7 was detected in cells 
transfected with Cactin-specific siRNA compared with cells transfected with a 
scrambled siRNA control.  It is possible that Cactin promotes K48-linked 
ubiquitination and proteosomal degradation of IRF7, thereby negatively regulating the 
production of Type 1 IFNs.  Type 1 IFNs play an important role in the pathogenesis of 
autoimmune diseases such as SLE and psoriasis (Baccala et al., 2007, Nestle et al., 
2005).  High levels of Type 1 IFNs are often observed in patients with SLE and high 
levels of IFNα are associated with susceptibility to the disease (Salloum and Niewold, 
2011).  IFNα production also plays a central role in the activation of autoreactive T 
cells in the progression of psoriasis (Nestle et al., 2005).  In both cases, self-nucleic 
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acids are recognised by endosomal TLRs leading to the production of Type 1 IFNs 
and the activation of an adaptive immune response to autoantigens.  Again this 
highlights the therapeutic potential of Cactin, as it can negatively regulate the 
production of Type 1 IFNs.  In a xenograft model Nestle et al. (2005) showed that 
blocking Type 1 IFNs can prevent the development of psoriasis.  The ability of Cactin 
to target IRF7 is of particular interest as it is considered the master regulator of IFNα 
production and so targeting IRF7 is potentially therapeutic in these disease situations.  
 Since Cactin displayed negative regulatory effects on a number of transcription 
factors it was possible that it acts as a global repressor of all transcription factor 
transactivation.  We were able to demonstrate, however, that this is not the case.  
Cactin failed to inhibit the transactivation of c-jun, a subunit of the AP-1 transcription 
factor.  Furthermore there was potentiation of MEKK1 mediated c-jun activation 
observed in the presence of Cactin.  This prompted an investigation into the affect of 
Cactin on MAPK activation in response to TLR ligands.  Intriguingly, Cactin 
positively regulated MAPK activation by Poly(I:C) but not LPS.  It will be interesting 
in the future to further examine the effects of Cactin on MAPK signalling pathways.   
 In an attempt to further dissect the mechanism by which Cactin negatively 
regulates NF-κB and IRF activation this study aimed to look at Cactin-interactors.  
Prior to the start of this project a proteomic-based analysis had been carried out to 
identify novel interactors of Cactin.  We decided to investigate two of the putative 
interactors that were identified using this approach. We focussed on PAK1IP1 and 
ASCC1 since these proteins had previously been implicated in the regulation of NF-
κB and as described earlier Cactin proved to be an effective regulator of this 
transcription factor. Thus it was envisaged that such interactions may shed light on the 
mechanism(s) underlying the regulatory effects of Cactin.  However, we failed to 
confirm the interaction of Cactin with PAK1IP1, by co-immunoprecipitation.  The 
second protein, ASCC1, did co-immunoprecipitate with Cactin and co-localisation of 
these two proteins was detectable in some cells by confocal microscopy.  ASCC1 is a 
subunit of a multiprotein coactivator complex called the ASC1 complex which 
positively regulates the transactivation of NF-κB and AP-1 (Jung et al., 2002).  
Therefore, the interaction of Cactin and ASCC1 was potentially interesting.  It seems 
plausible that Cactin’s interaction with ASCC1 could displace the subunit from the 
ASC-1 complex thus preventing the ASC-1 complex from positively regulating NF-
κB activation.  However, this project failed to reproduce the positive regulatory effects 
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of ASCC1 in HEK293 cells and ASCC1 showed modest inhibitory effects on the 
IRFs.  For this reason ASCC1 and Cactin association was not further investigated in 
this project. 
 Drosophila Cactin was identified as an interactor of Drosophila Cactus.  We 
therefore investigated if Cactin could interact with the human homologue of Cactus, 
IκBα.  It may seem unlikely that these two proteins would interact as IκBα is 
expressed predominantly in the cytoplasm.  However, following NF-κB activation, 
IκBα expression is upregulated and it can enter the nucleus and bind active NF-κB 
dimers resulting in their export to the cytoplasm.  However, no interaction of Cactin 
and IκBα was detectable.  Cells were also treated with IL-1β to determine if Cactin 
and IκBα interact in a stimulus-dependent manner but again no interaction was 
detected.  This prompted us to investigate if Cactin interacts with IκBL, a nuclear 
member of the IκB family.  IκBL co-immunoprecipitated with Cactin and confocal 
analysis revealed that they both display very similar patterns of expression within the 
nucleus.  Examination of the effects of IκBL on NF-κB and IRFs showed that IκBL 
mimics the inhibitory effects of Cactin. These findings were further confirmed by the 
use of shRNA to suppress the endogenous expression of IκBL.  Suppression of 
endogenous IκBL augmented LPS mediated NF-κB activation and Poly(I:C) mediated 
IRF3 and IRF7 activation.  Furthermore, suppression of endogenous IκBL augmented 
Poly(I:C) induction of IFNβ.  Interestingly both Cactin and IκBL inhibit the activation 
of IFNβ and target the same positive regulatory domain, PRDI-III, of the IFNβ 
promoter.  IκBL, like Cactin, had no effect on Poly(I:C) mediated IRF3 
phosphorylation suggesting that both of these proteins carry out their inhibitory effects 
in the nucleus.  A role for IκBL in mRNA processing or regulation of translation has 
been previously been suggested (Greetham et al., 2007).  Similarly, the mass 
spectrometry analysis suggested that Cactin may also have a role in similar processes.  
However shRNA-based studies revealed that Cactin and IκBL function independently, 
at least in terms of regulation of NF-κB, IRF3 and IRF7.  This suggests functional 
redundancy for Cactin and IκBL.  It is possible that they both function as part of the 
same multi-protein complex which regulates the activation of transcription factors in 
the nucleus.  IκBL has been a subject of interest in recent years as genetic defects in 
the gene coding for IκBL confers susceptibility to diseases such as RA (Greetham et 
al., 2007) and SLE (Castiblanco and Anaya, 2008).   
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Given the regulatory effects of Cactin on inflammatory signalling pathways, it 
will be interesting in the future to look at the role of Cactin in autoimmune diseases, 
initially looking at its expression levels in diseases such as SLE.  We are currently at 
somewhat of a disadvantage due to the lack of an antibody for endogenous Cactin and 
therefore must rely on over-expression studies.  Such antibodies will be of great use 
for future work on Cactin.  Looking forward, it would also be of great benefit to 
generate Cactin-deficient mice and examine the role of Cactin on TLR signalling in 
vivo. Such models would also offer the potential to evaluate the importance of Cactin 
in a various models of inflammatory disease. The present studies implicate Cactin as 
an effective molecular regulator of TLR signalling but we await with interest an 
interrogation of its functional importance in physiological and pathological settings.   
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